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Abstract
Rimonabant, a cannabinoid antagonist, had emerged as a promising drug in the fight 
against obesity. In animals, rimonabant had been shown to affect both appetite and 
energy expenditure. Further investigation was required to determine the direct 
metabolic effect of rimonabant in humans.
Fourteen obese postmenopausal women with a mean body mass index (BMI) of
ry
32.5kg/m (SEM ±0.44) were randomised to receive either 20mg rimonabant daily 
alongside an isocaloric diet (drug group) or a hypocaloric diet designed to result in 
matching weight loss to that in the drug group (diet group). The aim was to 
determine if, when energy intake was maintained at pre treatment levels, rimonabant 
induced weight loss through an effect on energy expenditure and to also determine 
the direct effects of rimonabant on body fat distribution and gene expression. As 
weight loss itself may alter metabolism, a control group undertaking a dietary 
intervention matched for the weight loss in the rimonabant group were investigated.
In this trial it was demonstrated, for the first time in humans, that treatment with 
rimonabant, whilst daily energy intake was maintained at pre-treatment levels, still 
induced weight loss (2.6±0.5kg). In a matched group, who followed a dietary 
intervention to achieve the same weight loss (3.1 ±1.1 kg), there was a decrease in 
resting energy expenditure (REE) (p=0.05) which was not found in the rimonabant 
group, suggesting that rimonabant may influence energy expenditure. A decrease in 
total body fat (p=0.046) and subcutaneous abdominal fat (p=0.028) was found in the 
diet group only. No significant differences in gene expression were found in muscle, 
however in adipose tissue there was a difference in expression of PPAR (Peroxisome 
Proliferator-activated Receptor) delta between the two groups (p=0.006) with PPAR 
delta decreasing post treatment in the rimonabant treated group.
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The trial produced interesting results with regards to the effect of rimonabant on REE 
and reinforced that the endocannabinoid system is a good potential target in the 
treatment of obesity. As antagonism of central receptors has been found to cause 
depression, however, an alternative medication to rimonabant that only produces the 
beneficial peripheral effects on energy expenditure is required.
Previous research has demonstrated that not all obese individuals display the 
expected metabolic risk factors and there is a distinction between the metabolically 
‘healthy’ and ‘unhealthy’. Factors that may influence metabolic risk, such as body 
fat distribution and variations in lipid metabolism, require further research in order 
that future treatments may be targeted effectively. Therefore a follow on study to the 
main rimonabant intervention was undertaken to gain a comprehensive 
understanding of the gender differences in energy expenditure, body fat distribution 
and lipid metabolism in 12 obese males (mean BMI 31.40 ± 0.34 kg/m ) and 12 
obese postmenopausal females (mean BMI 32.39 ± 0.53 kg/m ). Results showed that 
absolute REE was significantly higher in males than females (p<0.01), however, 
once expressed per kg fat free mass (FFM), females had the significantly higher REE 
(p=0.01). Males had significantly higher levels of internal fat (p=0.001) and visceral 
fat (p=0.003) and significantly lower levels of total body fat (p=0.002) and 
subcutaneous abdominal fat (p=0.004) than females. In adipose tissue, a 
significantly greater expression of Lipoprotein Lipase (LPL) was identified in 
females than males (p=0.01), but there were no further significant differences in gene 
expression in adipose or muscle tissue between the genders.
As there are gender differences in metabolism in obesity, there may be gender 
specific responses to any newly developed anti-obesity medications and these 
differences need to be evaluated.
ii
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Chapter 1 -  Introduction
1.1 Levels of obesity
In recent decades levels of obesity have increased to pandemic proportions. The 
World Health Organisation (WHO) estimated that in 2005 approximately 1.6 billion 
adults were overweight (BMI > 25 kg/m ) and over 400 million obese (BMI > 3 0  
kg/m ) worldwide and projected that by 2015, 2.3 billion adults would be overweight 
and 700 million obese (WHO, 2006). In England in 2004, two thirds of the 
population were estimated to be overweight or obese (House of Commons, 2004). 
This rise in obesity comes with a huge cost, not only in financial terms, but with 
regards to increases in mortality and morbidity. In socio-economic terms, obesity 
and its associated co-morbidities are sizeable and were estimated to cost 
approximately £3.5 billion in England in 2002 and account for up to 8% of overall 
health budgets in Europe (International Obesity Task Force (IOTF), 2002).
1.2 The consequences of obesity
Obesity is well documented to be linked to health problems such as cardiovascular 
disease, type II diabetes mellitus, and some cancers and respiratory diseases (Richard 
and Boisvert, 2006) and there are a number of metabolic disorders associated with 
obesity including hypertension, dyslipidaemia, elevated serum triglycerides, 
increased glucose levels and insulin resistance (National Cholesterol Education 
Program (NCEP), 2002). These metabolic disorders arise from excessive fat 
accumulation in muscle, adipose tissue and major organs involved in energy 
regulation resulting in inflammation and impaired tissue integrity (Maynadier et al., 
2009).
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1.3 Defining obesity and metabolic risk
Obesity has historically been defined using body mass index (BMI) a measure of 
weight in kg in relation to height in m (WHO, 1997). In epidemiological studies 
increases in BMI have been shown to be related to an increase in incidence of 
conditions such as coronary heart disease and diabetes (National Institutes of Health, 
1998). The relationship between levels of obesity and coronary heart disease risk is 
not straightforward however. Some obese patients, with high levels of body fat, may 
not display the expected metabolic risk factors, whereas their moderately obese 
counterparts may be found to have a number of metabolic complications (Despres et 
al., 2001). Work from the 1940s first suggested that the complications associated 
with obese individuals were more closely associated with the location of excess fat in 
the body rather than the level of excess weight itself (Despres et al., 2001). Studies 
have shown that high levels of abdominal fat are a major risk factor for coronary 
heart disease and that abdominal girth is actually a better predictor of heart disease 
than BMI or weight alone (Dagenais et a l , 2005). Many studies have used simple 
anthropometric measures such as waist circumference or waist hip ratio to estimate 
abdominal adipose tissue, but more accurate methods are available such as magnetic 
resonance imaging (MRI) scanning. Of the anthropometric measurements utilised, 
waist circumference rather than waist hip ratio has been shown to be a more accurate 
predictor of visceral adipose tissue stores. A study following changes in waist hip 
ratio in women over a twenty year period identified that, although the participants 
gained weight and accumulated visceral adipose tissue, their simultaneous increases 
in both waist and hip ratios resulted in a misleading stable waist-hip ratio (Despres, 
2001). Using these anthropometric measures it has been shown that, in addition to 
the increase in obesity rates as defined by BMI, there has been an increase in obesity
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as defined by a high risk waist circumference (a circumference of > 102cm in men 
and >88cm in women) (Ford et a l , 2003). In 2000 36.9% of men and 55.1% of 
women in the USA were found to have a high risk waist circumference (Ford et al., 
2003) and the incidence of abdominal obesity in the USA was found to have tripled 
over the past forty years (Okosun et al., 2004).
1.4 Energy balance
Energy balance refers to a state in which energy intake in the form of food and drinks 
matches energy expended by the body. Obesity occurs when there is a long term 
positive energy balance and energy intake exceeds energy expenditure (Prentice and 
Jebb, 1995). In a state of positive energy balance the body has surplus energy in 
relation to requirements and increases its energy stores.
1.4.1 Energy intake
Changes in lifestyle over recent decades have made it increasingly easy for 
individuals to have an energy intake exceeding their energy requirements. Energy 
dense foods are more readily available and in western countries there is a greater 
reliance on highly calorific convenience foods (House of Commons, 2004). In 
addition to the availability of energy dense foods, there are a number of elements that 
combine to influence energy intake. Environmental factors such as food availability, 
external factors such as stress and internal factors such as the effect of the central 
nervous system and hormones will all impact on energy intake (Gibney, 2002).
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1.4.2 Energy storage
The energy consumed in the diet that is not utilised for fuel can be stored in the body 
in the form of fat, glycogen or protein. Fat is the major storage form accounting for 
between 10-35% body weight, whereas body protein contributes between 10 and 
15% and glycogen only 0.6% to total weight in lean individuals. As described in 
section 1.2 excess energy intake may lead to excessive fat accumulation in muscle, 
adipose tissue and major organs negatively influencing energy regulation.
1.4.2.1 Gender differences in energy storage
Gender differences exist in both protein and fat storage. Body protein is generally 
higher in males than females due to a larger muscle mass (Gibney et al., 2002). 
Levels of body fat also differ and in adults of a healthy weight levels are 10-25% in 
males and 15-35% in females but these figures can be as high as 60-70% of body 
weight in obese individuals (Gibney et a l, 2002).
Gender differences are also found in fat distribution in obesity. In obese males 
excess fat frequently accumulates in the subcutaneous abdominal area and may be 
described as android or ‘apple shaped’ obesity. In premenopausal obese women 
subcutaneous fat accumulation more commonly occurs in the lower abdominal wall 
and gluteofemoral region and is described as gynoid or pear shaped’ obesity (Amer, 
1997). Postmenopausal obese women, however, tend to accumulate more abdominal 
and visceral fat (Lovejoy and Sainsbury, 2009).
1.4.3 Energy expenditure
Total energy expenditure is comprised of REE, dietary induced thermogenesis (DIT) 
and non resting energy expenditure. REE accounts for approximately 60% of total
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energy expenditure and refers to the energy required for metabolic and cellular 
processes. Dietary induced thermogenesis accounts for roughly 10% of total energy 
expenditure and this describes the energy expended in the digestion, transport and 
storage of macronutrients. The remaining 30% of total energy expenditure is 
accounted for through non resting energy expenditure (Leibel et al., 1995). Non 
resting energy expenditure, also described as activity thermogenesis, is comprised of 
physical activity, exercise and non-exercise thermogenesis (NEAT) and this is the 
most variable element of total energy expenditure between individuals (Levine,
2005). For individuals exercising regularly exercise related energy expenditure has 
been estimated at approximately 10% of total energy expenditure but for those 
undertaking no sporting exercise the level of exercise related energy expenditure is 
zero (Levine, 2005). NEAT refers to the energy expenditure of physical activities of 
daily living which includes fidgeting and maintaining posture when sitting or 
standing (Levine, 2005). As with exercise, levels of NEAT can be highly variable 
between individuals.
Levels of activity energy expenditure have fallen in recent decades contributing to 
the pandemic of obesity. In England in 2004, only a quarter of women and a third of 
men achieved the Department of Health’s target of 30 minutes of physical activity 5 
times a week. Car usage has doubled in the past 30 years, whilst levels of walking 
and cycling have fallen (House of Commons, 2004). With the invention of numerous 
labour saving devices, and increased leisure time spent watching television and 
playing computer games, total energy expenditure has been reduced.
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1.4.4 Measurement o f energy expenditure
Energy expenditure may be measured using direct, indirect calorimetry or non- 
calorimetric techniques. Direct calorimetry measures heat production by the body 
and there are several different types of direct calorimeter including isothermal, heat 
sink and convection systems (Levine, 2005). As direct calorimeters are very 
expensive to build and run, their use is limited. Indirect calorimetry measures the 
heat released through oxidative processes in the body through respiratory gas 
analysis (Jequier et al., 1987). There are a variety of approaches to the measurement 
of energy expenditure using indirect calorimetry including total collection systems, 
open-circuit indirect calorimetry systems, closed-circuit systems and respiratory 
chambers (Levine, 2005). Non-calorimetric methods estimate energy expenditure by 
extrapolation from physiological measurements. A key non-calorimetric method of 
estimating total energy expenditure is measurement of doubly labeled water. In this 
method an individual ingests a dose of heavy water isotopically labeled with both 
deuterium and oxygen-18. The differing rates of loss of these isotopes from the body 
are utilised to estimate the rate of carbon dioxide production and, from this, energy 
expenditure can be calculated (Gibney, 2002).
1.4.5 Gender differences in energy expenditure
Men tend to be taller, have a higher body weight and a greater proportion of fat free 
mass than women, and as levels of fat free mass are a key determinant of energy 
expenditure, men are reported, in absolute terms, to have greater energy expenditure 
than women. It is unclear, however, if these gender differences in energy 
expenditure are independent of body composition. Several studies have failed to find 
a gender difference in energy expenditure once adjustments have been made for body
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composition (Lovejoy and Sainsbury, 2009). Other studies have concluded, 
however, that after adjusting for differences in fat free mass, women do have lower 
energy expenditure than men (Morio et a l , 1997; Ferraro et a l , 1992).
Gender differences in response to activity energy expenditure have also been 
explored. Studies by Paul et a l (2004) and Westerterp and Goran (1997) reported 
that in men higher levels of physical activity were associated with a reduction in 
percentage of body fat but that this relationship was not seen in women. These 
studies included a range of both healthy weight and over weight participants. 
Responses to an exercise training program also differed with women demonstrating a 
smaller reduction in body fat and weight loss than men. These differing responses 
may reflect gender differences in the metabolic response to exercise combined with 
an increase in energy intake detected in women but not in men post exercise 
(Lovejoy and Sainsbury, 2009).
1.5 Genes involved in lipid metabolism
In recent years a number of genes involved in lipid metabolism have been identified 
and research undertaken to try to clarify their role in the development of obesity and 
its associated complications such as insulin resistance and dyslipidaemia. 
Adiponectin is an adipocyte-derived hormone that has received much attention as a 
potential therapeutic target in the treatment of obesity related disease. It has a role in 
the regulation of lipid and glucose metabolism, body weight and homeostasis 
(Maynadier et a l , 2009). In 2008, Yamauchi and Kadowaki demonstrated that in 
obese mice adiponectin decreases insulin resistance by reducing triglyceride content 
in both muscle and the liver. This effect was found to result from increased gene 
expression of molecules involved in fatty-acid transport, combustion and energy
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dissipation such as Cluster of Differentiation 36 (CD36), acyl Co A oxidase 
(ACOX1) and Uncoupling protein 2 (UCP2) in muscle. Levels of expression of 
adiponectin and its receptors, adiponectin receptor 1 and adiponectin receptor 2, are 
decreased in obese individuals (Yamauchi and Kadowaki, 2008).
Much research is also being undertaken into peroxisome proliferator-activated 
receptors (PPARs). These are a family of nuclear receptors comprised of different 
isoforms (PPARa, PPARS and PPARy). PPARa and PPARy have both been found 
to have roles in the regulation of lipid metabolism. PPARa is expressed in skeletal 
muscle, the heart and liver and controls the catabolism of fatty acids and PPARy is 
expressed in adipose tissue where it has a role in inducing fat cell differentiation and 
improving insulin sensitivity (Pagano et al., 2008). PPARS is found in both skeletal 
muscle and adipose tissue, increasing fat oxidation in muscle and lipolysis in the 
adipose tissue (de Lange et al., 2008).
There are many further genes being studied in addition to those described above and 
it is hoped that establishing a greater understanding of their role in energy 
metabolism may lead to improved treatments for both obesity and its associated 
metabolic disorders.
1.6 Gender differences in lipid metabolism
Women are at a lower risk of cardiovascular disease than men until they are 
postmenopausal when the risk becomes similar. High plasma triglycerides are 
independent and better predictors of cardiovascular disease than cholesterol in 
women (Meagher, 2004) suggesting that treatment of hypertriglyceridaemia may be 
more important in women than men. This finding may be related to differences in 
lipid metabolism between genders.
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In young lean subjects it has been shown that very low density lipoprotein (VLDL) 
triglyceride production by the liver is higher in women than men, but since clearance 
is also higher, this results in lower plasma triglyceride in women than men (Magkos 
et a l , 2007). There have been no studies of fatty acid kinetics and triglyceride 
metabolism in older obese men and postmenopausal women. A further interesting 
finding is that fatty acid production from adipose tissue has been shown to be greater 
in young lean women than men even when they are matched for adiposity 
(Mittendorfer et a l , 2001). Fatty acid production rate correlates with resting energy 
expenditure and a study by Nielsen et al (2003) found that young women (mean age 
30 years) produced 40% more fatty acids in relation to energy expenditure than men. 
As free fatty acid (FFA) concentrations are not different in men and women, fatty 
acid clearance from the circulation must also be higher in women than men.
Further research into gender differences in lipid metabolism should aid in the 
targeting of novel anti-obesity treatments.
1.7 Treatment for obesity
Much research is being undertaken to try and prevent the development, and to aid in 
the treatment of obesity and its associated metabolic risk factors. Currently the three 
treatment options for obesity are: lifestyle modification, bariatric surgery and 
pharmacotherapy.
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1.7.1 Lifestyle modification
Lifestyle modification is recommended for long term weight loss. A combination of 
sedentary lifestyle and a wealth of high energy foods contribute to the development 
of obesity and these issues may be addressed through dietary interventions and 
increasing physical activity. In reality, however, behavioural change is difficult to 
achieve and even harder to maintain in the longer term. A study comparing a range 
of popular dietary interventions in the USA showed that weight loss was modest with 
a mean reduction in weight of 3-4kg after one year. Additionally adherence to the 
diets was poor with drop out rates between 42 and 60% (Dasinger et al., 2005).
1.7.2 Bariatric surgery
Bariatric surgery refers to surgery on part of the digestive system to aid weight loss 
in obese individuals. Examples of bariatric surgery include gastric banding and 
gastric bypass. In order to be eligible for bariatric surgery strict criteria have to be
9 9 9met. Patients must have a BMI of >40kg/m or 35kg/m - 40kg/m with a disease 
that may improve if weight were lost. Additionally, all other non-surgical options 
must have been trialled and proven not to have been of benefit over a six month 
period (National Institute for Health and Clinical Excellence (NICE), 2006). Weight 
losses with bariatric surgery tend to be greater than with other obesity treatments and 
a review of the clinical effectiveness of obesity surgery found that surgical 
intervention resulted in a significantly greater weight loss of 23-37kg more weight 
after two years than with non surgical treatment (Clegg et al., 2003). However, 
bariatric surgery is only undertaken in 1% of obese adults annually (Goodpaster et 
a l, 2010).
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1.7.3 Pharmacotherapy
Currently only one anti-obesity medication, Orlistat (Xenical) a lipase inhibitor, is 
available on prescription in Europe. The action of orlistat is to reduce dietary fat 
absorption by approximately 30% thereby promoting weight loss. A randomized, 
double blind, placebo-controlled study in which participants received 120mg orlistat 
three times daily plus a hypocaloric diet for one year reported a weight loss of 8.76 ± 
0.37kg in the treatment group versus 5.81 ± 0.67kg in the placebo group (Davidson 
et al., 1999). Unfortunately orlistat is associated with a number of well documented 
adverse side effects including oily stools, oily spotting and passing flatus with 
discharge (Davidson et al., 1999).
Until recently Sibutramine (Reductil), a serotonin-adrenaline reuptake-inhibitor was 
available to prescribe to aid in the treatment of obesity, but in January 2010 the 
European Medicines Authority withdrew its licence after the cardiovascular risks of 
the drug were found to outweigh the benefits.
Other medications that have attracted interest recently due to their beneficial impact 
on weight reduction are the glucagon-like peptide-1 (GLP-1) analogues such as 
exenatide and liraglutide. These drugs prolong the half life of incretins resulting in 
delayed gastric emptying and induced satiety (Kennedy and Khoo, 2005). 
Liraglutide was initially developed for the treatment of Type II Diabetes but has been 
shown to induce dose dependent weight loss. In a clinical trial where liraglutide 
treatment for 20 weeks was compared to a placebo and to orlistat in obese 
individuals without diabetes, the mean weight loss with liraglutide was between 4.8- 
7.2kg (at doses between 1.2-3.0mg per day) in comparison to 4.1kg with orlistat and 
2.8kg with the placebo (Astrup et a l , 2009). It should be noted, however, that all 
participants were additionally instructed to follow a hypocaloric diet (500kcal/day
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deficit) and to maintain or increase physical activity. Currently the National Institute 
for Health and Clinical Excellence has recommended that liraglutide at a dose of 
1.2mg daily (in combination with metformin and/or sulfonylureas) only be used in 
the treatment of people with type II diabetes with a BMI > 35kgm2 and poor blood 
glucose control (NICE, 2010).
One further group of medications which have been under development and which 
have been emerging as a promising treatment in the fight against obesity are drugs 
targeting the endocannabinoid system. This novel field of research is examined in 
section 1.8.
2.7.4 Gender differences in response to obesity treatments
Greater weight loss has been reported in males than females following hypocaloric 
diets but it has been suggested that this is due to a higher initial starting weight or 
greater compliance with the dietary restriction rather than an inherent gender 
difference (Lovejoy and Sainsbury, 2009). Studies found that men lost more 
abdominal, visceral fat during weight loss than women (Wirth and Steinmetz, 1998; 
Janssen and Ross 1999), and that postmenopausal women lost less visceral fat than 
premenopausal women (Park and Lee, 2003). A study investigating gender 
differences following gastric bypass surgery found that for participants with matched 
BMI, men lost a greater amount of weight post surgery than women (Tymitz et a l ,
2007). There are, however, limited studies examining gender differences in response 
to anti-obesity medications (Lovejoy and Sainsbury, 2009).
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1.8 Discovery of the endocannabinoid system
Cannabis had been observed for many years to increase appetite but the active 
constituent of cannabis A9-tetrahydrocannabinol (THC) was not identified until 1964 
(Gaoni and Mechoulam, 1964). The potential importance of THC as an orexigenic 
agent was highlighted when it was observed that through smoking marijuana, 
patients with acquired immune deficiency syndrome (AIDS) experienced an 
enhanced appetite and less weight loss (Mechoulam et al., 2006). A synthetic form 
of THC, dronabinol, was subsequently created and this has been used to treat the 
nausea and sickness associated with chemotherapy in addition to the anorexia related 
to the human immunodeficiency virus infection (Gelfand and Cannon, 2006). 
Following identification of THC, years of research finally led to the characterisation 
and cloning of a receptor activated by THC and this was named the cannabinoid 
receptor type 1 or CBi (Howlett et al, 2002). Further research was then undertaken 
to identify any further cannabinoid receptors and potential endogenous ligands for 
these receptors. The endocannabinoid system is comprised of these cannabinoid 
receptors, the endogenous ligands (endocannabinoids) and the proteins required for 
their synthesis and degradation (Pagotto et a l, 2006).
1.9 Cannabinoid receptors
At this time two cannabinoid receptors have been identified; the CBi receptor cloned 
in 1990 and the CB2 receptor cloned in 1993 (Munro et al, 1993). Both receptors are 
members of the class A (rhodopsin-like) seven transmembrane spanning domain G 
protein-coupled receptor family and their activation inhibits adenylate cyclase 
activity leading to a reduction in intracellular cyclic adenosine monophosphate 
production (Pertwee, 1997).
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The two receptor subtypes have unique pharmacological profiles and are expressed 
in different tissues (Kyrou et al., 2006). CBi receptors are widely distributed 
throughout the body and have been found in the hypothalamus, nucleus accumbens, 
gastrointestinal tract, adipose tissue, liver and muscle (Duffy and Rader, 2007). CB2 
receptors are located throughout the immune system including the thymus, tonsils, 
spleen and mast cells (Cannon, 2005) and on blood cells (Pagotto et al., 2006). CB2 
receptors have also been identified in the central nervous system, for example on 
microglial cells (Pertwee, 2006).
1.10 Endogenous cannabinoids
In 1992, the first endogenous cannabinoid (endocannabinoid), 
arachidonoylethanolamide (anandamide) was discovered (Devane et al, 1992).
At first, it was believed that this was a specific receptor agonist for the CBi receptor 
but it has since been shown to be a CB2 receptor agonist too (Sharkey, 2006). Three 
years later a further endocannabinoid, 2-arachidonoylglycerol (2-AG) was identified 
with efficacy at both CB receptors (Mechoulam et al, 1995). These two 
endocannabinoids are metabolised via separate pathways as shown in Figures 1.1 and 
1.2 .
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ANANDAMIDE SYNTHESIS AND METABOLISM
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Figure 1.1 Anandamide synthesis and metabolism.
(A) Anandamide is synthesised de novo inside the cellular membranes. N-arachidonoyl- 
phosphatidylethanolamine (NAPE) is produced from phosphatidylethanolamine under the 
action of the enzyme N-acyltransferase (NAT). NAPE is subsequently hydrolysed to 
anandamide by a NAPE-selective phospholipase D (PLD).
(B) Intracellularly, anandamide is hydrolysed to arachidonic acid and ethanolamine under 
the catalytic action of fatty acid amide hydrolase (FAAH). From Kyrou et al., 2006 (text 
adapted).
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2-AG SYNTHESIS AND METABOLISM
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Figure 1.2. 2-Arachidonoylglycerol (2-AG) synthesis and metabolism.
(A) 2-AG is synthesised de novo inside the cellular membranes. The membrane phospholipid 
precursor (phosphatidylinositol) is hydrolysed to 1,2-diacylglycerol (1,2-DAG) and this is 
catalysed by phospholipase C (PLC). 1,2-DAG is then converted to 2-AG via the action of 
diacylglycerol lipase (DGL).
(B) Intracellularly, the hydrolysis of 2-AG to arachidonic acid and glycerol may be catalysed 
by either fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL). From 
Kyrou et al, 2006 (text adapted).
Other potential endocannabinoids have been identified including the amino-acid 
amides, virodhamine and noladin ether (Porter et al., 2002, Hanus et a l, 2001). 
These endogenous cannabinoids have a number of similarities. Firstly, they are 
amides, esters or ethers of arachidonic acid, and are derived from membrane 
phospholipids (Kyrou et a l, 2006). They are synthesised ‘de novo’ and upon 
demand and are not stored but immediately released from the cell (Di Marzo and 
Deutsch, 1998). They are subsequently rapidly inactivated by enzymes found in 
most cells (Woods, 2007) and removed by cellular uptake (Matias et a l, 2006). The
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endocannabinoids are found in the brain and peripheral tissues with a similar 
distribution pattern to CBi receptors (Kyrou et a l 2006).
In the brain endocannabinoids act as retrograde signallers as they are released from 
postsynaptic neurons and travel backwards across the synapse modulating 
neurotransmitter release from presynaptic terminals through the activation of CBi 
receptors (Figure 1.3) (Alger, 2002; Freund et al., 2003).
Figure 1.3. Endocannabinoids acting 
as retrograde messengers in the 
brain.
(a) Excitation of the neuron causes its 
depolarization and an influx o f calcium 
ions. This stimulates the synthesis of 
endocannabinoids such as 2-AG and 
anandamide which are released from the 
neuron.
(b) Endocannabinoids diffuse away and 
bind to CBi cannabinoid receptors on the 
presynaptic terminals o f neurons that form 
synapses with the stimulated neuron. This 
reduces inhibitory neurotransmitters being 
released.
(c) Endocannabinoids are taken up into 
neuronal and glial cells via a transporter 
and are then broken down by fatty acid 
amide hydrolase.
From MacDonald and Vaughan, 2001.
Matias et al (2006) have suggested the likely existence of an endocannabinoid 
membrane transporter that regulates the intracellular and extracellular distribution of 
endocannabinoids. Although, at this time, such a transporter has not been 
characterised there is evidence indicating that endocannabinoid transport across the 
cell membrane is an active process not one of simple passive diffusion.
Decreased 
probability 
Preeynapte of release 
neuron
V_.; Endocannabinoid 
|g j  CB1 cannabinoid receptor
C 3  '3 protein
2-sJ Neurotransmitter receptor 
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In a number of animal studies, endocannabinoids were found to increase food intake 
and promote weight gain through the activation of CBi receptors (Engeli and Jordan, 
2006). This discovery led to further research to generate specific antagonists for 
cannabinoid receptors. A number of compounds with CBi receptor antagonistic 
properties have been characterised including SR141716 (now known as 
Rimonabant), SR14778, AM251, AM281, LY320135 and SLV319 (Pagotto et a l, 
2006).
1.11 Central effects of endocannabinoids
Studies in animals suggested that the brain endocannabinoid system is involved in 
the regulation of food intake and that this occurs through two mechanisms. Firstly, 
the endocannabinoid system reinforces the motivation to find and consume palatable 
foods, possibly through an effect on mesolimbic pathways connected with reward 
mechanisms. Studies utilising the CBi antagonist rimonabant discovered 
administration greatly reduced the consumption of palatable food (e.g. sweet food) in 
animals fed ad libitum and reduced the intake of normal food but not water in food 
deprived animals (Simiand et a l, 1998; Colombo et a l, 1998; Rowland et a l,  2001). 
Secondly, it is activated in the hypothalamus after fasting and regulates other 
anorectic and orexigenic mediators of appetite (Di Marzo et a l 2005).
The importance of the role of the endocannabinoid system in the hypothalamus for 
the control of food intake has been shown in a number of animal studies and levels of 
endocannabinoids in the brain have been shown to alter during fasting and feeding 
(Bellocchio et a l, 2006). A study by Kirkham et a l (2002) measured levels of 
anandamide and 2-AG in feeding-associated areas of rats brains during feeding and 
fasting. Their results detected an increase in anandamide and 2-AG levels in the
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limbic forebrain, a region of the brain involved with the motivational aspects of 
eating during fasting. They also detected an increase in 2-AG in the hypothalamus 
during fasting although not to the same extent as that in the limbic forebrain. The 
level of 2-AG in the hypothalamus subsequently decreased during feeding. Further 
evidence for a hypothalamic site of action was provided by the finding that food 
intake was increased in rats following an injection of anandamide into the 
dorsomedial hypothalamic nucleus (Osei-Hyiaman et a l , 2006).
Changes in endocannabinoid levels in the hypothalamus have also been shown to 
inversely correlate with levels of leptin in the blood. Leptin is the key signal through 
which the hypothalamus controls food intake, reducing food intake through the 
upregulation of anorexigenic neuropeptides and the down regulation of orexigenic 
factors such as neuropeptide Y. Di Marzo et al. (2001) investigated the relationship 
between leptin and endocannabinoid levels in rats and knockout mice. Di Marzo et 
al (2001) found that acute leptin treatment of both normal rats and ob/ob mice 
reduced hypothalamic levels of anandamide and 2-arachidonoylglycerol and that 
defective leptin signalling was associated with elevated levels of endocannabinoids 
in the hypothalamus.
Animal studies also indicated that grehlin may be involved in the regulation of 
endocannabinoid levels. Ghrelin is a 28-amino-acid peptide, which is synthesised in 
the stomach and the brain during food deprivation and signals to the hypothalamus to 
increase food intake (Rigamonti et a l , 2006). A study by Tucci et a l (2004) 
suggests that endocannabinoids are actually involved in ghrelin’s actions on appetite. 
They demonstrated that blocking the CBi receptors in the paraventricular nucleus 
(PVN) of the hypothalamus with rimonabant prevented the orexigenic action of an 
intra-PVN injection of ghrelin. It has been shown in rats that the hypothalamic
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concentrations of anandamide and 2-arachidonoylglycerol alter during the different 
stages of food ingestion; levels are highest during fasting, when leptin levels are 
lowest and ghrelin levels are highest and lowest during feeding when leptin is highest 
and ghrelin lowest (Kirkham et al., 2002).
1.12 Peripheral effects of endocannabinoids
A study of marihuana smokers by Greenberg et al. (1976) provided the first 
indication that cannabinoids might affect energy homeostasis through mechanisms 
other than central effects on food intake. Under ward conditions, energy intake and 
body weight were monitored in marihuana users before, during and after 21 days of 
marihuana smoking. It was reported that marihuana initially caused an increase in 
food intake and weight gain. After the first few days, however, caloric intake was 
reduced yet the weight gain continued for the duration of the study indicating an 
independent effect on peripheral metabolism.
Effects on peripheral metabolism have also been reported in studies using the 
endocannabinoid receptor rimonabant. Colombo et a l (1998) administered 
rimonabant to non-obese Wistar rats and found that tolerance to the anorectic effect 
of the drug developed within five days, yet the reduced body weight seen in these 
treated rats was maintained for the entire 14 days of the treatment period. Bellochio 
et al. (2006) noted that similar observations were reported in a number of animal 
studies where the CBi receptor was either removed or pharmacologically 
antagonised. All of the studies described a transient reduction in food intake but a 
persistent reduction in body weight following blockage of the cannabinoid receptor. 
CBi receptor knockout mice were shown to resist developing diet induced obesity 
and insulin resistance whilst being fed a high fat diet (Ravinet Trillou et a l , 2004).
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These observations clearly suggested that weight reduction was being influenced by 
a factor independent of food intake, energy expenditure.
Further research was undertaken and results suggested that a number of peripheral 
sites were involved in endocannabinoid activity including the liver, white adipose 
tissue, brown adipose tissue and skeletal muscle (Bellocchio et a l , 2006). A study 
by Osei-Hyiaman et a l (2005) showed that the liver is a site of action for 
endocannabinoids. They demonstrated that activation of CBi in mice increased de 
novo fatty acid synthesis. This occurred through an increased expression of sterol 
regulatory element binding protein-1C, a lipogenic transcription factor, and its target 
enzymes fatty acid synthase and acetyl coenzyme-A carboxylase-1. A high fat diet 
fed to the mice for three weeks led to an increase in hepatic anandamide and an 
increase in the basal rate of hepatic fatty acid synthesis. The increase in anandamide 
was not due to an increase in synthesis but rather to a decrease in its degradation by 
fatty acid amide hydrolase. Subsequent administration of the CBi antagonist, 
rimonabant, reduced both basal levels of fatty acid synthesis and development of 
hepatic steatosis caused by the high fat diet (Osei-Hyiaman et a l, 2005).
Like the liver, adipose tissue is another important peripheral site of action for 
endocannabinoids. Studies have shown that adipocytes express the CBi receptor and 
that CBi expression is increased in mature adipocytes in comparison to preadipocytes 
suggesting that the receptors are important for the function of these mature cells 
(Engeli et a l , 2005). A study by Jbilo et a l (2005) provided evidence as to the 
mechanisms of action of the endocannabinoid system on adipose tissue. They treated 
dietary induced obese mice with rimonabant and were able to reverse the phenotype 
of obese adipocytes. The weights of the lumbar white and brown fat adipose tissue 
were both reduced by more than 50% following treatment and they found that this
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was not due to adipocyte apoptosis but rather a depletion of the adipocyte’s fat 
content. In addition they discovered that major alterations in gene expression levels 
induced by a high fat diet were mostly reversed in rimonabant treated obese mice. 
Analysis showed that the reduction of adipose mass by the drug was due to enhanced 
lipolysis through the induction of the enzymes of beta-oxidation and the tricarboxylic 
acid cycle; increased energy expenditure and regulation of glucose homeostasis 
(Jbilo et a l , 2005).
A further important finding with regards to adipose tissue was that activation of CBi 
receptors in adipocytes regulates the hormone adiponectin (Bensaid et a l,  2003). 
Adiponectin is the most abundantly secreted adipokine and it has antiatherogenic and 
anti diabetic properties (Pagotto et al., 2006). In men, high levels of the adipokine 
are associated with a decreased risk of myocardial infarction (Pi-Sunyer, 2006) and 
increases in adiponectin have been shown to improve insulin sensitivity (Pagotto et 
al., 2006). Reduced adiponectin levels are reported in obese individuals and in those 
with type II diabetes, coronary artery disease, hypertension and polycystic ovary 
syndrome (Pi-Sunyer, 2006). Bensaid et al. (2002) found that the CBi antagonist, 
rimonabant, stimulated adiponectin messenger ribonucleic acid (mRNA) expression 
in adipose tissue and decreased hyperinsulinaemia in obese (fa/fa) rats.
To further examine the relationship between adipose tissue and dysregulation of the 
endocannabinoid system, Bluher et al. (2006) studied the association between 
visceral adipose tissue accumulation and circulating endocannabinoid levels. They 
reported that levels of 2-AG were increased in obese compared to lean participants 
and that a significant correlation was found between circulating 2-AG and fat mass. 
They also identified a high expression of CBi receptors in visceral adipose tissue and 
suggested that these could be a primary target for blockade with a CBi antagonist.
23
Chapter 1 -  Introduction
Brown adipose tissue has recently been studied as another potential site of 
endocannabinoid activity. It has been suggested that blocking the endocannabinoid 
system may increase thermogenesis, as one study showed that mice with dietary 
induced obesity treated with the CBi antagonist AM251 increased levels of both 
uncoupling protein-1 (UCP1) and uncoupling protein-3 (UCP3) mRNA in brown 
adipose tissue (Pagotto et a l , 2006).
Skeletal muscle is another tissue to express the CBi receptor although this expression 
is low in comparison to the brain (Engeli and Jordan, 2006). A study by Liu et a l 
(2005) investigated the effect of treatment with rimonabant for seven days on oxygen 
consumption, and thus thermogenesis, in obese (Lepob/Lepob) mice. They 
demonstrated that rimonabant had a direct effect on energy expenditure, significantly 
increasing basal oxygen consumption compared with vehicle treated animals and 
significantly increasing glucose uptake in isolated soleus muscle preparations. They 
concluded that rimonabant may directly impact energy expenditure at the skeletal 
muscle level and suggested that the antiobesity effect of rimonabant was due to a 
combination of hypophagia and activation of thermogenesis (Liu et a l, 2005). The 
increase reported in glucose uptake in the soleus muscle during treatment with 
rimonabant may contribute to the improvement in glycaemic profile observed in 
other studies (Pagotto et a l , 2006).
An overview of the metabolic effects of antagonism of CBi receptors is shown in 
Figure 1.4.
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Figure 1.4 An overview of the metabolic effects of antagonism of CBi receptors
HDL, High-density Lipoprotein; LDL, Low-density Lipoprotein; TNFa, Tumour Necrosis 
Factor Alpha, hs-CRP, high-sensitivity CRP. From Duffy and Rader, 2007.
1.13 Hyperactivity of the endocannabinoid system
Recent studies demonstrate a close relationship between obesity and overactivation 
of the endocannabinoid system (Bellocchio et al., 2006). This has been shown 
through an increase in endocannabinoid production or an increase in cannabinoid 
receptor expression in obese animals and humans. Bellochio et a l (2006) have 
summarised the five possible sites of endocannabinoid activation as 1) the 
hypothalamus as increased levels of endocannabinoids were identified in the 
hypothalamus of obese ob/ob mice; 2) the liver as an increase in anandamide content 
and numbers of CBi receptors following a high fat diet was observed in rodents; 3) 
skeletal muscle as an increase in CBi receptor expression has been seen following a 
high fat diet; 4) pancreatic beta cells as elevated levels of anandamide and 2-
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arachidonoylglycerol were seen under conditions mimicking hyperglycaemia and 5) 
white adipose tissue as higher levels of endocannabinoids have been observed in 
visceral tissue from obese individuals compared to lean participants.
The mechanism behind the overactivation of the endocannabinoid system seen in 
obesity has still not been identified but may be related to nutrition and genetics. A 
genetic mutation has been identified in obese participants in the enzyme that 
degrades anandamide, fatty acid amide hydrolase. An investigation of 2,667 black, 
white and Asian subjects found that the defective fatty acid amide hydrolase gene 
was significantly associated with obesity in both the black and white subjects (Sipe et 
a l, 2005). Individuals with this mutation have approximately 50% enzymatic 
activity resulting in a potential impact on the clearance of endocannabinoids.
Woods (2007) proposed that a combination of factors may result in hyperactivity of 
the endocannabinoid system in obesity. He suggests that consumption of a high fat 
diet is related to elevated levels of omega-6 polyunsaturated fatty acids. As these 
fatty acids are the precursors for endocannabinoids then elevated levels may lead to 
overproduction of endocannabinoids. The overabundance of endocannabinoids will 
lead to obesity which may in turn contribute to leptin resistance. Dysfunction of 
other endocrine systems may then occur and finally a number of individuals may 
have a missense polymorphism in the fatty acid amide hydrolase gene resulting in 
defective clearance of endocannabinoids.
1.14 Rimonabant
Due to the emerging importance of the endocannabinoid system in food intake and 
energy balance regulation it was hypothesised that a cannabinoid antagonist would 
be of therapeutic benefit in treating obesity (Pagotto et a l, 2006). Rimonabant or
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SR141716 was developed by Sanofi-Synthelabo (now Sanofi-Aventis) in 1994 and 
its structure is shown in Figure 1.5. It was the first cannabinoid receptor antagonist 
to be characterised and binds to both CBi and CB2 receptors with a 1000-fold higher 
affinity for the CBi than the CB2 receptor (Tonstad, 2006).
Cl
Figure 1.5. The chemical structure of rimonabant
Rimonabant is an active lipophilic compound and is best taken with food 
(Wierzbicki, 2006). Its half-life varies according to BMI and for individuals with a 
BMI of 18-28 kg/m2 the half life of rimonabant is 6-9 days and is 16 days for those 
with a BMI > 30 kg/m (Wierzbicki, 2006). Rimonabant is metabolised by the liver, 
excreted in bile and eliminated in faeces (Padwal and Majumdar, 2007).
Rimonabant had been seen as a promising drug for the treatment of obesity as it had 
shown no significant interactions with other drugs commonly prescribed to patients 
for conditions associated with obesity such as hypertension and type II diabetes 
(Tonstad, 2006).
The results of rimonabant studies in animals had produced some positive results as 
described above. Blockade of the cannabinoid receptors had been shown to reduce 
food intake, influence peripheral metabolism and modify the appeal of palatable 
foods (Ravinet Trillou et al., 2004). Due to these findings it was hoped that equally 
positive results would be observed in humans and four large scale phase III clinical
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trials were undertaken: RIO (Rimonabant In Obesity) - Europe, RIO-Lipids, RIO- 
North America and RIO-Diabetes (Costa, 2007).
1.15 Initial clinical trials in humans
The four clinical trials were very similar in design with the major differences being 
the duration of the trial and the population group studied. The RIO-Europe (Van 
Gaal et al., 2005) and RIO-North America (Pi-Sunyer et al., 2006) trials recruited 
obese or overweight adults with treated or untreated hypertension, dyslipidaemia or 
both. The RIO-Europe trial enrolled 1047 participants and was undertaken for a year 
in comparison to the 3045 subjects enrolled on to the RIO-North America trial, 
which ran for two years. Following these studies in obese and overweight people, 
the RIO-Lipids study (Despres et a l, 2005) investigated 1036 overweight or obese 
adults with untreated dyslipidaemia to determine the effects of rimonabant in those 
with a higher risk of cardiovascular disease. Finally the RIO-Diabetes trial (Scheen 
et ah, 2006) was undertaken to establish the efficacy and safety of rimonabant in 
overweight and obese patients with type II diabetes that was poorly controlled with 
metformin or sulphonylureas.
These were all double-blind placebo controlled studies in which participants were 
randomised to receive either a placebo, 5mg rimonabant or 20mg rimonabant daily 
for one year in addition to a hypocaloric diet (600kcal/day deficit). For the second 
year of the RIO-North America study the rimonabant groups were then rerandomised 
to receive either the placebo or to continue receiving the same rimonabant dose while 
the placebo group continued to receive the placebo.
Primary outcome measures for the different trials included weight loss and waist 
circumference with secondary measures including changes in haemoglobin A le
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(HbAlc), fasting glucose, fasting insulin, lipid levels, C-reactive protein, leptin 
concentrations, waist circumference, blood pressure and prevalence of metabolic 
syndrome.
Fifty one to sixty six percent of all study participants completed the one year follow 
up and drop-out rates were similar in the placebo and treated groups. In all studies, 
the patients treated with 20mg of rimonabant daily had a significantly greater 
reduction in weight than the placebo groups. For the groups receiving 20mg 
rimonabant the mean weight loss was 5.3kg-8.6kg and between 49-67% of patients 
treated with the 20mg of rimonabant daily achieved > 5% weight loss. This weight 
loss mainly occurred in the first nine months of the study after which weight 
stabilised. In the RIO-North America study (Pi-Sunyer et a l, 2006), when the 
rimonabant groups were re-randomised in the second year, the participants that were 
switched from the 20mg rimonabant group to the placebo regained the majority of 
weight lost whereas those continuing to receive 20mg rimonabant maintained their 
weight loss.
In addition to weight loss, a significantly greater decrease was seen in waist 
circumference in the 20mg rimonabant groups compared to the placebo groups. The 
mean decrease in waist circumference in subjects treated with 20mg of rimonabant 
was 5.2-6. lcm.
With regards to the markers of cardiovascular disease that were measured, 
significantly greater improvements were seen in high-density lipoprotein (HDL) 
cholesterol, triglycerides and insulin resistance in the subjects receiving 20mg 
rimonabant compared to the placebo groups. HDL-cholesterol increased by 7.2- 
16.2% and triglycerides concentrations fell by 6.8-13.2% in the groups receiving 
20mg rimonabant. Investigators used weight loss as a covariate to try and establish
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what proportion of the observed improvements in HDL-cholesterol and triglycerides 
following treatment with 20mg rimonabant were independent of weight loss. In the 
RIO-Europe trial (Van Gaal et al., 2005) approximately 40% of the increase in HDL- 
cholesterol and 55% decrease in triglycerides were found to be independent of 
weight loss but in the RIO-Diabetes study (Scheen et al., 2006) when the positive 
effects on triglycerides in the 20mg rimonabant group were adjusted for weight loss, 
the results were no longer significant. There were no significant reductions in low- 
density lipoprotein (LDL) concentration reported but the RIO-Lipids study 
determined that the proportion of large LDL particles was greater in those receiving 
20mg of rimonabant. When compared to the placebo group, there was a difference 
of 1.1 A in the peak LDL particle size and a 4.6% lower proportion of small LDL 
particles in the 20mg rimonabant group (Despres et al., 2005).
Improvements in insulin sensitivity were seen in the 20mg rimonabant groups 
compared to the placebo groups with a significant decrease in both fasting plasma 
insulin levels and areas under the curve for insulin and glucose during an oral 
glucose tolerance test. In the RIO-Diabetes study HbAlc levels were lower with both 
doses of rimonabant than with the placebo but only the reduction with the 20mg of 
rimonabant was significantly different. HbAlc was reduced by 0.6% in the 20mg 
rimonabant group compared to a rise of + 1% in the placebo group. Further analysis 
was undertaken which demonstrated that the effect of the 20mg of rimonabant on 
HbAlc was approximately twice that attributable to weight loss alone (Scheen et al.,
2006).
With regards to the additional secondary outcome measures which were considered 
in the RIO-Lipids study, improvements were seen in adiponectin, leptin and C- 
reactive protein levels. Mean adiponectin levels increased by 2.7pg/ml in the 20mg
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rimonabant treated group compared with 0.8pg/ml in the placebo group. As weight 
loss is correlated with adiponectin levels, further covariate analysis was undertaken 
which determined that 57% of the increase in adiponectin observed in those treated 
with 20mg of rimonabant could not be attributed to weight loss. There was a 
positive correlation between the changes in adiponectin levels and the changes in 
HDL-cholesterol. The plasma leptin levels decreased significantly in those receiving 
the 20mg of rimonabant, as did the plasma levels of C-reactive protein (Despres et 
al., 2005).
In addition to these results, the RIO-Diabetes study reported that subjects receiving 
20mg of rimonabant per day reported significantly lower appetite, less desire for 
sweets and less desire for high fat foods than the placebo group. A greater 
improvement in physical functioning as determined by a health survey questionnaire 
was also reported for the group treated with 20mg of rimonabant at one year.
A number of adverse events were reported during the trials and the frequency of 
these events was slightly higher in the groups treated with 20mg rimonabant than the 
placebo group. Commonly reported adverse events in the rimonabant treated groups 
were nausea, diarrhoea, vomiting, fatigue, dizziness and anxiety. These events were 
considered to be mild and transient in nature, occurring mainly in the first few 
months of the study. Depressed mood disorders were also seen more frequently in 
the participants treated with 20mg of rimonabant than in other groups, but the 
discontinuation rate due to this effect were reported to be very similar between the 
20mg rimonabant groups and the participants receiving the placebo.
The results of these four trials together indicated that a 20mg dose of rimonabant 
could bring about significant reductions in weight loss and waist circumference 
measurements in overweight and obese individuals. Few significant findings were
31
Chapter 1 -  Introduction
reported in the studies with a 5mg daily dose of rimonabant. In addition to the 
reduction in cardiovascular risk brought about by the weight loss and decreased 
abdominal girth measurement with 20mg rimonabant, the drug appeared to be having 
a direct effect on metabolic risk factors independent of the weight loss. From the 
studies, positive changes have been reported in HDL-cholesterol levels, insulin 
sensitivity, adiponectin levels, leptin levels and plasma levels of C-reactive protein. 
To try and establish whether these improvements in cardiovascular risk factors would 
translate to a true reduction in cardiovascular events and the effects of rimonabant in 
other population groups a number of further human clinical trials were then 
undertaken.
1.16 Further Human Clinical Trials
STRADIVARIUS (Strategy to Reduce Atherosclerosis Development InVolving 
Administration of Rimonabant -  the Intravascular Ultrasound study) (Nissen et al.,
2008) investigated the effect of rimonabant on cardiovascular risk. Eight hundred 
and thirty nine abdominally obese patients with coronary artery disease were 
recruited and randomised to receive either a placebo or 20mg rimonabant for 18 
months. An intravascular ultrasound was performed pre and post the treatment and 
the primary endpoint was the change in percentage atheroma volume (PAV) with a 
secondary endpoint of change in normalised total atheroma volume (TAV). As seen 
in the RIO trials, rimonabant had a beneficial effect on weight, waist circumference, 
HDL cholesterol levels, triacylglycerol levels and HbAlc. Rimonabant did slow the 
rate of progression in PAV but it was not significantly different to the placebo group 
(PAV increased by 0.25% in the rimonabant group versus 0.57% in the placebo
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group, P=0.22). In the secondary endpoint, TAV, however, a significant decrease 
was seen in the rimonabant group.
The ADAGIO-Lipids study (An International Study of Rimonabant in Dyslipidemia 
with AtheroGenic Risk in Abdominally Obese Patients) examined the effects of 
rimonabant on cardiometabolic risk factors in 803 patients with severe abdominal 
obesity (Despres et a l , 2009). Participants were randomised to receive either 20mg 
rimonabant daily or a placebo and were prescribed a diet which reduced their daily 
energy intake by 600 kcal. The results confirmed the previously reported positive 
effects of rimonabant on HDL-cholesterol and triglyceride levels but additionally a 
CT (computerised tomography) scan showed that rimonabant reduced visceral 
adipose tissue (-10.1% versus placebo, P=<0.0005) to a larger extent than 
subcutaneous fat (-5.1% versus placebo, P=<0.005) and significantly decreased fat 
accumulation in the liver.
A summary of findings from key rimonabant papers may be seen in Table 1.1.
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Table 1.1 Summary of findings from key rimonabant trials.
Study 1 Participants Treatment Primary end pointsf Secondary end 
pointsf
RIO-Europe
(Van Gaal et al., 
2005)
60 sites in Europe 
20 sites in USA
1 1507 (309 males,
1 1198 females) BMI 
1 27-40kg/m2
Rimonabant 
5mg, 20mg 
or placebo 
daily for 1 
yr
4.7 kg weight loss*, 
4cm waist decrease
TGf
HOMA-IR f 
HDL-C t
RIO-Lipids
(Despres et al., 
2005)
67 sites in 8 
countries
1 1033 (407 males, 
1 626 females)
1 BMI 27-40kg/m2
Rimonabant 
5mg, 20mg 
or placebo 
daily for 1
yr
5.4kg weight loss*, 
5.7cm waist decrease
TGf
HDL-C T
LDL particle size f 
Adiponectin f
RIO-Diabetes
(Scheen et al.,
2006)
159 sites in 11 
countries in Europe, 
North America & 
South America
1 1045 (513 males,
1 532 females) Type 
1 II DM (treated with 
I oral agents)
1 BMI 27-40kg/m2
Rimonabant 
5mg, 20mg 
or placebo 
daily for 1 
yr
3.9 kg* weight loss, 
3.3cm weight 
decrease HbA)c f
TGf
HDL-C f
RIO-North
America
(Pi-Sunyer et al., 
2006)
64 sites in USA, 8 
sites in Canada
1 3040 (588 males, 
1 2452 females)
1 BMI 27-40kg/m2
Rimonabant 
5mg, 20mg 
or placebo 
daily for 1 
yr
4.7kg* weight loss, 
5.4cm waist decrease. 
Weight regained once 
drug stopped
TGf
HOMA-IR f 
HDL-C f
STRADIVARIUS
(Nissen et al., 2008) 
112 sites in North 
America, Europe & 
Australia
1 839 (545 males,
1 294 females)
I abdominally obese 
1 (waist circ. >88cm 
I in females,
1 > 102cm in males)
Rimonabant 
20mg daily 
vs. placebo 
for 18-20 
mths.
No significant 
difference in rate of 
progression in PAV
TAVf 
Weight f 
Waist circ. f
ADAGIO
(Despres et al., 
2009)
53 sites in 14 
countries
I 799 (371 males,
I 428 females)
1 abdominally obese 
1 (waist circ. >88cm 
I in females,
1 > 102cm in males)
1 with dyslipidemia
Rimonabant 
20mg daily 
vs. placebo 
for 1 yr
TGf
HDL-C t
Abdominal AT f 
Visceral AT f 
Weight f 
Waist circ. f
Mean placebo subtracted one year weight loss; ADAGIO, An International Study of 
Rimonabant in Dyslipidemia with AtheroGenic Risk in Abdominally Obese Patients; AT, 
Adipose Tissue; Diabetes Mellitus; HbAlC, haemoglobin A]c; HDL-C, High Density 
Lipoprotein Cholesterol; HOMA-IR, Homeostasis Assessment Model o f Insulin Resistance; 
PAV, percentage atheroma volume; STRADIVARIUS, Strategy to Reduce Atherosclerosis 
Development InVolving Administration of Rimonabant -  the Intravascular Ultrasound study; 
TAV, total atheroma volume; TG, Triglycerides; Type II DM, type 2 diabetes mellitus. 
t  Results are for rimonabant 20mg/day versus placebo (p<0.05).
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1.17 Rationale for the current studies 
L I 7.1 Rimonabant Study
As described in section 1.11, animal studies had demonstrated that the effect of 
rimonabant on appetite was transient, yet weight loss persisted, suggesting a major 
impact on energy expenditure. Further animal studies had provided evidence that the 
effect on energy expenditure was due to an increase in fatty acid oxidation. As this 
previous research was undertaken in animals, further investigation was required to 
determine whether rimonabant increased energy expenditure in humans. Previous 
research had also not determined to what extent the metabolic effects seen from 
rimonabant treatment were due to a direct effect of the drug rather than a 
consequence of weight loss.
The RIO studies described above had attempted to determine the proportion of the 
metabolic effects that arose as a direct effect of the drug and that which had occurred 
secondary to the reduction in body weight through covariate analysis but did not 
measure this directly. Additionally in these studies visceral fat, liver fat and muscle 
fat were not assessed but the weight loss reported would be expected to have resulted 
in significant effects on fat distribution as shown in other weight loss studies of 
obesity (Markovic et a l , 1998; Tiikkainen et al., 2003). The ADAGIO trial 
examining visceral adipose tissue as a secondary outcome measure was published 
three years after this study commenced.
Weight loss due to dietary intervention had been reported to reduce energy 
expenditure (Ravussin et al., 1985; De Boer et al., 1986), fasting rate of lipolysis 
(Nicklas et al., 1997) and whole body fat oxidation (Nicklas et a l , 1997; Franssila- 
Kallunki et a l , 1992). This was the opposite of the expected effect of rimonabant 
treatment. Weight loss due to dietary intervention had been shown to reduce both
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visceral fat and liver fat (Goodpaster et al., 1999; Tiikkainen et a l, 2003) resulting in 
health benefits such as improvements in insulin sensitivity. Few studies had been 
undertaken examining the effects of weight loss due to energy restriction on levels of 
intramyocellular lipid (IMCL).
In order to elucidate further the direct effects of rimonabant in obese individuals a 
trial examining the direct effect of the drug on energy expenditure, body fat 
distribution and gene expression of regulators of fatty acid metabolism in adipose 
tissue and muscle was planned. Since the aim of the study was to measure the effects 
of drug treatment on energy expenditure and not energy intake in individuals treated 
with rimonabant, energy intake was to be maintained during the study at a level 
matched to energy expenditure determined in a run-in period. To understand how 
much of the effects on body composition and metabolism were actually a direct 
effect, rather than a consequence of weight loss, a control group was to be studied 
with weight loss due to dietary intervention matched for the weight loss in the 
rimonabant treated group.
This was a collaborative study involving another PhD student (who examined the 
effects of rimonabant on fatty acid and triglyceride metabolism), colleagues at the 
Postgraduate Medical School, the Royal Surrey County Hospital and the MRC 
Clinical Sciences Centre, at Imperial College School of Medicine, Hammersmith 
Hospital.
Hypothesis for rimonabant study
When energy intake was maintained at pre treatment levels in the rimonabant group 
weight loss would be induced due to an increase in energy expenditure. The fuel for 
the increased energy expenditure would be provided by increased fat oxidation and
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an increase in gene expression of regulators of fat oxidation would be seen. 
Accompanying the weight loss, a reduction in total body fat, visceral fat, and liver 
and muscle fat would be found in the rimonabant group. In a control group 
following a dietary intervention, with matching weight loss to that in the rimonabant 
group, there would be a decrease in energy expenditure and fat oxidation and a 
reduction in visceral fat, liver fat and muscle fat similar to that of the rimonabant 
group.
Prior to commencement of the Rimonabant study a Pilot Study was to be undertaken 
to test the dietary methodology proposed for both groups in the trial.
1.17.2 Pilot Study
In the rimonabant study design a diet of commercially available modular energy 
controlled foods (Slim.Fast, Unilever) was to be used for the seventeen week 
duration of the trial to allow for energy and macronutrient control of the diet in both 
the diet and the control group. A pilot study was undertaken in order to establish 
whether the Slim.Fast products were acceptable to participants and whether they 
could be consumed at the level that was to be required for the duration of the 
rimonabant study. Additionally it was important to assess whether a tightly 
controlled level of weight loss was achievable if the energy provided by Slim.Fast 
products prescribed was lower than energy requirements and these products were the 
sole source of nutrition.
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1.17.3 Gender differences study
There was, and still is, a huge clinical need for the development of an effective 
treatment which can produce a sustainable loss in body weight in obesity. As 
described in section 1.3-1.6, there was some evidence for gender differences in body 
fat distribution and lipid metabolism and, as obesity is inextricably linked with both, 
a better understanding of gender differences in these areas could aid in the targeting 
of different anti-obesity treatments. Although previous research had investigated 
gender differences in individual elements of energy expenditure and body fat 
distribution, no one study had comprehensively researched resting energy 
expenditure, activity energy expenditure, body fat distribution and gene expression 
of key regulators of lipid and glucose metabolism in the same participants. It was 
proposed that this approach would provide a fuller understanding of the differences 
in metabolism in obese men and women.
A study was undertaken in obese men and postmenopausal women, matched for age 
and BMI, to compare differences in energy expenditure, body fat distribution and 
gene expression of regulators of fatty acid metabolism in adipose tissue and muscle.
H ypothesis fo r  gender differences study
REE would be lower in women than men. Total body fat would be higher in females 
than males and men would have greater levels of visceral fat. There would be a 
greater expression of genes involved in both the clearance of triglycerides and the 
regulation of lipolysis in adipose tissue in women. In muscle there would be a 
greater expression of genes involved in fatty acid transport into muscle in females 
than males.
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1.18 Summary of studies
As outlined above, three studies were undertaken:
1. A pilot study to establish the feasibility and acceptability of meeting energy 
requirements in target study participants through the use of a commercially 
available modular energy controlled diet (Slim.Fast, Unilever).
2. A study to determine if a) when energy intake was maintained at pre 
treatment levels, rimonabant still induced weight loss through an effect on 
energy expenditure and b) the direct effects of rimonabant on body fat 
distribution and gene expression.
3. A study to determine how gender influences energy expenditure, body fat 
distribution and gene expression in obesity.
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Chapter 2
General Methods
Chapter 2 — General Methods
This chapter outlines the general methods used in the studies. Individual 
comprehensive protocols are provided for each study in the relevant chapter along 
with any further detail or alterations to the methods described below.
2.1 Participant recruitment
Participants were recruited for the studies through recruitment emails sent to staff at 
the University of Surrey and posters displayed throughout the University campus, 
local GP surgeries and nearby hospitals. In addition recruitment letters were sent to 
previous participants of studies and adverts and articles appeared in local 
newspapers.
2.2 Screening of participants
Prior to the screening visit participants were requested to refrain from drinking 
alcohol and to fast for a twelve hour period. All participants had been provided with 
a participant information sheet and the study design was fully explained before 
written consent was obtained.
During the screening visit a number of measurements were undertaken including 
weight, height, percentage body fat, blood pressure and waist and hip 
circumferences. A physical examination was performed by a doctor and a medical 
history and any current medications recorded. Blood was taken to measure 
haemoglobin, white blood cell count, platelet count, sodium, potassium, creatinine, 
total protein, albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), 
thyroid stimulating hormone (TSH), triglyceride, total cholesterol, blood glucose and 
insulin (more details are provided in section 2.2.4 below). A self certified medical
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questionnaire (Appendix 1) was completed to assess whether participants met the 
inclusion and exclusion criteria. A Dutch Eating Behaviour Questionnaire 
(Appendix 2) was completed for the pilot and rimonabant studies to establish eating 
behaviours and potential participants for the rimonabant study were additionally 
administered with a Beck Depression Inventory-II questionnaire (Appendix 3) in 
order to assess current levels of depression. (Further details on all questionnaires 
provided below).
If a participant fulfilled all of the inclusion criteria and none of the exclusion criteria 
they were accepted into the study. A letter was then sent to the participant’s GP to 
explain the trial and notify them of their patient’s involvement.
2,2.1 Self-certified medical questionnaire
Exclusion criteria were assessed through the completion of the self-certified medical 
questionnaire (Appendix 1). Participants were excluded from the studies if they 
reported a history of diabetes, cardiovascular disease, endocrine disease, hepatic and 
renal disorders, neurological or psychological illness, eating disorders, drug or 
alcohol abuse, depression or if they had undergone a previous surgical procedure for 
weight loss. Exclusion criteria also included the prescribed use of any medications 
known to alter body weight or appetite and p-blockers, fibrates and metformin. For 
studies involving an MRI scan it was confirmed that participants did not have any 
metal implants within the body and that they were not claustrophobic.
2.2.2. Dutch Eating Behaviour Questionnaire
As the measurement of food intake was a key element of the pilot and rimonabant 
studies, restrained eaters were to be excluded and therefore potential participants’
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eating behaviour was established using the Dutch Eating Behaviour Questionnaire 
(Appendix 2). Participants were excluded from the study if they had a restrained 
eating score of >4.
The Dutch Eating Behaviour Questionnaire was developed by Van Strein et al. in 
1986 with the aim of understanding eating behaviours in obese individuals. The 
questionnaire is constructed of 33 questions. The 33 questions are divided into three 
different behavioural patterns: emotional eating (13 questions), restrained eating (10 
questions) and external eating (10 questions). The responses that may be given are 
Never, Seldom, Sometimes, Often and Very Often and for 12 of the questions there 
is a Not Relevant option.
The answers are scored as follows: Never (1), Seldom (2), Sometimes (3), Often (4),
Very Often (5) and Not relevant (0) with the exception of question 26 which is
scored in reverse. Scores are then totalled for each of the three separate categories
i.e. emotional, external and restrained eating. The final score for the category is
determined by dividing the total score calculated by the number of questions for that
category. Each time a participant chooses the Not Relevant option then the number
of questions used as a division factor is reduced by one for that category.
e.g. Emotional eating score = Total score from emotional eating questions
Number of emotional eating questions
e.g. Emotional eating score = 37_ = 2.8
13
See Appendix 2 for an annotated copy of the questionnaire.
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2,2.3 Beck Depression Inventory II
The Beck Depression Inventory II is a questionnaire consisting of 21 items for the 
self reporting of levels of depression in adults and adolescents over the age of 13 
(Beck et al. 1996). It measures the severity of depression and is a self administered 
questionnaire taking between 5-10 minutes to complete (Appendix 3).
The 21 items are (1) Sadness, (2) Pessimism, (3) Past Failure, (4) Loss of pleasure, 
(5) Guilty Feelings, (6) Punishment Feelings, (7) Self-Dislike, (8) Self-Criticalness, 
(9) Suicidal Thoughts or Wishes, (10) Crying, (11) Agitation, (12) Loss of Interest, 
(13) Indecisiveness, (14) Worthlessness, (15) Loss of Energy, (16) Changes in 
Sleeping Pattern, (17) Irritability, (18) Changes in Appetite, (19) Concentration 
Difficulty, (20) Tiredness or fatigue and (21) Loss of Interest in Sex.
Each item has four alternative responses provided. These responses are descriptive 
statements of symptoms and attitudes and are organized according to the severity of 
their content. They are rated on a four point scale from 0-3 with 0 being the score for 
the null option through to 3 for the statement with the greatest severity of content.
e.g. Loss of Interest:
0 I have not lost interest in other people or activities
1 I am less interested in other people or things than before
2 I have lost most of my interest in other people or things
3 It’s hard to get interested in anything
Participants were instructed to read each statement and to choose the one statement 
which best represented how they had been feeling over the past two weeks. The total 
score was calculated by summing the ratings for the 21 items. Levels of depression 
were then categorized as:
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Total scores Range
Minimal0-13
20-28
14-19 Mild
Moderate
29-63 Severe
If the total score for a participant was 14 or above then they were excluded from 
participating in the rimonabant study. The Beck Depression Inventory II was 
additionally used on a fortnightly basis to monitor levels of depression in participants 
undertaking the rimonabant study.
2.2.4 Screening blood samples
A 14ml blood sample was taken at the screening visit by a doctor. Venous blood was 
collected in one 2ml tube containing sodium fluoride/potassium oxalate for the 
analysis of glucose, three 4ml tubes containing serum separation clot activator for the 
biochemical profile, thyroid function test and insulin analysis, and one 4ml tube 
containing EDTA (ethylene diamine tetraacetic acid) to measure full blood count. 
The vacuettes were sent within 30 minutes to the Biochemistry Laboratory at the 
Royal Surrey County Hospital for analysis. The methods used to analyse the 
samples are shown in Table 2.1.
45
Chapter 2 -  General Methods
Table 2.1 Methods used for analysis of screening blood samples.
Analyte Method Analyser
Sodium Indirect ISE
Potassium Indirect ISE
Creatinine Alkaline Picrate Jaffe/O’Leary
Total Protein Biuret
Albumin Bromocresol Green Siemens Advia 1650
ALT IFCC Conditions
ALP IFCC (AMP buffer)
Cholesterol Cholesterol oxidase
Triglycerides Enzymic (GPO/PAP)
Glucose Hexokinase
Insulin ELISA Mercodia Iso-insulin ELISA kit
TSH Chemiluminescence Siemens Advia Centaur
ISE, ion selective electrodes; IFCC, International Federation of Clinical Chemistry; GPO- 
PAP glycerophosphate oxidase-peroxidase-4-aminophenazone; ELISA, Enzyme-linked 
immunosorbent assay.
2.2.5 Screening diet diaries
Following the screening appointment each participant potentially participating in the 
rimonabant or gender differences study was asked to complete a four day diet diary. 
For potential participants of the gender differences study this was simply to ensure 
that individuals were consuming a diet of a composition similar to the national 
average. For the rimonabant study participants this was in order to ensure that they 
were competent to comprehensively complete a diary for the duration of the study 
and to check for under-reporting. As under-reporting of dietary intake is a problem 
frequently encountered when requesting free living participants to record their food 
consumption and has the potential to affect the validity of the study results, it was 
essential to identify this. Participants classified as under-reporters, as defined by 
Goldberg et al (1991), were excluded from taking part in the rimonabant study. The 
reported energy intake from the participants four day diet diary was examined to
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identify under-reporting. Cut off limits as defined by Goldberg et a l (1991) were 
utilised to test whether the energy intake recorded by each participant was actually a 
plausible measure of the food consumed over the four day period. The basal 
metabolic rate (BMR) was estimated using the Schofield equation (1985) for each 
participant and the BMR to energy intake ratio calculated. Participants with an 
energy to BMR ratio of less than 1.06 were categorised as under-reporters.
2.3 Anthropometric measurements
2.3.1 Height
Height was only measured at the screening visit. Participants were asked to stand on 
a stadiometer with their heels together and their back straight and gentle traction was 
applied to the mastoid processes to ensure that the participant was stretched upwards 
as fully as possible. Height was measured to the nearest 0.5 centimetre.
2.3.2 Weight
The same set of calibrated electronic scales was used for the entire duration of each 
study. For the pilot study Seca 864 scales (Birmingham, United Kingdom) were 
utilised and Tanita BC-418 MA Scales (Tokyo, Japan) for the rimonabant trial and 
gender differences study. For the pilot study participants were asked to remove any 
heavy clothing and shoes before their weight was recorded. In the rimonabant trial 
and gender differences study participants were asked to remove shoes and all 
clothing with the exception of underwear and wear a provided dressing gown of 
known weight (0.8kg). The participant’s weight was recorded in kg (to the nearest 
0.1kg) and their BMI was calculated from the weight and height measurements using 
the following equation:
BMI = Weight in kg / height in metres2.
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2.3.3 Waist and hip circumference
The participant was asked to stand in an upright but relaxed position. The waist 
circumference was measured around the umbilicus and the hip circumference around 
the widest part of the participant’s body to the nearest 0.5cm. Each measurement 
was repeated three times and undertaken by the same investigator to minimise inter 
operator error.
2.3.4 Body fa t
Body composition was measured using a Tanita BC-418 MA Scales (Tokyo, Japan). 
The Tanita uses bioimpedance to calculate percentage of body fat and water. 
Participants were asked to remove socks and empty their bladder prior to standing 
upon the machine.
2.4 Diet diaries
Four day screening diet diaries were completed for all studies as described above and 
seven day diet diaries for the pilot and rimonabant study.
Participants were instructed to record all food and drinks consumed and photographs 
of varying portion sizes of common foods were provided to aid in portion size 
estimation. Participants were encouraged to provide as much information as possible 
such as brands of foods, types of food, quantities consumed and cooking methods. 
Each diet diary was examined with the participant prior to analysis to ensure that the 
information provided was as comprehensive and accurate as possible.
The dietary information recorded in the diaries was analysed using the nutritional 
analysis programme Windiets Professional 2005 (The Robert Gordon University, 
Aberdeen, Scotland). This programme contains the nutritional breakdown for an
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extensive number of generic foods available in the United Kingdom. If specific 
brands of food were provided by the participant then the nutritional composition for 
the food was obtained and manually added to the analysis programme.
Mean four day or weekly intakes of energy and macronutrient composition of the 
diet were calculated for each food diary for every participant.
2.5 Visual Analogue Scales
Visual Analogue Scales (VAS) were only completed by participants undertaking the 
pilot study. VAS were developed as a measure of subjective feelings of hunger, 
fullness etc (Blundell and Rogers, 1980). The scales consist of a 10 cm line with 
words at each end describing extreme sensations, 
e.g.
Nothing at all
How much do you think you can eat?
A lot
Participants were asked to rate their own feelings by drawing a vertical mark through 
the line indicating how they felt at that exact moment in time. The position of the 
mark on the line was then measured and converted to a score. The minimum score on 
the scale is 0 with a maximum score of 10.
The participants were given the visual analogue scales as a booklet with each scale 
printed onto a separate page so that previous ratings could not be seen. Participants 
were asked to rate their feelings on four topics: hunger, appetite, satiety and thirst.
2.6 Resting energy expenditure measurement
On the day prior to the measurement of REE, participants were requested to refrain 
from heavy exercise and from consuming alcohol. They were provided with a
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standardised low fat, low fibre meal the evening before the study and were instructed 
to fast for 12 hours before the appointment. On arrival the participants were weighed 
and then allowed to rest for 30 minutes in a quiet room. Their REE was then 
measured using a Gas Exchange Monitor (GEM), which is ventilated hood open- 
circuit indirect calorimetry (GEMNutrition Limited, Cheshire, UK). A 40 minute 
measurement of REE was taken to ensure that a steady state measurement was 
achieved. The GEM was calibrated each morning prior to the study using a zero gas 
(high purity N2) and a span gas (20% O2 , 1% CO2 , balance N2) supplied by BOC 
(Guildford, UK).
2.6.1 GEM operation
The GEM was designed for the measurement of energy expenditure and substrate 
oxidation in spontaneously breathing patients. Its performance has been assessed 
using reference gas injections and has been reported to produce a mean error of 
0.3±2% in oxygen consumption (VO2), 1.8±1% in carbon dioxide production 
(VCO2) and 14±1.5% in the respiratory quotient (RQ) (Nicholson et al. 1996).
The GEM is controlled by Windows style software on a standard computer and 
allows for real time collection and analysis of data. To measure REE participants 
were required to lie down and a clear plastic hemispherical hood was placed over 
their head. This hood was attached to the calorimeter by a length of 22mm diameter 
flexible tubing. Air was drawn through the hood by a pump and the rate of this air 
flow was controlled using a pump controller. The mean level of CO2 was provided 
every 60 seconds as it was essential that the rate of air flow was sufficient to 
maintain CO2 levels in the hood of approximately 0.5%. If the CO2 concentration 
falls too low then errors in measurement may occur and if it rises above 1% both
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respiratory effort and energy expenditure will be increased. Alterations to air flow 
were made as required.
Participants were requested to relax and attempt to breathe normally and mean values 
for VO2 and VCO2 were computed over each one minute during the 40 minute 
measurement period by the GEM. From these measurements the GEM calculated 
REE using the modified Weir formula (Nicholson et al., 1996):
REE (Kcal) = 1.44. (3.9V02 + 1.1VC02)
Where REE = Energy expenditure in kcal/24 hours 
VO2 = O2 consumption in ml/min 
VCO2 = CO2 production in ml/min
2.6.2 Resting energy expenditure measurement validation
Prior to the start of the studies a new Cardi02 Ultima (Medgraphics, Minnesota, 
USA) was purchased for the purpose of measuring REE. Extensive validation work 
was undertaken and showed that the Cardi02 Ultima was unable to provide a reliable 
measurement of REE.
Following the difficulties experienced with the CardiC>2 Ultima it was decided that 
the GEM (GEMNutrition Limited, Cheshire, UK) would be utilised to measure REE. 
To ensure that the measurements of REE provided by the GEM indirect calorimeter 
were reproducible validation work was undertaken. Three individuals had their REE 
measured for forty minutes on 5-10 occasions. Participants undertook a variable 
number of readings, but each individual had REE measurements taken on separate 
days to establish whether REE varied from day to day, as well as repeated 
measurements on the same day to examine any changes in REE with time rested. 
Both male and female and normal weight and overweight individuals were studied to
51
Chapter 2 -  General Methods
ensure that the results would be representative of future study samples. These results 
are illustrated in Figures 2.1-2.3 below.
□  Day 1 [ J D a y 2  Q D a y  3 Q D a y 4  ^ D a y 5
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Figure 2.1 Repeated REE measurements for participant V03 using GEM 
indirect calorimeter. Two forty minute measurements were taken each day for five 
days. Data expressed as means ± SEM.
As can be seen from Figure 2.1, the readings were very similar with mean REE of 
1374±17 kcal/day and a Coefficient of Variation (CV) of 4%.
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Figure 2.2 Repeated REE measurements for participant V04 using GEM 
indirect calorimeter. Three forty minute measurements were taken each day for 
three days. Data expressed as means ± SEM.
As before, the REE measurements for participant V04 were shown to be repeatable 
with a mean REE of 1811±10 kcal/day and a CV of 1.7%.
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Figure 2.3 Repeated REE measurements for participant V05 using GEM 
indirect calorimeter. One forty minute measurement was taken on day 1 and two 
forty minute measurements on day 2 and 3. Data expressed as means ± SEM.
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As shown in Figure 2.3, REE measurements were similar for participant V05 with a 
mean reading of 1342±13 kcal/day and a CV of 2.2%.
All validation measurements undertaken indicated that the GEM indirect calorimeter 
produced reproducible recordings of REE and would be suitable for use in the 
rimonabant study.
2.7 Carbohydrate, fat and protein oxidation
Carbohydrate and fat oxidation were calculated from the measurements of oxygen 
consumption and carbon dioxide production taken using the GEM. Protein oxidation 
was also calculated through the measurement of urinary nitrogen excretion. The 
following equations (Frayn, 1983) were used to calculate substrate oxidation:
Carbohydate (g/min) = 4.55 VC02 - 3.21 V 02 - 2.87n 
Fat (g/min) = 1.67 V 02 - 1.67 VC02 - 1.92n 
Protein (g/min) = 6.25n
Where VC02 = C 02 production in litres per minute 
V 02 = 0 2 consumption in litres per minute 
n = Urinary nitrogen in grams per minute
To establish urinary nitrogen excretion, participants were requested to collect a 24 
hour urine collection. The collection commenced in the morning. Upon waking, 
participants were requested to empty their bladder as usual but not to retain the 
specimen. Participants were instructed to record the time and the collection started 
from this point. For the next 24 hours participants urinated into a plastic jug and then 
transferred their urine into the 24 hour urine collection container. The importance of
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retaining every sample was highlighted and it was explained that one missed sample 
would invalidate the results. The urine collection finished exactly 24 hours after it 
commenced and to ensure the collection was complete participants were asked to 
empty their bladder, even if they did not have the urge to urinate, five minutes prior 
to the end time.
Five grams of boric acid powder was added to the urine collection containers to 
prevent nitrogen loss through evaporation. The total volume of urine was measured 
and nitrogen concentration was measured by colleagues at the University of 
Newcastle using a LECO FP-428 (LECO Corporation, St. Joseph, MI, USA) 
nitrogen analyser.
2.8 Activity energy expenditure measurement
Activity energy expenditure (AEE) was measured in both the rimonabant trial and 
gender differences study with an Actiheart monitor.
2.8.1 The Actiheart Monitor
The Actiheart monitor combines measurements of acceleration with heart rate data to 
accurately estimate activity energy expenditure. The Actiheart computer software 
provides an estimate of daily total energy expenditure based on a combination of 
measured (or estimated) REE, activity energy expenditure and dietary induced 
thermogenesis (the software calculates this as 10% of total daily energy expenditure). 
Validation work undertaken by Brage et al. (2005) confirmed that the Actiheart is 
able to accurately record activity energy expenditure during walking and running. 
The reported CV was 0.5% for movement and 0.03% for heart rate. This study, 
however, did not assess validity during other activities or free living.
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As NEAT is variable between individuals (Levine, 2005), and contributes to total 
energy expenditure, a small validation study was undertaken to establish if the 
actiheart monitor could identify activities such as fidgeting and standing. Three 
individuals were fitted with a monitor and AEE recorded for a five minute period for 
each of the following activities: finger tapping, foot tapping, leg shaking, pen 
tapping, typing and standing. No movement was allowed with the exception of the 
activity being tested. No AEE was recorded for any of the activities indicating that 
the Actiheart Monitor was unable to identify elements of NEAT.
2.8.2 Activity energy expenditure measurement
The Actiheart monitor was worn on two standard electrocardiogram (ECG) pads 
(Pulse Medical Limited, Woking, UK) placed on the upper chest of the participant. 
Prior to application of the pads the top layer of the skin was removed using Cardio- 
Prep Single use abrasive pads (Pulse Medical Limited, Woking, UK) to ensure that 
the R wave signal of the heart could be captured by the device. A five minute signal 
test was undertaken to ensure that the level of the R wave signal being picked up by 
the Actiheart was adequate. The monitors were then calibrated before use by each 
participant using an 8 minute linear ramped step test. The step test commenced at a 
speed of 15 steps per minute increasing to 33 steps per minute at the end of the 8 
minute period. Once calibrated, the participants were asked to wear the monitor 
continuously for a five day period. To try and ensure measurements were an 
accurate representation of weekly activity participants were asked to wear the 
monitor during both week and weekend days. The Actiheart data was downloaded at 
the end of each five day period and AEE calculated using a branched chain equation 
model (Brage et al. 2005). The model allows the intensity and energy expenditure of
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physical activity to be calculated from the activity data or heart rate data alone or 
from both.
2.9 Body fat distribution
Measurements of body fat, intrahepatocellular lipid (IHCL) and intramyocellular 
lipid (IMCL) were undertaken by colleagues at the MRC (Medical Research 
Council) Clinical Sciences Centre, Hammersmith Hospital. Following a ten hour fast 
participants were asked to attend the unit where three procedures were undertaken: a 
15 minute magnetic resonance imaging (MRI) scan of the total body fat, a 15 minute 
magnetic resonance spectroscopy (MRS) examination of the liver and a 15 minute 
MRS examination of the calf.
Whole body MR imaging of body fat content, IHCL and IMCL levels were acquired 
on an Intera 1.5T Achieva multinuclear system (Philips Medical Systems, Best, 
Holland) as previously reported (Thomas et al. 2005).
2.9.1 Total body fa t measurement
Total and regional adipose tissue volumes were measured after imaging data was 
analysed using the SliceOmatic image analysis program (Tomovision, Montreal, 
Quebec, Canada). Participants were scanned from their fingertips to their toes by 
acquiring 10 mm thick transverse images with 30mm gaps between slices in their 
arms and legs and 10 mm gaps between slices in their abdomen. All images were 
acquired as single slices at the isocentre of the magnet to avoid image distortion.
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2.9.2 Intrahepatocellular lipid and intramyocellular lipid measurement
Both intrahepatocellular lipid and intramyocellular lipid were measured by 1H- 
magnetic resonance spectroscopy. Intrahepatocellular lipid spectra were acquired 
from the right lobe of the liver and intramyocellular lipid spectra from the tibialis 
muscle group in the left lower leg. All spectra were analysed in the time domain 
using the AMARES (advanced method for accurate, robust and efficient spectral 
fitting) algorithm included in the MRUI (Magnetic Resonance User Interface) 
software package (Naressi et al. 2001). IMCL was expressed as a ratio to the muscle 
creatine signal. IHCL was expressed as a ratio to liver water content.
2.10 Muscle and adipose tissue biopsies
Muscle and adipose tissue biopsies were taken in order that key regulators of lipid 
metabolism could be measured by real-time polymerase chain reaction (rtPCR). In 
the adipose tissue samples CD36, adiponectin, adiponectin receptor 1, adiponectin 
receptor 2, UCP2, lipoprotein lipase, hormone sensitive lipase, PPAR gamma and 
PPAR delta were measured and in muscle CD36, adiponectin receptor 1, adiponectin 
receptor 2, UCP2, UCP3 (Uncoupling protein 3), lipoprotein lipase, CPT1 (Carnitine 
palmitoyltransferase 1), CPT2 (Carnitine palmitoyltransferase 2), ACOX1, PPAR 
delta and PPAR alpha. A summary of the key functions of these genes is shown in 
Table 2.2.
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Table 2.2 Key functions of genes studied.
i
Tissue in which 1
Gene gene expression i 
measured \
Function
Binds long-chain fatty acids and facilitates their 
transport into cells, influencing muscle lipid 
utilization, adipose energy storage, and gut fat 
absorption
Has insulin-sensitizing effects in tissues involved 
in glucose and lipid metabolism
Involved in the oxidation of fatty acids and 
glucose.
Involved in mediating energy expenditure and in 
fatty acid metabolism
Hydrolysis of triglycerides from chylomicrons and 
VLDLs
Degradation of triglycerides to diacylglycerol and 
free fatty acids
Mediates transport of long chain fatty acids
Mediates transport of long chain fatty acids
Controls catabolism of fatty acids 
Induces fat cell differentiation
Increases fat oxidation in muscle and lipolysis in 
adipose tissue
Involved in fatty acid oxidation
CD36, Cluster of Differentiation 36; UCP2, Uncoupling protein 2; UCP3, Uncoupling
protein 3; CPT1, Carnitine palmitoyltransferase 1; CPT2, Carnitine palmitoyltransferase 2;
PPARa, Peroxisome proliferator-activated receptor alpha; PPARy, Peroxisome proliferator- 
activated receptor gamma; PPAR8 Peroxisome proliferator-activated receptor delta, 
ACOX1, Acyl CoA Oxidase 1.
2.10.1 B iopsy procedu re
Whilst participants were fasted, two separate biopsies were taken under sterile 
conditions. An adipose tissue sample from the lower back and a muscle tissue 
sample from the vastus lateralis muscle. Both sites were cleaned with betadine 
solution and local anaesthetic (2% lidocaine hydrochloride) injected. Approximately
CD36
Adiponectin Adipose
UCP2
UCP3
Muscle and 
adipose
Muscle
Lipoprotein Muscle and
Lipase adipose
Hormone
sensitive Adipose
lipase
CPT1 Muscle
CPT2 Muscle
PPARa Muscle
PPARy Adipose
PPAR5 Muscle and adipose
ACOX1 Muscle
Muscle and 
adipose
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lOOmg of adipose tissue was taken using a standard biopsy pack (Synergy 
Healthcare, Derby, UK) and an Bergstrom muscle biopsy needle (Hillside Medical, 
Newark, Nottinghamshire) was utilized to obtain lOOmg of muscle tissue. A stitch 
was placed in the incision on the lower back and steri strips applied to the thigh 
incision and both sites were covered with a sterile dressing. The adipose and muscle 
tissue samples were cleaned of any visible blood and were snap frozen in liquid 
nitrogen and then stored at -80°C before batch analysis of gene expression was 
undertaken.
2.11 Adipose and muscle gene expression
2.11.1 Tissue processing
The frozen muscle and adipose tissue biopsies were hand-homogenized using a 
liquid nitrogen cooled pestle and mortar. Once samples had been ground to a very 
fine powder they were transferred to a sterile cooled tube and weighed to determine 
the amount of tissue acquired.
2.11.2 RNA extraction
The SV Total RNA Isolation System (Promega, USA) was used to isolate the RNA 
from both the muscle and adipose tissue. Levels of RNA was analysed using the 
Nanodrop spectrophotometer (Thermo Scientific, Delaware, USA). 1.2 pi of each 
sample were loaded on the Nanodrop and only samples with an mRNA level of 
lOmg/pl or greater were reverse transcribed. Any samples found to have an mRNA 
level of between 5 and 1 Omg/pl were concentrated to double the amount of mRNA 
available.
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2.11.3 Reverse transcription and cDNA Synthesis
First strand complementary DNA (cDNA) was synthesized using the Reverse 
Transcription System (Promega USA). For the reverse transcription lOpl of total 
RNA extracted from the fat and muscle tissue was reverse transcribed using both 
01igo(dT)i5 and random primers.
2.11.4 Primers fo r  rtPCR
PCR amplification of the first-strand cDNA was undertaken using the primers 
(Eurogentec, Seraing, Belgium) shown in Table 2.3.
Table 2.3 Primers used for rtPCR
Gene Forward Primer Sequence Reverse Prim er Sequence
CD36 tgcaaaacggctgcaggtca gcaacaaacatcaccacaccaaca
Adiponectin aagggagacatcggtgaaaccgga aagcgaatgggcatgttgggga
Adiponectin receptor 1 tgccatcattgtggcgcagt agcagcataaaggccagctcca
Adiponectin receptor 2 tgtgctgggcattgcagccatt agaggctggccatcagcatcaa
UCP2 cctgcagcgccaaatgagcttt tcgggcaatggtcttgtaggca
UCP3 tcactgacaacttcccctgcca acgttccaggatcccaaacgca
Lipoprotein Lipase aaaacttgtggccgccctgt acttcctgcaatgccagcagca
Hormone sensitive 
lipase tgtcaggcgtttttgccggtgt aagaagatgctgcggcggtt
CPT1B ttccaaaacagtgccaggcggt tgcagcgcgatctgcacaaa
CPT2 agcactgccgcattcaagca tggcccattgctgcttctttggt
PPARa acggacacgctttcaccagctt agctgcggtcgcacttgtcata
PPARy accgcccaggtttgctgaatgt agctgcacgtgttccgtgacaa
PPAR5 actgggcatgtcacacaacgct tgctgcgggccttctttttggt
ACOX1 taaggcgtgcaccattgcca agggcatgaagctcaggcagtt
GAPDH atggggaaggtgaaggtcgga gagatgatgacccttttggc
CD36, Cluster o f Differentiation 36; UCP2, Uncoupling protein 2; UCP3, Uncoupling 
protein 3; CPT1, Carnitine palmitoyltransferase 1; CPT2, Carnitine palmitoyltransferase 2; 
GAPDH, Glyceraldehyde-3-phosphate-dehydrogenase PPARa, Peroxisome proliferator- 
activated receptor alpha; PPARy, Peroxisome proliferator-activated receptor gamma; PPAR5 
Peroxisome proliferator-activated receptor delta, ACOX1, Acyl CoA Oxidase 1.
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2.11.5 PCR Amplification
PCR amplification of the first-strand cDNA was undertaken using a Stratagene 
Mx3005P™ System as per the manufacturer’s instructions. The rtPCR was performed 
in a final volume of 50pl containing 2pi of cDNA, 25pi of GoTaq® qPCR Master 
Mix, 21 pi of nuclease-free water and lp l each of the specific forward and reverse 
primers. The temperature profile used for the PCR amplification was: a denaturing 
step at 95°C for 10 minutes and 40 cycles consisting of 95°C for 30 seconds, 62°C for 
1 minute and 72°C for 30 seconds. All samples were measured in triplicate and the 
mean relative mRNA expression levels results normalized against expression of the 
housekeeping gene GAPDH.
2.12 Statistical Analysis
All statistical analysis was carried out using SPSS Version 17.0 (SPSS Inc., Chicago, 
USA). The results are presented as means ± SEM unless otherwise stated. Statistical 
significance was assumed at P<0.05. All variables were checked for normality using 
the Kolmogorov-Smimov test. Within group changes were analysed by paired T-test 
and Wilcoxon Signed Ranks Test as appropriate and differences between groups by 
Independent Sample T-tests or Mann-Whitney U Test. If outliers were identified 
using SPSS, then the data was reanalysed removing any outliers and this is clearly 
indicated in the relevant results section.
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Chapter 3
Pilot study to establish the feasibility 
and acceptability of meeting energy 
requirements in target participants 
using a modular energy controlled diet.
Chapter 3 — Pilot Study
3.1 Introduction
3.1.1 Background
A study was planned to examine the effect of rimonabant on energy expenditure, 
gene expression and body fat distribution. The rimonabant study aimed to examine 
the direct effects of the drug i.e. independent of weight loss, and therefore a group of 
participants taking the rimonabant were to be compared to a group of participants 
subject to a dietary intervention. The weight loss in the dietary intervention group 
was to match that found in the rimonabant group. Based on previous studies, it was 
estimated that rimonabant treatment would lead to a 0.5kg weight loss per week. As 
the aim of the rimonabant study was to measure the effects of treatment on energy 
expenditure and not energy intake in the rimonabant group, it was essential for 
energy intake to be maintained during the study. The energy intake was to be 
maintained at a level matching the participant’s energy expenditure determined in a 
run-in period. In the dietary intervention group a very specific level of weight loss 
would be required.
The original rimonabant project was designed prior to commencement of this PhD 
and it had been proposed that a diet of commercially available modular energy 
controlled foods (Slim.Fast, Unilever) be used for the seventeen week duration of the 
trial to allow for energy and macronutrient control of the diet in both the rimonabant 
and dietary treated groups. Due to the Author’s concerns regarding this dietary 
methodology, a pilot study was undertaken in order to ascertain the acceptability and 
feasibility of adopting such an approach.
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3.1.2 The Modular Diet
Slim.Fast products had been selected for the study as they allowed for energy and 
macronutrient control of the diet and were available on the market for the public to 
purchase. The products were to be used for both the treatment group and the diet 
group in the rimonabant study. The treatment group was to be given an energy 
prescription to meet their expenditure and was, therefore, to be prescribed an 
appropriate number of Slim.Fast products to consume daily to meet their energy 
requirements. In the control group weight loss was required and therefore the energy 
prescription was to be lower than energy requirements. This weight loss would have 
to match that achieved in the rimonabant group so the rate of weight loss would need 
to be able to be tightly controlled.
Slim.Fast food products had previously been shown to be effective when used as a 
weight loss tool (Morgan et al., 2008) but are marketed as a low fat meal 
replacement not as a sole source of nutrition. The advice provided with Slim.Fast 
products is that one or two meals a day should be replaced with either a Slim.Fast 
shake, smoothie, soup or meal bar. Previous research had shown that when used as a 
twice daily meal replacement, Slim.Fast products resulted in a mean weight loss of 
3.7 ± 3.5kg over a two month period (Truby et ah, 2006). In order to meet the 
participant’s daily energy requirements (even the reduced requirements in the diet 
group) they would need to consume a much greater number of products each day 
than is recommended by the manufacturer. Although vitamin/mineral fortified liquid 
meals have been used as a sole nutrient source before, this has been in cases where 
the diet provided has been very low in calories and rapid weight loss has been 
urgently required (Heymsfield et ah 2003). Studies have not been undertaken in 
which Slim.Fast products replace all meals and snacks.
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3.1.3 Study rationale
A pilot study was required in order to establish whether the Slim.Fast products were 
acceptable to participants and whether they could be consumed at the level that was 
to be required for the 17 week duration of the rimonabant study. Additionally it was 
important to assess whether a tightly controlled level of weight loss was achievable if 
the energy provided by Slim.Fast products prescribed was lower than energy 
requirements and these products were the sole source of nutrition.
3.2 Aim
To establish whether a diet of Slim.Fast products was feasible and acceptable to the 
target study group.
3.3 Objectives
■ To investigate whether the Slim.Fast products could be consumed by the 
participants at the level that would be required for the 17 week duration of the 
study.
■ To assess whether a 0.5kg weight loss per week was achievable, if the energy 
provided by Slim.Fast products prescribed was 500 kcal lower per day than 
energy requirements.
3.4 Methodology
3.4.1 Participants
Four overweight female participants, closely matched to the target study group, were 
recruited for the pilot study through a recruitment email sent to all staff at the
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University of Surrey and posters displayed throughout the University campus. The 
participants mean age was 46 ± 4.8 years and their mean BMI was 31.5 ± 2.1 kg/m . 
The inclusion and exclusion criteria for the study can be seen in Table 3.1. With the 
exception of restrained eating, the exclusion criteria were assessed through the 
completion of a self-certified medical questionnaire (Appendix 1). As the 
measurement of food intake was a key objective of the study, restrained eaters were 
identified using the Dutch Eating Behaviour Questionnaire (see chapter two, section 
2 .2 .2).
Table 3.1 Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
30-65 years History of diabetes or endocrine disease
BMI of 28 -35 History of cardiovascular disease
Weight stable for a 3 month History of hepatic and renal disorders
period
History of neurological or psychological 
illness 
History of depression
Previous surgical procedure for weight loss 
Taking medication that may affect weight or 
appetite 
Food allergies or intolerances 
Restrained eaters
All participants were provided with a participant information sheet and the study 
design was explained before written consent was obtained. Ethical approval for the 
study protocol was obtained from the University of Surrey Ethics Committee 
(EC/2007/14/SBMS). Participants were not paid for their participation.
3.4.2 Study Design
The pilot study was undertaken over a five week period. In the first week REE and 
activity energy expenditure were measured. In weeks two and three weight
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maintenance was the aim. Participants were given an energy prescription to match 
their estimated total energy expenditure and prescribed an appropriate number of 
Slim.Fast products to consume daily to meet their energy requirements. In weeks 
four and five weight loss was desired and therefore participants were prescribed a 
reduced number of Slim.Fast products providing an energy intake lower than energy 
requirements.
3.4.3 Nutritional information for Slim.Fast products
A range of products was prescribed including shakes, smoothies, soups and snack 
bars. Each Slim.Fast product had a precise balance of fat, protein and carbohydrate 
with essential vitamins and minerals and the diets prescribed to the participants 
comprised of 55% carbohydrate, 21% fat and 24% protein. A full breakdown of the 
nutritional composition of the products utilised in the study is shown in Appendix 4.
3.4.4 Protocol
All participants were asked to attend the Clinical Investigation Unit (CIU) at the 
University of Surrey on four occasions (Figure 3.1). Details of the four visits are 
provided below.
WEEK 1 WEEKS 2-3 WEEKS 4-5
Initial
Screening
Energy expenditure 
calculation
Actiheart M onitor
Visit 1 Visit 2
Weight Maintenance 
1st dietary intervention
Diet diaries
Weight Loss
2nd dietary intervention
Diet diaries
Visit 3 Visit 4
Figure 3.1 Outline of study.
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3.4.4.1 Visit 1: Energy expenditure calculation
Resting energy expenditure measurement
The participants were weighed and their height was taken (chapter two, section 2.6). 
Their REE was measured using ventilated hood open-circuit indirect calorimetry 
(GEM, GEMNutrition Limited). See chapter two, section 2.6 for further details.
Activity energy expenditure measurement
In order to then estimate the amount of energy expended in everyday activities each 
participant was fitted with an Actiheart monitor (chapter two, section 2.8). 
Participants were asked to wear the monitor for a five day period. An estimation of 
dietary induced thermogenesis (10% of total energy expenditure) was combined with 
the results from the indirect calorimetry and the Actiheart monitor to estimate total 
energy expenditure.
3.4.4.2 Visit 2: Dietary intervention -  Weight maintenance
On the second visit each participant was weighed. The total energy expenditure 
calculated for each participant was then used to provide a personal dietary 
prescription.
Dietary prescription
An example dietary prescription may be seen in Appendix 5. The aim was to 
provide a daily energy intake for each participant equal to their energy requirement. 
The products were supplied from the Slim.Fast range and had been donated by 
Unilever. A range of products was prescribed including shakes, smoothies, soups 
and snack bars. Participants were asked to consume a variety of the different
69
Chapter 3 -  Pilot Study
products so that acceptability of different foods could be assessed. In order to 
enhance compliance, each participant was provided with a list of all Slim.Fast 
products available (Appendix 6) and asked to indicate if any were unacceptable to 
them. Participants were asked to follow this eating plan for a period of two weeks 
and to refrain from drinking alcohol for the duration of the pilot study.
Assessment o f  compliance and side effects
In order to aid assessment of suitability of Slim.Fast products for use in a longer 
study, participants were asked to complete a 24-hour diet diary on every day of the 
two week period. They were asked to write down all of the foods and drinks that 
they consumed during each day. They were asked to note which Slim.Fast products 
they had eaten, and when, and to note occasions on which foods or drinks were only 
partially eaten/drunk or omitted and reasons for this. Space was available in the 
diary for participants to provide comments on any adverse side effects that they 
experienced.
Assessment o f  satiety
On the final day of week two of the study participants were asked to complete a 
Visual Analogue Scale six times daily. These were utilised as an additional means of 
ascertaining levels of satiety, appetite and thirst as these may potentially impact on 
compliance. They were undertaken at this time point as participants would have had 
several days to adjust to their new dietary regimen. The minimum score on the scale 
was 0 with a maximum score of 10. A mean visual analogue score for all 
participants was calculated for four questions at six different time points during the 
day. The four questions asked were:
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How hungry do you feel?
How much do you think you can eat?
How full do you feel?
How thirsty do you feel?
Participants were asked to rate their feelings on these topics pre and post breakfast, 
lunch and dinner as described in chapter two, section 2.5.
3.4.4.3 Visit 3: Dietary intervention -  Weight loss
Following the two week period on the energy controlled diet, participants were 
invited to the CIU for the third visit. All participants were weighed to assess whether 
they had remained weight stable following the eating plan. Twenty four hour diet 
diaries and Visual Analogue Scales were collected. Participants were then provided 
with their second personal dietary prescription. In this stage of the study weight loss 
was desired and therefore participants were prescribed a reduced number of 
Slim.Fast products to provide an energy intake lower than their energy requirements. 
The aim was for a weight loss of approximately 0.5 kg per week and, therefore, the 
dietary prescription was reduced by about 500 kcal per day. As before, this energy 
controlled diet was to be followed for two weeks and participants were asked to keep 
a 24 hour diet diary daily.
3.4.4.4 Visit 4
On completion of the two week dietary intervention, participants attended the CIU 
for a fourth visit. On this final visit participants were weighed. Completed diet 
diaries were requested and participants were asked a series of questions to try and 
obtain as much qualitative feedback as possible regarding the pilot study.
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Participants were asked questions regarding compliance to the diet, adverse side 
effects and ability to tolerate the products (see Appendix 7 for End of Pilot 
Questionnaire).
3.5 Statistical Analysis
This was a feasibility study and one of the main aims was to understand participant 
compliance. The data obtained was mainly qualitative. For the element of the pilot 
study that assessed potential weight loss, simple comparison statistics were used.
3.6 Results
3.6.1 Total energy expenditure
Table 3.2 shows the baseline REE measurements, activity energy expenditure 
measurements and estimates of dietary induced thermogenesis and total energy 
expenditure (TEE) for the four participants.
Table 3.2 Mean total energy expenditure results during week one for all 
participants. Data expressed as means ± SEM.
Participant Age
(years)
Weight
(kg)
REE
(kcal/day)
AEE
(kcal/day)
DIT
(kcal/day)
TEE
(kcal/day)
P01 49 91.6 1116 ± 5 712 ± 178 203 2031
P02 54 95.0 1001 ± 6 290 * 143 1434
P03 32 76.0 1053 ± 8 295 ± 18 149 1497
P04 49 89.6 1310 ± 8 680 ±61 221 2211
Results were calculated from a combination of resting energy expenditure (REE) readings, 
estimated dietary induced thermogenesis (DIT) and activity energy expenditure (AEE) 
measured by the Actiheart Monitor.
(* No SEM available due to technical problems with Actiheart monitor resulting in one days 
recording only).
As can be seen in Table 3.2, the AEE for participants P02 and P03 was very low with 
a mean reading of 290-295kcal/day. These low levels of physical activity were
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confirmed with the participants. The AEE recordings for P01 and P04 were higher 
resulting in higher estimates of total energy expenditure. These estimates of total 
energy expenditure were utilised to provide the personal dietary prescriptions for the 
participants.
3.6.2 Dietary analysis
Participants kept a record of all Slim.Fast products consumed and the mean daily 
intake of energy was calculated. A comparison of the prescribed energy intake and 
the mean daily intake of energy reported during both the two week weight 
maintenance intervention and the two week weight loss intervention is shown in 
Figures 3.2 and 3.3.
Prescribed □  Consumed
2500
*  1500
OX)
r  1000
P01 P02 P03 P04
Participant
Figure 3.2 Mean daily intake of energy for four participants during the maintenance 
intervention in comparison to prescribed daily energy intake.
Data expressed as means ± SEM.
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■  Prescribed □  Consumed
P01 P02 P03
Participant
Figure 3.3 Mean daily intake of energy for three participants during the weight loss 
intervention in comparison to prescribed daily energy intake.
Data expressed as means ± SEM.
As can be seen in Figure 3.2, all participants reported a mean daily energy intake 
lower than that prescribed in the weight maintenance intervention. During the 
weight loss intervention the daily prescribed energy intake was reduced by 500 kcal 
yet, as shown in Figure 3.3, participants P02 and P03 continued to report a mean 
daily energy intake lower than that prescribed. One participant had to withdraw from 
the trial during the weight loss intervention stage due to diagnosis of an unexpected 
health problem (unrelated to the study).
3.6.3 Analysis o f  weight change
All participants were weighed at the beginning and the end of the two week weight 
maintenance intervention period. The weight measurements are shown in Figure 3.4.
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Figure 3.4 Weight measurements for four participants at the beginning and the end of a 
two week weight maintenance intervention period.
As shown in Figure 3.4 all participants had a reduction in weight over the two week 
period with a mean weight loss of 1.6 ± 0.4kg.
Participants were subsequently weighed before and after the two week weight loss 
intervention and these results are shown in Figure 3.5.
-♦ -P 0 1  —•— P02 P03
WD-X
JCM
'3
£
100 -I
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90 
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Visit
Figure 3.5 Weight measurements for three participants at the beginning and the end of 
a two week weight loss intervention period.
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As shown in Figure 3.5, all participants lost weight during the weight loss 
intervention period with a mean loss of 2.3 ± 0.1kg.
3.6.4 Visual Analogue Scores
The mean VAS scores for participants for the four separate questions How hungry do 
you feel? How much do you think you can eat? How full do you feel? and How thirsty 
do you feel? were calculated and these are shown in Figures 3.6-3.9 below.
10
8
6
4
2
0
Pre breakfast Post breakfast Pre lunch Post lunch Pre dinner Post dinner
Time
Figure 3.6 Mean VAS scores ± SEM for all participants pre and post meal for the 
question ‘How hungry do you fe e l? \
10
8
6
4
2
0
Pre breakfast Post breakfast Pre lunch Post lunch Pre dinner Post dinner
Time
Figure 3.7 Mean VAS scores ± SEM for all participants pre and post meal for the 
question ‘How much do you think you can eat?\
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Figure 3.8 Mean VAS scores ± SEM for all participants pre and post meal for the 
question 'How fu ll do you fee l? ’.
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Figure 3.9 Mean VAS scores ± SEM for all participants pre and post meal for the 
question 'H ow thirsty do yo u  fe e l? ’.
The VAS scores indicated that participants were moderately full all day with the 
highest satiety scores being recorded following the evening meal. Similar hunger 
scores were recorded prior to the three meals of the day with a subsequent reduction 
in hunger following eating. Participants reported moderate thirst throughout the day.
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3.6.5 Questionnaire results
All participants reported that they would feel unable to consume a diet of Slim.Fast 
products for a 17 week period. One participant suggested that they might have been 
able to comply with the diet for 17 weeks if more savoury products had been 
provided.
Changes in bowel habits reported included more frequent passing of stools and mild 
diarrhoea, although one participant reported no changes. Side effects experienced 
whilst following the diet included flatulence, occasional bloating and nausea.
3.7 Discussion
During the initial weight maintenance two weeks of the trial every participant lost 
weight, which was probably due to reduced energy intake, since activity energy 
expenditure was unchanged. All participants reported a mean daily energy intake 
lower than that prescribed in the weight maintenance period and this would account 
for the weight loss recorded. Participants reported that it was difficult to consume 
the number of Slim.Fast products that they were prescribed for each day and 
therefore could not meet their energy requirements. Although underreporting is a 
well documented phenomenon when using diet diaries (Goldberg et al., 1991) this 
does not appear to have been an issue in this study as reported levels of intake 
corresponded with weight lost.
The estimated energy requirements for participants P02 and P03 were low if 
compared to REE calculated using the Schofield equation (1985) and this may have 
been due to measurement error. These two participants also had very low recordings 
of AEE but reported that they incorporated very little activity into their usual day e.g. 
they travelled to work by car, had sedentary jobs and relaxed on a sofa every
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evening. Despite the apparently low energy requirements for P02 and P03, and thus 
a lower energy prescription, neither participant was able to consume all of the 
products prescribed. It should be taken into consideration that the participants of the 
pilot study were overweight and even though the study objectives were explained to 
them may have felt motivated or wished to lose weight. Even with low 
measurements of TEE in two individuals, all participants failed to meet their 
estimated total energy expenditure requirements in the weight maintenance phase 
utilising the Slim.Fast products and no participant was able to consume all of the 
products prescribed.
In the second two weeks where the aim was for a weight loss of approximately 0.5 
kg per week the average weight loss was over four times greater. This weight loss 
greatly exceeded the required loss of 1kg over the two week period. The daily 
prescribed energy intake had been reduced by 500 kcal, therefore requiring fewer 
products to be consumed each day, however participants P02 and P03 continued to 
report a mean daily energy intake lower than prescribed. In comparison to the mean 
daily energy intake over the first two weeks a further mean daily reduction of 
approximately 300kcal was reported during this two week period and this would 
account for the greater weight loss. It should be noted that previous research has 
identified that the fastest rate of weight loss in individuals undertaking a meal 
replacement weight loss intervention is during the initial two months (Truby et al., 
2006).
All participants reported that they would feel unable to consume a diet of Slim.Fast 
products for a 17 week period. This supports findings by Dasinger et a l (2005), 
when examining a range of popular diets, that the more extreme the eating plan the 
poorer the adherence. Reasons cited for not being able to follow a diet using
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Slim.Fast foods for 17 weeks included that it was hard to eat out socially whilst 
consuming this diet and it was difficult to adhere to when cooking for a family. The 
Slim.Fast products were additionally reported as being either too sweet or tasteless. 
All participants reported introducing additional foods during the four week period of 
the trial. The reasons provided for this were the desire to eat ‘normal’ foods at social 
occasions and a need to eat ‘proper’ foods after a few days. These findings are in 
agreement with previous research in which lifestyle barriers to successful dieting had 
been reported as family commitments, social life and work (Herriot et al., 2008). It 
is unsurprising that participants wished to eat ‘normal’ foods as Slim.Fast products 
are designed to replace one or two meals a day and are not used as a sole source of 
nutrition. In a previous study, 14.5% of participants following the Slim.Fast diet 
withdrew from the trial with the reason provided that they could not tolerate the diet 
(Truby et al., 2006). Further detail was not provided as to whether this was due to 
practical reasons, taste or adverse side effects.
In the end of study questionnaire, three participants reported that the Slim.Fast 
products were satiating, particularly the shakes and that usual feelings of hunger 
disappeared. One participant, however, felt very hungry and that the foods ‘gave no 
satisfaction’. This finding corresponds with disadvantages of ‘feeling hungry’ and 
finding the products ‘boring’ cited by a group of participants undertaking a study 
using the Slim.Fast meal replacements twice a day (Herriot et al., 2008). Differing 
feelings of satiety may have been related to the type of product consumed, as 
previous work by Tieken et a l (2007) has shown that solid meal replacement 
products are more satiating than liquid meal replacement products. All participants 
reported increased thirst which was reflected in the VAS scores. Although there is 
anecdotal evidence that meal replacement products may increase thirst levels, few
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studies have investigated this potential side effect. A study examining the hunger 
changes in obese participants following ingestion of a meal replacement bar did also 
measure thirst, and found it to be below baseline levels for three hours following 
consumption (Rothacker and Watemberg, 2004). However the participants were 
instructed to take their meal replacement bar with a glass of water which may have 
aided in the reduction of thirst sensation. Additionally, participants in this trial were 
taking large quantities of replacement products so direct comparisons are invalid. It 
is possible that, as participants in the study were having several shakes each day, 
they reduced their intake of additional or alternative fluids such as water. Few 
additional drinks were recorded on the diet diaries.
The side effects reported during the study of flatulence, bloating and nausea were 
cited as a further reason for not being able to comply with the diet for a seventeen 
week period. It is possible that these effects may have been due to the high fibre 
content of the diet as the prescribed diets had 35-40g fibre per day. This is likely to 
be higher than the participants’ usual fibre intake as a recent investigation reported 
average fibre intake in the UK adult population to be 21.2g per day (Cust et a l , 
2009). Higher intakes of fibre can be tolerated by most individuals but fibre intake 
needs to be gradually increased over time, however this was not the situation with 
this study in which fibre intake was likely to have increased abruptly. The major 
side effect of a high fibre diet is increased flatulence but this does decrease as 
individuals adapt to a high fibre diet (Anderson et al., 1994).
Slim.Fast products are designed as a meal replacement and have not been used in 
previous studies as a sole source of nutrition. The major issues regarding the 
products as a sole nutrient source are palatability and the safety of providing 
participants with large doses of micronutrients. As the Slim.Fast products were
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designed as meal replacements each shake/smoothie/meal bar provides between 20- 
59% of the recommended daily amount (RDA) for each micronutrient. Therefore if 
two products are consumed per day as advised by Slim.Fast, individuals may meet 
their RDA for each micronutrient. In the pilot study, however, participants were 
consuming up to eight products each day and the RDAs for each micronutrient were 
being greatly exceeded. Water-soluble vitamins are excreted from the body but there 
is the potential for the fat-soluble vitamins to be stored. As the rimonabant study 
was only to be of 17 weeks duration this would have been unlikely to cause health 
problems for the participants but it was an additional consideration.
From the results of the pilot study it was established that the Slim.Fast products were 
not acceptable to participants and that they were not able to be consumed at the level 
that was to be required for the 17 week duration of the rimonabant study. It was 
found that weight loss was achievable if the energy provided by Slim.Fast products 
prescribed was lower than energy requirements, as would be required in the diet 
group of the rimonabant study, but this weight loss may have been greater than 
necessary and could not be tightly controlled. On the basis of these findings it was 
decided that utilising foods normally consumed by participants would be more 
effective at meeting energy requirements in the rimonabant clinical trial. This 
approach was considered appropriate for the group receiving rimonabant, in which 
energy intake would be required to meet energy requirements, and would also allow 
for prescription of a reduced energy intake in the diet group. Macronutrient 
composition of the diet could still be monitored through diet diary analysis and 
compliance to the diet was likely to be greater than was seen with Slim.Fast 
products.
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Chapter 4
The effect of rimonabant 
on energy expenditure, 
gene expression and body 
fat distribution
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4.1 Introduction/Background
In light of the ever increasing worldwide problem of obesity, new approaches for the 
prevention and treatment of obesity need to be identified. Weight loss through 
lifestyle modification is challenging and largely unsuccessful. There is thus a huge 
clinical need for the development of an effective treatment which can produce a 
sustainable loss in body weight.
The endocannabinoid system is involved in the control of food intake and energy 
balance regulation (Pagotto, 2006) and has emerged as a promising target in the fight 
against obesity. The system is overactivated in obesity, which is demonstrated 
through an increase in endocannabinoid production, or an increase in cannabinoid 
receptor expression in obese animals and humans (Bellocchio et a l 2006). 
Rimonabant, a CBi antagonist, was shown to reduce food intake in obese Zucker rats 
(Bensaid et al., 2003) and in diet induced obese mice. The effect on food intake was 
only transient, however, while a decrease in body weight was prolonged also 
suggesting energy expenditure was affected. A study investigating the effect of 
rimonabant treatment in obese (Lepob/Lepob) mice showed that basal oxygen 
consumption significantly increased compared to control animals and that there was 
a significant increase in glucose uptake in isolated soleus muscle preparations (Liu et 
al. 2005). The cause of the increase in energy expenditure was unclear but in the 
diet induced obese mouse, rimonabant increased gene expression in adipose tissue of 
key enzymes in fatty acid oxidation, suggesting an increase in fatty acid oxidation 
was potentially the mechanism (Jbilo et al., 2005).
The four large clinical RIO trials, discussed in chapter one, examined the effects of 
rimonabant in obese humans. The results of these four trials together indicated that a 
daily 20mg dose of rimonabant for one year, in addition to a hypocaloric diet
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(600kcal/day deficit), resulted in weight loss, reductions in waist circumference and 
positive changes in HDL-cholesterol, adiponectin and leptin levels and insulin 
sensitivity.
As discussed in chapter one, further investigation was still required as to the 
metabolic effects of rimonabant. The rationale and hypothesis for the study are 
described in chapter one, section 1.17.
4.2 Aims 
Study aim:
The aim of this study was to determine if, when energy intake was maintained at pre 
treatment levels, rimonabant still induced weight loss through an effect on energy 
expenditure and the direct effects of rimonabant on body fat distribution and gene 
expression. As weight loss itself may result in alterations in metabolism, the study 
investigated changes in energy expenditure, body fat distribution and gene 
expression in a control group undertaking a dietary intervention matched for the 
weight loss in the rimonabant group.
Specific aims: To investigate in obese participants the following:
1. If, when food intake is maintained at pre treatment levels, rimonabant reduces 
body weight.
2. If a reduction in body weight was induced in the rimonabant group, whether this 
was due to an increase in resting energy expenditure.
3. The effects of rimonabant treatment on fat and carbohydrate oxidation rate.
4. The effect of rimonabant on whole body fat distribution, intrahepatocellular lipid 
(IHCL) and intramyocellular (IMCL) lipid.
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5. The effect of rimonabant on adipose tissue and muscle mRNA levels of key 
regulators of fatty acid metabolism.
6. In a control group following a dietary intervention, with weight loss matched to 
that achieved by the drug group, changes in REE, fat and carbohydrate oxidation 
rate, body fat distribution and gene expression in comparison to the rimonabant 
group.
4.3 Methodology
4.3.1 Study power
The power calculation was undertaken by a medical statistician. The primary 
endpoint of the study was an increase in total energy expenditure. It had been 
assumed for the purposes of the power calculation that there would be no change in 
total energy expenditure in the diet group, as it was difficult to predict how much this 
would decrease. Over 12 weeks, rimonabant treatment of 20mg per day resulted in a 
weight loss of approximately 5.0kg in the clinical trials whereas the placebo group 
lost approximately 2.5kg. If it was assumed that the extra 2.5kg weight loss was due 
to an increased energy expenditure, this was approximately 178 kcals/day. Based on 
an SD of REE measured by indirect calorimetry of 12% (Nielsen et a l , 2003) it was 
calculated that this study required 15 participants in each group. The probability was 
80% that the study would detect this increase in energy expenditure in the 
rimonabant group after 12 weeks treatment compared to the dietary intervention 
group at a two-sided 5 % level of significance.
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4.3.2 Participants
Fourteen obese postmenopausal females aged 50-65 years were recruited for the 
study from the local Guildford population using the recruitment strategies outlined in 
Chapter 2. To be eligible for the study participants required a BMI of 30-35kg/m 
and must have been weight stable for at least a three month period. Participants were 
excluded from the study if they fulfilled any of the exclusion criteria detailed in 
Chapter 2 (section 2.2.1). Over two hundred potential participants were excluded 
during an initial screening telephone call and the three primary reasons for exclusion 
were a past history of depression, not meeting the BMI criteria and the use of 
medications prohibited for the trial.
All participants were provided with a participant information sheet and the study 
design was fully explained before written consent was obtained. This study was 
registered with ClinicalTrials.gov (NCT00584389) and was approved by the UK 
Medicines and Healthcare Products Regulatory Agency (Eudract 2006-006424-18), 
the University of Surrey Ethics Committee and the East Kent Research Ethics 
Committee (07/Q1803/1).
4.3.3 Study design
In the original study design 32 participants were to be randomised into two groups for 
the study:
Group 1:16 participants. Rimonabant dose 20mg/day for 13 weeks with energy intake 
matched for energy expenditure determined in the run-in period.
Group 2: 16 participants. Dietary intervention for 13 weeks, with the aim of achieving 
the same weight loss as group 1.
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Participants were to be studied in blocks of four i.e. four participants randomised to 
group 1 were to be studied in the first block, followed by four participants in group 2, 
then this was to be repeated. This allowed for the monitoring of weight loss in the 
drug treated group which then set the intervention for the dietary intervention group. 
Half way through the trial, in November 2008, the licence for Rimonabant was 
suspended by the European Medicines Agency. Rimonabant was subsequently 
withdrawn from the market and the study was prematurely terminated. At this time, 
14 participants had completed the study. Group 1 (n=7) received rimonabant 
20mg/day for 13 weeks with energy intake matched to their energy requirements and 
group 2 (n=7) followed a dietary intervention to achieve the same weight loss as 
group 1.
As planned, four participants in group 1 were studied first in order to monitor weight 
loss and thus set the intervention for group 2. Eight weeks after group 1 began the 
study four participants from group 2 started the dietary intervention. This was then 
repeated with a block of three participants in each group.
The study was of 17 weeks duration and comprised of a run-in period of four weeks, 
a treatment period of twelve weeks and post treatment tests of one week (treatment 
continued during the post treatment tests) (Figure 4.1 and 4.2).
88
Chapter 4 -  Rimonabant Study
Treatment period 
(12 weeks)
Run-in period 
(4 weeks)
Post treatment tests 
(1 week)
Screening (Visit 1)
Rimonabant OR reduced dietary intake 
Fortnightly visit to dietitian (Visit 8-12) 
Fortnightly call from dietitian 
AEE by actiheart (during week 12)
REE, Acetate infusion and Clamp* (Visit 13) 
Fat distribution (MRI/MRS) (Visit 14) 
Adipose and muscle tissue biopsies taken for 
gene expression. TG/ FFA metabolism* (Visit
REE and 5 day measurement of AEE by 
Actiheart (Visit 2)
Provision of isocaloric diet (Visit 3)
Diet control and adjustment (Visit 4)
Repeated REE, Acetate infusion and Clamp* 
(Visit 5)
Fat distribution (MRI/MRS) (Visit 6)
Adipose and muscle tissue biopsies taken for 
gene expression. TG/ FFA metabolism* (Visit 7)
Figure 4.1 Study schedule (* These procedures were undertaken by another PhD student) 
REE, resting energy expenditure; AEE, activity energy expenditure; MRI, magnetic 
resonance imaging; MRS, magnetic resonance spectroscopy ; TG, triglyceride; FFA, free 
fatty acid.
4.3.4 Protocol 
Screening
Visit 1: Details of the screening visit are in Chapter 2 (section 2.2). Due to the 
potential side effects of rimonabant, participants were asked to complete a Beck 
Depression Inventory-II questionnaire in order to assess current levels of depression.
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A Dutch Eating Behaviour Questionnaire was also completed to establish eating 
behaviour. Following the screening visit, participants were requested to complete a 
four day diet diary in order that under reporters could be excluded from the trial. If 
the participant fulfilled all of the inclusion criteria and none of the exclusion criteria 
they were accepted into the study. A letter was then sent to the participant’s GP to 
explain the trial and notify them of their patient’s involvement.
Once 8 participants were accepted into the study they were randomised to the 
rimonabant treatment or the dietary intervention. Participants were randomised 
through the selection of a sealed envelope containing either the rimonabant or dietary 
treatment option by an independent individual not involved in the trial. Due to the 
considerable amount of time required for Visits 5 and 7 only one participant was able 
to commence on the study each week. For the participants allocated to the dietary 
intervention group there was a delay of eight weeks before they started this part of 
the study. This was in order to establish the mean amount of weight loss being 
achieved by the rimonabant group.
Diet diaries
Visit 2 3 4 5,6,7 8 9 10 11 12 13,14,15
r w i H _ r i r T T T V T V T T i _ r
Weeks -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13
JJ Visit to Dietitian
^  Telephone call by Dietitian 
Y777Z Metabolic Measurements
Figure 4.2 Study design.
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Run-in period
Visit 2: The purpose of this visit was to establish the participants’ energy 
expenditure. Participants were weighed. REE was measured as described in Chapter 
2 (section 2.6).
In order to then estimate the amount of energy expended in everyday activities and 
exercise each participant was fitted with an Actiheart monitor (Chapter 2/section 
2 .8).
Visit 3: At this visit the total energy expenditure calculated for each participant was 
used to provide a personal dietary prescription. The aim was for a participant’s 
energy intake to match the estimated total energy expenditure determined during the 
first week of the run-in period. In both groups the macronutrient composition of the 
diet was required to be equal and this was continually monitored through the analysis 
of diet diaries. It was decided to aim for a diet with a macronutrient composition 
representative of the Guildford population (approximately 46% carbohydrate, 37% 
fat and 17% protein) as previously reported in a study by Wilkinson et a l  (2005). 
Participants that usually consumed moderate or high quantities of alcohol were asked 
to reduce their intake during the study. At this visit participants in the dietary 
intervention group undertook a comprehensive dietary interview in order to establish 
regular eating habits. This interview was utilised to form the basis of their 
personalised diet plan, which was to be followed for the 12 week treatment period.
Visit 4: This was undertaken two weeks after visit 3 to check compliance with the 
dietary prescription and to ensure that the diet was meeting the participant’s energy 
requirements. If the participant was weight stable (less than 1 kg variation), they
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proceeded to visit 5, otherwise the diet was adjusted as appropriate and the visit was 
repeated a fortnight later.
Visit 5: This visit was undertaken during the last week of the run-in period. 
Participants were weighed and, as before, REE was measured by indirect 
calorimetry. To establish urinary nitrogen excretion, participants were requested to 
collect a 24 hour urine collection throughout the day before the visit as described in 
Chapter 2 (section 2.7).
Visit 6: Measurements of body fat, intrahepatocellular lipid and intramyocellular 
lipid were taken at the MRC Clinical Sciences Centre, Hammersmith Hospital. Any 
participants with metal implants or claustrophobia were excluded from this section of 
the study (Chapter 2. Section 2.9).
Visit 7: This visit was scheduled 5-7 days after visit 5. Participants were weighed 
and a needle biopsy of the vastus lateralis muscle in the thigh and subcutaneous 
adipose tissue was taken under local anaesthesia by a physician trained in this 
procedure. The biopsies were snap frozen in liquid nitrogen and stored at -80 °C in 
preparation for batch analysis. These biopsies were utilised to measure mRNA levels 
of key regulators of fatty acid metabolism (Chapter 2. Section 2.11).
Dietary intervention/Rimonabant treatment
At the end of the study day each participant was advised on their dietary intake for 
the next two weeks. Participants in the rimonabant group had a consultation with a 
doctor who prescribed the drug and provided advice on possible side effects.
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Each participant commenced with either rimonabant treatment or dietary intervention 
on the following day. If a participant had been randomised to the drug treatment 
group they were asked to maintain their dietary intake at the same level as during the 
run-in period (i.e. their energy intake should match their measured energy 
requirements) and if they had been randomised to the dietary intervention group they 
were provided with a very detailed diet plan to reduce their dietary intake. The energy 
prescription provided to participants in the diet group was based on the estimate of the 
energy deficit required to create equal weight loss to that seen in the rimonabant 
treated group, i.e. the participant’s total daily energy expenditure as determined 
during the run-in period minus the appropriate number of kcal daily to achieve equal 
weight loss to the drug group. The diet plan utilised foods usually consumed by the 
participant for convenience and to aid with compliance. Participants were asked to 
complete a seven day diet diary for the full 17 week duration of the study.
Treatment Period
Visit 8-12: These visits took place on a fortnightly basis. The participants were 
weighed and dietary compliance discussed. Participants were advised as to any 
changes that were required to the diet and self reported levels of physical activity 
were recorded. For participants in the rimonabant treated group medication 
compliance was assessed by tablet counting and levels of depression monitored 
through the completion of the Beck Depression Inventory-II. Any adverse events or 
potential side effects of the medication were also recorded and any necessary action 
taken. Between these visits each participant received a fortnightly telephone call to 
review dietary and medication compliance and to record any self reported changes in 
physical activity levels.
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On visit 12 participants were fitted with an Actiheart monitor to remeasure energy 
expenditure for a five day period during week 12.
Post treatment tests
Visit 13: This took place after the 12 week intervention period and was identical to 
visit 5.
Visit 14: This visit was undertaken after the 12 week intervention period and was 
identical to visit 6.
Visit 15: This took place 5-7 days after visit 13 and was identical to visit 7.
Participants in the rimonabant group continued with their treatment, and in the 
dietary control group the hypocaloric diet, until the post treatment tests were 
completed.
4.4 Results
4.4.1 Screening data
All participants were screened at Visit 1 and a summary of their characteristics may 
be seen in Table 4.1. There was no significant difference in any of these 
characteristics between the two groups.
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Table 4.1 Screening characteristics. Data expressed as mean ± SEM
Characteristic
Rimonabant 
Group (n=7)
Diet Group 
(n=7)
Age (years) 58.14 ±1.87 57.43 ± 1.86
Weight (kg) 88.10 ±2.20 82.96 ± 2.86
Height (cm) 164.50 ±1.22 159.57 ±2.60
BMI (kg/m2) 32.47 ± 0.72 32.54 ±0.58
Waist circumference (cm) 97.71 ± 2.99 96.57 ± 2.54
Hip circumference (cm) 116.00 ± 1.69 114.64 ±3.18
Waist hip ratio 0.84 ± 0.03 0.84 ± 0.02
Fat mass (%)* 45.46 ± 0.77 43.66 ±1.11
Glucose (mmol/1) 5.53 ± 0.08 5.29 ±0.15
Cholesterol (mmol/1) 6.47 ±0.44 5.64 ±0.38
Triglyceride (mmol/1) 1.87 ±0.43 1.12 ± 0.14
* Fat mass as measured by impedance.
4.4.2 Dietary analysis
Diet diary analysis was undertaken on a weekly basis to ensure that each participant 
was consuming a diet that provided the correct amount of energy to meet their 
requirements.
Mean daily energy intake was maintained in the rimonabant group throughout the 
run-in period and treatment period as shown in Figure 4.3. In the rimonabant group 
the mean daily intake of kcal per day was 1991 ±99 in the run-in period versus 
1963±73 kcal/day during the treatment period (p= 0.630).
In the diet group there was a difference in daily energy intake between the run-in 
period and during the treatment as per the study design. There was a reduction in 
mean daily energy intake between the run-in and treatment period of 341±55 
kcal/day (p<0.001).
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The change in energy intake between the run-in period and treatment period was 
significantly different (p=0.002) between the two groups (Table 4.2).
□ During run in ■ During treatment
Rimonabant Diet
Figure 4.3 Mean daily energy intake during the four week run-in period and the 
treatment period in the rimonabant and diet group. Data are expressed as mean daily 
energy intake in kcal/day ±SEM.
Figure 4.4 shows that the mean energy intake was very steady in both groups during 
the run-in period as per the study design. There was a reduction in energy intake in 
the diet group during the treatment period as prescribed and the mean energy intake 
was very consistent every week in the rimonabant group.
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— Rimonabant — Diet
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Intervention period
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Week
Figure 4.4 Mean energy intake during the four week run-in period and the treatment 
period in the rimonabant and diet group. Data are expressed as mean energy intake in 
kcal/day ±SEM.
In the dietary intervention group the reduction in mean energy intake was due to a 
decrease in fat intake, mainly saturated and monounsaturated fatty acids and 
carbohydrate intake (Table 4.2).
Table 4.2 Mean daily macronutrient intake during the run-in and the 
intervention period for the rimonabant and diet group.
Rimonabant Group Diet Group A
rimonabant
(n=7) (n=7) versus A diet 
group
Run-In J Intervention
i
Run-In | Intervention
i
Energy intake 
(kcal/day) 1991±99 1963±73 1905±36 1564±56* P=0.002
Fat (g/day) 87±5 84±3 82±3 61±4* P=0.001
SFA (g/day) 31±2 29±1 28±2 21±1* P=0.046
PUFA (g/day) 14±1 13±1 15±1 12±1* NS
MUFA (g/day) 28±3 26±2 24±1 19±1* NS
Carbohydrate
(g/day) 215±21 213±16 215±10 185±10* P=0.03
Protein (g/day) 78±2 81±4 78±4 73±2 NS
SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated 
fatty acids. *significantly different from run-in period, p<0.05. Data expressed as mean ± 
SEM.
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The mean percentage contribution of each macronutrient to total energy intake 
during both the run-in period and intervention was also calculated for both groups 
and this is shown in Table 4.3. There were no significant differences between the 
run-in period and intervention period in macronutrient composition of the diet in the 
rimonabant group. In the diet group, however, there was a significant decrease in the 
proportion of energy provided by fat (p=0.02) and a significant increase in 
percentage of energy provided by protein (p<0.01) between the run-in and 
intervention periods. When comparing between groups there was no significant 
difference in the percentage contribution of fat or protein to total energy intake 
during the run-in period but the mean percentage contribution of carbohydrate was 
higher (p=0.02) and mean percentage of alcohol lower (p<0.01) in the diet group 
than the rimonabant group during the run-in period. During the intervention period 
the mean percentage contribution of fat (p<0.01) and alcohol (p<0.01) to energy 
intake was significantly lower in the diet group and the mean percentage contribution 
of protein (p<0.01) and carbohydrate (p=0.04) to energy intake lower in the 
rimonabant group.
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Table 4.3 Mean percentage contribution of macronutrients to total energy 
intake during the run-in and the intervention period for the rimonabant and 
diet group.
-------------------------
Rimonabant Group
(n=7)
Run-In i Intervention
i
Diet
(n
Run-In
Group
=7)
Intervention
---------------
p  Rimon
versus
Run-In
abant Group 
Diet Group
Intervention
Fat
(% of energy)
Carbohydrate 
(% of energy) 
Protein 
(% of energy) 
Alcohol 
(% of energy)
38.65 ± ! 37.76 ± 
1.39 | 1.22
i
40.89 ± | 41.65 ± 
2.56 i 2.04
16.23 ± ! 16.84 ± 
0.72 | 0.64 
4.22 ± | 3.76 ± 
1.36 ! 0.88
38.22 ± 
1.51
43.23 ± 
1.66
16.68 ± 
0.74 
1.82 ± 
0.53
34.39 ± 
1.44*
45.20 ± 
1.40 
19.25 ± 
1.01* 
1.18 ± 
0.35
NS
p = 0.02
NS
p < 0.01
p  < 0.01
p = 0.04
p < 0 .01
/?<0.01
*significantly different from run-in period, p<0.05
4.4.3 B ody weight
As shown in Figure 4.5 participants in the rimonabant group were weight stable 
during the run-in period of the study as per the study protocol and then, despite mean 
weekly energy intake being maintained during the intervention period, there was a
reduction in body weight.
Weight Mean energy intake
Intervention period 2500Run-in period
2000o  94
1500
1000
500
Visit
Figure 4.5 The relationship between mean energy intake in kcal/day and mean
weight in kg for participants in the rimonabant group. Data expressed as mean ± 
SEM (n=7).
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During the intervention period mean energy intake was reduced in the dietary group 
and a corresponding weight reduction was observed (Figure 4.6)
I I Weight Mean energy' intake
2500
Run-in period Intervention period
2000 |  ^  
1500
1000 B w
500
Visit
Figure 4.6 The relationship between mean energy intake in kcal/day and mean 
weight in kg for participants in the dietary intervention group. Data expressed 
as mean ± SEM (n=7).
Mean weight loss was very similar in both the rimonabant and diet group as per the 
study design. In the rimonabant group, despite energy intake maintenance during the 
study, the mean weight loss was 2.6±0.5kg (p=0.003). In the dietary intervention 
group, where energy intake was reduced during the treatment period, a weight loss of 
3.1±l.lkg (p=0.027) was achieved (Figure 4.7). There was no significant difference 
between groups.
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Figure 4.7 Mean body weight pre and post treatment for the rim onabant and 
diet group. Data expressed as mean ± SEM (n=7 in each group).
4.4.4 R esting  energy expenditure
REE was measured at visit 2 and visit 5. The measurement taken at visit 2 was a
practice reading to familiarise the participants with the procedure and the REE
measurement taken at visit 5 was used as the baseline REE for all participants in the
trial. There was no significant difference between the mean REE measurements
taken at visit 2 and visit 5 (Figure 4.8).
□ Pre ■ Post
p=0.003 p=0.027
T
Rimonabant Diet
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□ Visit 2 ■ Visit 5
^  2000 
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H 1000 H 
X
g 500<u
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Participant
Figure 4.8 Comparison of mean REE measured at visit 2 and visit 5 for all 
participants. Data expressed as mean ± SEM.
Pre and post REE results were analysed for both groups. REE decreased in the 
dietary intervention group (p=0.054) as expected with weight loss, but was 
maintained in the rimonabant group despite a reduction in weight (Figure 4.9). There 
was no significant difference between groups. Once adjusted to REE/kg fat free 
mass, the significant difference in the diet group was lost.
po po 73 po 73 po 73 73 *3 73 73 73 73 73
i I i I S I i 2 i i 1 i 1 io o o o o o o o o 1— * 1—- —
— u> Os 00 o K ) U )po po po 73 D u a a 73 73 73 a a o
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p=0.054
□ Pre ■ Post
b  1200ax
OiD
•S 1000
Rimonabant
Figure 4.9 Mean REE pre and post treatment for the rimonabant and diet 
group. Data expressed as mean ± SEM (n=7 in each group).
To ensure that the REE readings recorded were realistic for participant’s body mass 
the measured REE was compared to predicted REE using the Schofield equations 
(Schofield et al. 1985) and the results were very similar (Table 4.4).
Table 4.4 Mean measured REE versus mean predicted REE for both the 
rimonabant and diet group. All figures mean ± SEM (n=7 in each group).
Mean Weight 
Pre (kg)
Mean
Predicted
REE
(kcal/day)
Mean 
Measured 
REE Pre 
(kcal/day)
Mean 
Measured 
REE as % of  
predicted
Rimonabant group 89.0 ± 2.2 1539 ± 19.2 1460 ±51.9 94.7 ± 2.5
Diet group 84.2 ± 2.9 1487 ± 28.7 1453 ± 70.2 97.7± 4.3
As may be seen in Table 4.4 the mean measured REE for the rimonabant group was 
94.7% of that predicted and in the diet group the mean measured REE was 97.7% of 
that predicted.
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4.4.5 C arbohydrate and f a t  oxidation
Carbohydrate and fat oxidation rates did not change significantly in either group pre 
and post treatment (Table 4.5). There was no significant difference between groups.
Table 4.5 Carbohydrate and fat oxidation rates and mean respiratory quotient 
pre and post treatment for the rimonabant and diet group. Data expressed as 
mean ± SEM.
Rimonabant Group
(n=7) Diet Group (n=7)
p  A 
rimonabant
Pre Post Pre Post vs. A diet
Carbohydrate 
oxidation (g/min) 0.11 ±0.01 0.11 ±0.02 0.12 ± 0.01 0.14 ± 0.01 NS
Fat oxidation 
(g/min) 0.04 ±0.01 0.04 ±0.01 0.03 ±0.01 0.02 ±0 .00 NS
Respiratory
Quotient 0.85 ±0.01 0.86 ±0.03 0.86 ±0.01 0.88 ±0.01 NS
4.4.6 A ctiv ity  energy expenditure
AEE was analysed for a five day period for each participant pre and post treatment. 
Data was not available for two participants in the rimonabant group. One participant 
was found to have a malfunctioning monitor after a five day recording period and 
declined a repeat measurement, and for the second participant it was not possible to 
obtain a strong heart beat signal. Different monitors were trialed, but the participant 
had large adipose tissue deposits interrupting the R wave signal, thus preventing a 
recording.
The Actiheart software provided data on both heart rate changes as well as 
movement and, as described in Chapter 2 (section 2.8.2). An example of one 
participants AEE recording for one day can be seen in Figure 4.10.
A summary of REE, AEE, DIT and TEE for the five day period could also be 
downloaded for each participant as shown in Figure 4.11. The bar graph in the
104
Chapter 4 -  Rimonabant Study
summary shows the average distribution of AEE over 24 hours during the five day 
recording period.
Activity, Heart Rate and Energy Expenditure
User ID RIM12D Weight 70.5kg Epoch 60 s e c s
Age 57 Height 1.465m
User sex Female BMI 33
V02 max 23.9 (from step  test)  
HR max 170 (m easured)
Sleep HR 65
Fri 30-May-2338 BPM an*d Activity
100
Figure 4.10 AEE recording for one participant using the Actiheart monitor. The
red line represents the heart rate data and the black blocks movement detected by the 
accelerometer. The blue line indicates a time when the monitor is not detecting an 
adequate R wave of the heart beat. On this occasion the blue line coincided with the 
time that the participant had removed the monitor whilst showering.
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Actiheart Energy Expenditure
User ID 
Age
User se x  
RMR
RIM03R
60
Female
1403
0  P E E - E E
Wed 31/10/200? 
Thu 01/11/2007 
Fri 02/11/2007 
Sat 03/11/2007 
Sun 04/11/2007 
Mon 05/11/2007 
Tue 06/11/200?
A r e 'a g s  -u .n .
MZI
Weight
Height
BMI
91.6kg
1.645m
34
RCtll
REE AEE DIT TEE
922 660 176 1758
1493 850 260 2603
1493 672 240 2405
1493 417 212 2122
1493 409 211 2112
1493 779 252 2524
1054 423 184 1641
1493 626 235 2353
PAL
1.74
1.61
1.42
1.42 
1.69
1.58
Average clistr ilxition of AEE for all full (lays
Figure 4.11 AEE daily energy expenditure summary for one participant using 
the Actiheart monitor for a five day period. The figures in bold represent days 
upon which the monitor was recording for a full 24 hour period whereas the figures 
in grey represent recordings of a part day only. REE, Resting Energy Expenditure; 
AEE, Activity Energy Expenditure; DIT, Dietary Induced Thermogenesis (an 
estimated value of 10% of TEE); TEE, Total Energy Expenditure; PAL, Physical 
Activity Level (TEE/REE).
AEE was measured in participants pre and post treatment. In the rimonabant group 
mean AEE was unchanged at 367±78 kcal/day pre treatment to 361±56 kcal/day post 
treatment (p=0.93) (Figure 4.12). AEE decreased from 533±99 kcal/day to 476±82 
kcal/day in the dietary intervention group, but this difference was not significant 
(p=0.10).
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□ Pre ■ Post
P=0.93 P=0.10
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“  300
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Rimonabant Diet
Figure 4.12 Mean activity energy expenditure pre and post treatment for the 
rimonabant and diet group. Data expressed as mean ± SEM (n = 5 in rimonabant 
group, n = 7 in diet group).
4 .4 .7  W aist and  hip circum ference changes
Although energy intake was maintained in the rimonabant group there was a mean 
waist circumference decrease of 3.7±1.4cm (p=0.036). In the diet group following a 
hypocaloric diet a reduction of 5.7±1.7cm (p=0.016) in waist circumference was 
achieved (Figure 4.13). There was no significant difference between the two groups.
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□ Pre ■ Post
p= 0.036 p =0.016
Rimonabant Diet
Figure 4.13 Mean waist circumference pre and post treatm ent for the 
rimonabant and diet group. Data expressed as mean ± SEM (n=7 in both groups).
Changes in hip circumference and waist hip ratio are shown in Table 4.6. Despite 
weight loss there was no significant reduction in hip circumference or waist hip ratio 
pre and post treatment in the rimonabant group. A significant reduction in hip 
circumference was seen in the diet group post treatment, but this did not translate to a 
significant change in waist hip ratio. There was no significant difference in either 
hip circumference or waist hip ratio between groups.
Table 4.6 Changes in hip circumference and waist hip ratio pre and post 
treatment for the rimonabant and diet group. Data expressed as mean ± SEM 
(n=14).
Anthropometric
Measure
Rimonabant Group 
(n=7) Diet Group (n=7)
P
A rimonabant
Pre Post Pre Post vs A diet
Hip circumference 115.87 ± 114.38 ± 112.45 ± 109.64 ± NS(cm) 2.14 1.61 2.64 2.99*
Waist hip ratio 0.94 ± 0.03
0.92 ± 
0.02
0.96 ± 
0.04
0.93 ± 
0.04 NS
*significantly different from Pre measurement, p< 0.05
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4.4.8 B ody f a t  distribution
Two participants in the rimonabant group and one participant in the control group 
were unable to have scans due to metal implants.
Participants initially undertook an MRI scan of body fat in which they were scanned 
from their fingertips to their toes as described in Chapter 2 (section 2.9). An 
example of the images taken may be seen in Figure 4.14.
Muscle Fat
Figure 4.14 Example single slice MRI images of body fat in the upper thigh and 
pelvic area for one participant. Participants were scanned from their fingertips to 
their toes by acquiring 10 mm thick transverse images with 30mm gaps between 
slices in their arms and legs and 10 mm gaps between slices in their abdomen. The 
white areas of fat can clearly be distinguished in comparison to the dark muscle.
MRI results showed a significant decrease in total body fat (p=0.046), subcutaneous 
fat (p=0.028), subcutaneous abdominal fat (p=0.028) and subcutaneous peripheral fat
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(p=0.028) in the diet group pre and post treatment, however there were no significant 
differences in the rimonabant group or between treatments (Table 4.7).
Table 4.7 MRI measurements of body fat pre and post treatm ent for the 
rimonabant and diet group. Data expressed as mean ± SEM (Rimonabant group, 
n=5. Diet group, n=6).
------------ ................ ...... ............................
Rimonabant Group (n=5)
----------------------------------------
Diet Group (n=6)
.........................
p  A 
rimonabant
Pre Post Pre Post vs A diet
Total body fat (litres) 46.91 ± 1.82 46.84 ± 1.82 44.17 ± 2.41 42.15 ±2.16* NS
Subcutaneous fat (litres) 38.13 ± 1.62 37.72 ± 1.30 36.82 ±2.50 35.15 ±2.43* NS
Internal fat (litres) 8.78 ± 1.17 9.12 ± 1.40 7.35 ±0.70 7.00 ± 0 .60 NS
Subcutaneous abdominal 
fat (litres) 11.53 ±0.69 11.04 ±0.76 10.93 ± 1.21 10.37 ± 1.14* NS
Subcutaneous peripheral 
fat (litres) 26.61 ± 1.18 26.32 ±0.58 25.89 ± 1.48 24.78 ± 1.42* NS
Visceral fat (litres) 5.45 ± 0.94 5.47 ± 1.05 4.01 ±0.36 3.79 ±0.31 NS
Non visceral fat (litres) 3.33 ±0.33 3.65 ±0.40 3.34 ±0.37 3.21 ±0.33 NS
* significantly different from Pre measurement, p< 0.05.
As mean total body fat appeared unchanged in the rimonabant group despite weight 
loss the individual measurements were examined to identify if participants had 
increases, decreases or maintenance of body fat levels (Figure 4.15).
^  40
Pre - Post
RIM02R
RIM04R
RIM09R 
RIM10R 
RIM11R 
RIM05D 
RIM06D 
RIM07D 
RIM 12D 
RIM13D 
RIM14D
Figure 4.15 Individual measurements of total body fat (litres) for all 
participants pre and post treatment. Blue lines = rimonabant group, pink lines = 
diet group.
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Figure 4.15 shows that although three of the participants treated with rimonabant lost 
body fat, participants RIM 1 OR and RIM11R actually had an increase in total body fat 
despite weight loss. In the diet group a reduction in total body fat was seen in all 
participants with the exception of RIM 12D in which total body fat was stable (35.98 
litres pre versus 36.37 litres post).
The relationship between fat free mass measured by MRI and the Tanita 
bioimpedance method was investigated using Pearson product-moment correlation 
coefficient (Figure 4.16). There was a strong positive correlation between the two 
variables, r = 0.918, n = 11, p < 0.001.
55-
$  45“
R2 Linear = 0.835
35-
43 45 48 50 53
TANITA measurment of kg of FFM
Figure 4.16 Correlation between MRI and Tanita measurements of fat free 
mass in kg post intervention (n=ll).
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4.4.9 Intrahepatocellular lipid and intramyocellular lipid
Both intrahepatocellular lipid and intramyocellular lipid were measured by 1H- 
magnetic resonance spectroscopy as described in Chapter 2 (section 2.9). An 
example of an intrahepatocellular lipid spectra for one participant pre and post 
treatment may be seen in Figure 4.17.
Baseline
Fat CH.
Fat CH3
Follow-up
 !
- 1.00
f—
5.00
]
1.007.00 3.00
ppm
Figure 4.17 Example proton magnetic resonance spectra for one participant pre 
and post treatment. Resonances from water and IHCL are shown. IHCL, 
intrahepatocellular lipid.
Levels of IHCL were expressed as a ratio to liver water content and the percentage 
change in IHCL pre and post treatment calculated. No significant differences were 
found in IHCL pre and post treatment in either group or between groups (Figure 
4.18). The results for participant RIM09R were confirmed with the MRC Clinical 
Sciences Centre who undertook the MRS scan. This participant is an outlier and 
despite weight loss was found to have an increase in IHCL. The results were
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reanalysed excluding this participant but this did not alter the findings and no 
significant differences in IHCL were found pre and post treatment in either group or 
between groups.
RIM09R
S 100
Rimonabant Diet
Treatment type
Figure 4.18 Box plots of the % difference in intrahepatocellular fat pre and post 
treatment for the rimonabant and diet group. Data expressed as median and 
interquartile range (Rimonabant group, n=5. Diet group, n=6).
Levels of intramyocellular lipid were also calculated. Despite weight loss the 
rimonabant group showed an increase in both soleus and tibialis intramyocellular 
lipid (SIMCL and TIMCL) following treatment (Table 4.8). These increases were 
not statistically significant. The diet group also had an increase in TIMCL, but a 
decrease in SIMCL was found following treatment. There was a borderline
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significant difference in SIMCL between the diet and the rimonabant group (p = 
0.05).
Table 4.8 MRS measurements of SIMCL and TIMCL pre and post treatment 
for the rimonabant and diet group. Data expressed as mean ± SEM.
Rimor
Group
Pre
tabant
(n=5)
Post
Diet Gro 
Pre
up (n=6) 
Post
Rimonabant 
Group (n=5)
Mean % 
change
Diet
Group
(n=6)
Mean % 
change
A
rimonabant 
vs A diet
SIMCL
TIMCL
10.42 ± 
2.14 
6.19 ± 
0.99
11.85 ± 
2.63 
6.84 ± 
1.21
11.09 ± 
2.21 
8.13 ± 
0.88
9.59 ± 
2.13 
10.98 ± 
2.01
13.7 ± 
11.2 
25.26 ± 
29.26
-11.96 ± 
8.99 
49.34 ± 
42.06
P = 0.05 
NS
SIMCL, soleus intramyocellular lipid; TIMCL, tibialis intramyocellular lipid.
4.4.10 A dipose and  m uscle gene expression
In adipose tissue, a significant difference was found in gene expression of PPAR 
delta between the rimonabant and diet group pre and post treatment (p=0.006). 
There were no further significant differences in gene expression in adipose tissue 
found pre-post treatment in either the diet or the rimonabant group or between groups 
(Figure 4.19).
No significant differences in gene expression in muscle tissue were found pre-post 
treatment in either the diet or the rimonabant group or between groups (Figure 4.20).
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Figure 4.19 Post:pre gene expression in adipose tissue normalized to the 
housekeeping gene GAPDH. Data expressed as ratios. (Rimonabant group, n=4. 
Diet group, n=5). CD36, Cluster of Differentiation 36; A, Adiponectin; AR1,
adiponectin receptor 1; UCP2, Uncoupling protein 2; LPL, lipoprotein lipase; HSL, 
Hormone sensitive lipase; PG, Peroxisome proliferator-activated gamma; PD, 
Peroxisome proliferator-activated delta.
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Figure 4.20 Postipre gene expression in muscle normalized to the housekeeping 
gene GAPDH. Data expressed as ratios. (Rimonabant group, n=2. Diet group, 
n=4). CD36, Cluster of Differentiation 36; AR1, adiponectin receptor 1; UCP2, 
Uncoupling protein 2; UCP3, Uncoupling protein 3; LPL, lipoprotein lipase; PD, 
Peroxisome proliferator-activated delta; PA, Peroxisome proliferator-activated alpha; 
ACOX1, acyl Co A oxidase; CPT1, Carnitine palmitoyltransferase 1; CPT2, 
Carnitine palmitoyltransferase 2.
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4.4.11 Beck depression scores
In the rimonabant treated group participants levels of depression were monitored 
fortnightly through the completion of the Beck Depression Inventory II. The mean 
depression scores at each fortnightly visit are shown in Table 4.9.
Table 4.9 Mean Beck Depression Inventory II scores for the rimonabant group.
Data are expressed as mean ± SEM (n=7). The maximum score on the inventory is 
63.
Mean Beck Depression 
Inventory II Score
Screening 6.86 ±0.46
Visit 8 1.86 ±0.46
Visit 9 3.43 ± 1.34
Visit 10 3.29 ±2.16
Visit 11 3.00 ± 1.38
Visit 12 3.43 ± 1.02
A score of 0-13 on the Beck Depression Inventory II is categorised as minimal 
depression and the mean score at each visit belonged to this category. The highest 
mean depression score recorded was actually at the screening visit with the lowest 
mean score two weeks into the drug treatment period.
The statements of symptoms and attitudes that scored most highly are shown in 
Figure 4.21.
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3 1
■  Tiredness or fatigue
□  Changes in appetite
■  Changes in sleep pattern
■  Loss o f  energy'
□  Agitation
■  Crying
□  Suicidal thoughts
□  Sadness
Screening Visit 8 Visit 9 Visit 10 Visit 11 Visit 12
Visit
Figure 4.21 Mean scores for statements of symptoms that scored most highly on the 
Beck Depression Inventory II. Data is for rimonabant group (n=7) and is expressed as 
stacked mean scores.
The statements with the highest scores at the screening visit were tiredness or fatigue 
and loss of energy. During the treatment period an increase in sadness and agitation 
scores were seen in comparison to the screening visit. Changes in appetite were also 
evident for the duration of the treatment period. Only one participant undertaking 
the study reported fleeting suicidal thoughts and this was at visit 11 near the end of 
the treatment period.
4.5 Discussion
The aim of this clinical trial was to determine if, when energy intake was maintained 
at pre treatment levels, rimonabant still induced weight loss through an effect on 
energy expenditure and the direct effects of rimonabant on body fat distribution and 
gene expression.
In this trial it was demonstrated, for the first time in humans, that treatment with 
rimonabant for a 13 week period, whilst daily energy intake was maintained at pre-
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treatment levels, did induce weight loss. Additionally it was shown that, despite 
weight loss following rimonabant treatment, there was no change in REE and, since 
REE would be expected to decrease, this could have contributed to the weight loss.
Weight loss
Over the course of the 13 week trial both the rimonabant and diet group lost similar 
amounts of weight as per the study design. The weight loss in the rimonabant group 
was less than the average loss of 4kg-5.5kg (Van Gaal et al., 2005; Despres et al., 
2005; Pi-Sunyer et al., 2006; Scheen et a l , 2006) over the first 12 week period in the 
RIO human trials. It is reasonable that the weight loss seen in this study was less as 
in the study design for the RIO trials all participants were advised to adhere to a 
hypocaloric diet (600 kcal/day deficit) and instructed to increase their level of 
physical activity throughout the study, which should have increased levels of weight 
loss in comparison to drug treatment alone. Levels of adherence to the diet and 
increased activity were not reported in the RIO papers, however, and a 600 kcal/day 
deficit alone over a 12 month period should have resulted in greater annual weight 
loss than 5.3-8.6kg suggesting non compliance from participants.
In order to induce a weight loss of 1kg a deficit of 7000kcal of energy is required. 
The weight loss in the diet group can be explained by their daily reduction in energy 
intake during the treatment period. The rimonabant group, however, maintained 
energy intake thereby indicating that a change in energy expenditure was responsible 
for the weight reduction in this group.
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Energy expenditure
Total energy expenditure is comprised of REE, non-resting energy expenditure 
(including AEE) and DIT. REE contributes 60%, non-resting energy expenditure 
and AEE 30% and dietary induced thermogenesis approximately 10% of TEE. A 
study in obese participants by Leibel et a l (1995) found that a weight reduction of 
10% was associated with a decrease in TEE of 8kcal/day/kg fat free mass. It was 
shown that approximately half the decrease in TEE was due to a decrease in REE and 
half to a decrease in non-resting energy expenditure. In this study this would 
correspond to the weight loss in the diet group being associated with a decrease in 
TEE of 120kcal/day. The mean decrease in REE in the diet group was actually 
67kcal/day which is consistent with these previous findings and in line with the 
expected reduction of REE in the hypothesis. The remaining decrease in energy 
expenditure is likely to be accounted for by reductions in non-resting energy 
expenditure. AEE, an element of non resting energy expenditure was measured for a 
five day period at the end of the treatment period and did decrease by 57kcal/day in 
the diet group, although this decrease was not statistically significant.
In the rimonabant group the maintenance in REE can partially account for the weight 
loss but cannot fully explain it. As there was no change in AEE in the rimonabant 
group pre and post treatment this also cannot explain the weight reduction. It must 
be taken into consideration, however, that AEE was only measured for two five day 
periods and not for the duration of the intervention period. In addition, participants 
were instructed not to alter exercise patterns over the course of the trial and 
questioned regarding their activity levels at every visit to try and minimise 
variability.
119
Chapter 4 -  Rimonabant Study
To induce the weight reduction recorded in the rimonabant group an increase in TEE 
of approximately 200 kcal/day was required and therefore an increase in REE was 
expected as stated in the hypothesis. The initial study power calculation determined 
that 30 participants would be required in total to detect differences in REE, yet at the 
point at which the trial was prematurely terminated only 14 participants had been 
studied. It is possible that due to the reduced number of participants indirect 
calorimetry may not have been sufficiently sensitive to detect any small changes in 
REE.
There are some disadvantages associated with measuring REE using indirect 
calorimetry. Firstly REE was only measured at two time points during the study and 
over a recording period of 40 minutes. It is questionable whether this provides an 
accurate picture of REE over a thirteen week period although there was no 
significant difference in the REE measurements at Visit 2 and Visit 5. An alternative 
method of measuring energy expenditure, however, such as doubly labeled water 
may have yielded more accurate results. Secondly there are a number of 
assumptions utilized when using indirect calorimetry to measure REE. For example, 
an assumption is made that the body pools that can affect the respiratory exchange 
measurements, such as the urea pool and the bicarbonate pool, remain stable (Jequier 
et al., 1987). Finally, some participants found laying under the Perspex hood for 40 
minutes slightly distressing and it is possible that the associated hyperventilation 
contributed to an increased RQ. The reported RQ for pure fat oxidation is 0.707 and 
for carbohydrate oxidation 1.0 (Gibney et a l , 2002). The mean RQ varied between 
0.85±0.01 and 0.88±0.01 and as the SEMs were small suggested a systematic overestimation 
in RQ. Interestingly this may be explained by the reported mean error in RQ of 14±1.5%
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when the GEM performance was assessed using reference gases (Nicholson et al., 
1996).
Doubly labeled water is the gold standard method for calculating total energy 
expenditure. In this method an individual ingests a dose of heavy water isotopically 
labeled with deuterium and oxygen-18. The differing rates of loss of these isotopes 
from the body are utilised to estimate the rate of carbon dioxide and energy 
expenditure (Gibney, 2002). The major advantages of this method in comparison to 
indirect calorimetry are that it is non-invasive and energy expenditure can be 
measured over an extended period. The REE measurements in this trial were 
conducted over a forty minute recording period whereas using doubly labeled water 
energy expenditure may be measured for up to 7-14 days. Additionally the doubly 
labeled water method allows for individuals to have energy expenditure measured
under free-living conditions. There are some disadvantages to the method. Not only
•  •  • • 10is there a requirement for expensive equipment to analyse the samples but the O
isotope costs approximately £400 for a 70kg adult (Gibney, 2002) so for a trial of 
this nature, when energy expenditure was to be measured twice in participants with 
higher body weight, the expense would have been great. Additionally no 
information may be obtained regarding the different components of activity 
thermogenesis (Levine, 2005).
Several problems were also encountered in the measurement of AEE. As previously 
described in the methods chapter, the Actiheart Monitor was unable to detect various 
fidgeting elements of NEAT such as leg shaking, finger tapping, foot tapping etc. 
The Actiheart monitor can only detect movement in the vertical plane, hence the
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requirement for the branched chain equation model (Brage et al. 2005) allowing the 
intensity and energy expenditure of physical activity to be calculated from the 
activity data or heart rate data alone or from both. As the monitor was unable to 
detect some components of NEAT, a potential contributor to TEE had been omitted. 
NEAT has been found to vary immensely between individuals, and for the many 
individuals not participating in regular purposeful physical activity, is the major 
contributor to activity thermogenesis (Levine and Kotz, 2005).
One methodological problem encountered whilst measuring AEE was an inability to 
obtain a strong R wave signal in several participants. As all participants were female 
and obese, several had abundant breast tissue. Research had been published with 
recommendations to place the ECG pads on the breast, rather than under (Rautaharju 
et a l ,  1998), which was followed, but signal problems were still encountered. This 
may have led to a slight underestimation in AEE as the estimations of AEE would 
have been based more heavily on the accelerometer data and, as discussed 
previously, the monitor could only detect movement in the vertical plane.
Fat and carbohydrate oxidation and gene expression
Fat and carbohydrate oxidation measured by indirect calorimetry were not 
significantly different in either group pre and post treatment. This was contrary to 
the hypothesis that a reduction in fat oxidation would be seen in the dietary 
intervention group, as weight loss due to dietary intervention had previously been 
reported to reduce whole body fat oxidation (Nicklas et a l,  1997; Franssila-Kallunki 
et a l ,  1992). The anticipated increase in oxidation rates in the rimonabant group, as 
had previously been reported in animal studies, were also not discovered. The
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oxidation rates did correspond well to measurements of REE but it is possible that 
this method was too insensitive to detect any changes due to the reduced numbers of 
participants in this study. Interestingly, Dr Sarac (collaborating PhD student on the 
trial) used stable isotope techniques to measure fatty acid oxidation and identified an 
increase in fatty acid oxidation rate in the rimonabant group compared to the diet 
group, in which fatty acid oxidation rate decreased. The mean increase in fatty acid 
oxidation rate in the rimonabant group would have yielded 220 kcals per day, which 
could fully account for the weight loss with rimonabant. The decrease identified in 
fatty acid oxidation in the diet group could also explain the reduction found in REE 
in this group.
In the hypothesis it was proposed that an increase in gene expression of regulators of 
fat oxidation would be seen in the rimonabant group yet no significant differences 
were found pre and post treatment. A significant difference was identified, however, 
between the rimonabant and diet group in expression of PPAR delta in adipose 
tissue. PPAR delta actually decreased post treatment in the rimonabant treated group 
and, as the role of PPAR delta involves increasing fat oxidation in muscle and 
lipolysis in the adipose tissue (de Lange et al., 2008), this was the opposite effect of 
that predicted in the hypothesis. It was interesting that no change was found in the 
rimonabant group in adiponectin or the adiponectin receptors gene expression, as in 
the RIO-Lipids study (Despres et a l ,  2005) adiponectin levels were increased in the 
rimonabant treated group compared to the placebo group and it was hypothesized 
that this may be the mechanism by which rimonabant causes weight loss. In this 
study (data from thesis of Dr Ivana Sarac) there was no significant change in plasma 
adiponectin found in the rimonabant group despite an increase in fatty acid oxidation,
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suggesting the mechanism of weight loss is not mediated by adiponectin. It is 
possible that the lack of significant findings with regards to gene expression in this 
study is directly related to the small participant number. As biopsies were optional, a 
number of participants did not undertake them resulting in underpowering.
Waist circumference
As was found in previous human trials using rimonabant (Van Gaal et al., 2005; 
Despres et al., 2005; Pi-Sunyer et al., 2006; Scheen et al., 2006) weight loss was 
accompanied by a decrease in waist circumference. In this study waist 
circumference decreases were found both in the rimonabant and diet group. All 
participants had a high risk waist circumference measurement pre treatment, with 
one participant in the diet group reducing her waist circumference measurement to 
the lower risk category post treatment. No significant changes were seen in waist- 
hip ratio pre and post treatment in either group, but as previously mentioned 
measurements of waist-hip ratio have limited use due to the simultaneous fat 
reduction from both areas during weight loss.
Body fa t distribution
As waist circumference decreased it was surprising that a corresponding significant 
reduction in subcutaneous abdominal fat measured by MRI was not found in the 
rimonabant group, although a significant decrease was identified pre and post 
treatment in the diet group. This is contradictory to the findings of the ADAGIO 
trial (Despres et al., 2009) which reported a significant reduction in subcutaneous 
abdominal fat accompanying a significant reduction in waist circumference in a 
rimonabant treated group when compared to a placebo group. In the ADAGIO trial,
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however, participant numbers were far greater and 20mg of rimonabant was given 
daily for a one year period resulting in a greater mean weight loss of 5.8kg. It is 
possible that if early termination of this trial had not resulted in underpowering that a 
significant result might have been achieved.
From the MRI scans it was shown that fat free mass declined in two of the 
rimonabant treated participants, yet interestingly this decrease was not accompanied 
by a reduction in REE in either of these participants. This finding was in line with 
the hypothesis that rimonabant would increase (or in this case maintain) REE. It has 
been shown in previous studies that the loss of lean body mass is correlated with a 
reduction in energy expenditure (Ravussin et a l , 1982) so a decrease might have 
been expected had these participants lost weight through dietary intervention. As 
proposed in the hypothesis a reduction in energy expenditure was observed in the 
diet group, however reductions in total body fat were recorded in all but one of the 
participants, as opposed to reductions in fat free mass.
MRI results showed a significant decrease in total body fat, subcutaneous fat, 
subcutaneous abdominal fat, and subcutaneous peripheral fat in the diet group as 
expected, however the hypothesised differences in body fat distribution in the 
rimonabant group were not seen. This finding was surprising, as the weight loss 
reported in both groups would be expected to have resulted in significant effects on 
fat distribution as shown in other weight loss studies of obesity (Markovic et a l ,  
1998; Tiikkainen et al., 2003). A further unexpected result was the non significant 
change in visceral fat in both groups. This finding contradicts the significant 
reduction in visceral fat reported in the rimonabant treated group compared to the
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placebo group in the ADAGIO trial (Despres et a l , 2009). However, due to the 
differences between this trial and the ADAGIO trial as outlined above, it is hard to 
draw direct comparisons. The non-significant finding in the diet group also 
contradicts previous research, in which significant reductions in visceral fat were 
identified following weight loss interventions (Goodpaster et a l, 1999; Goodpaster 
et a l , 2010). Once again, the underpowering of this trial and the larger weight loss 
and longer duration of the Goodpaster et a l studies must be taken into consideration.
IHCL
IHCL had been predicted to decrease in both the rimonabant and diet group. 
Surprisingly, no significant differences were found in IHCL pre and post treatment in 
either group or between groups. This is contrary to previous research, in which both 
weight loss due to dietary intervention (Tiikkainen et a l , 2003) and with rimonabant 
treatment (Despres et a l , 2009) had been shown to reduce liver fat. In these studies, 
however, greater weight loss was achieved and in the ADAGIO trial the rimonabant 
was taken for one year as opposed to 12-13 weeks.
IMCL
Previous studies have presented contradictory findings with regards to changes in 
IMCL following weight loss. IMCL has been found to be increased in obesity and 
there is a strong correlation between levels of IMCL and insulin resistance 
(Simoneau et a l , 1999). As expected the levels of SIMCL and TIMCL in all 
participants were greater than that reported in healthy individuals in a previous study. 
Li et a l (2008) reported SIMCL to be 2.6±1.5 (IMCL/water %) and TIMCL to be 
0.6±0.2 (IMCL/water %) in insulin sensitive healthy weight participants (mean BMI
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24.2±3.2) compared to SIMCL measurements of 9-11 (IMCL/water %) and TIMCL 
of 6-10 (IMCL/water %) in this trial. Two studies of obese participants with weight 
losses of 14kg and 15kg respectively both reported significant reductions in IMCL 
(Greco et al., 2002; Goodpaster et a l, 1999) whereas a small study of obese 
participants with an 11kg weight loss found no effect on IMCL (Malenfant et a l, 
2001). The results from this study also do not provide a consistent message. Despite 
weight loss the rimonabant group showed no significant change in either soleus or 
tibialis IMCL following treatment. The diet group were also reported to have an 
increase in TIMCL post weight loss, but a decrease in SIMCL resulting in a 
significant difference in SIMCL between the diet and the rimonabant group (p =
0.05).
Rimonabant side effects
The Rimonabant was well tolerated and any side effects noted were mild. In the RIO 
trials (Van Gaal (2005), Despres (2005), Pi-Sunyer (2006), Scheen (2006)) 
commonly reported adverse events in the rimonabant treated groups were nausea, 
diarrhoea, vomiting, fatigue, dizziness, anxiety and depressed mood disorder. 
During this study no participants reported any physical side effects such as nausea, 
vomiting or diarrhoea. In the RIO trials the Hospital Anxiety and Depression Scale 
was utilised to assess psychological well being, but in this trial a similar tool, The 
Beck Depression Inventory II, was used. In the RIO trials psychiatric disorders 
(depression, anxiety, agitation and sleep disorders) were reported in 2.1-7% of 
participants and were the most common reason given for prematurely withdrawing 
from the trial. In this study a lowering of mood was noted by one participant in the 
last week of the treatment period, but this may also have been influenced by personal
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problems reported by the individual at that time. Another participant reported 
fleeting suicidal thoughts although interestingly not accompanied by feelings of 
sadness or crying. Overall in this trial, although increased sadness and crying was 
noted by three participants, the mood lowering effects of the rimonabant appeared 
minimal and no participants withdrew from the trial. It was during the 
CRESCENDO trial (Topol et al., 2010), in which the effect of rimonabant on 
cardiovascular disease was being investigated, that it was discovered that serious 
psychiatric disorders were more common in patients prescribed rimonabant than 
previously reported in the clinical trials. Four patients in the rimonabant group and 
one in the placebo group in the trial had committed suicide resulting in immediate 
termination of the trial and the decision to suspend the licence for rimonabant.
In this study the most frequently scored categories on the Beck Depression Inventory 
II during the treatment period were not lowering in mood, but changes in sleep 
pattern and changes in appetite. These changes in appetite were reductions in hunger 
and these changes were expected from previous studies in animals (Bellochio et a l , 
2006). However, several participants reported loss of appetite for the duration of the 
treatment period, which is contradictory to the finding of only a transient reduction in 
appetite seen in rats (Colombo et a l , 1998). Participants were requested to continue 
with their usual food intake despite experiencing a reduced appetite and the findings 
from the analysed diet diaries confirm their compliance.
Dietary data
One major consideration whilst undertaking the study was the potential for 
participants to misreport their dietary intake. During the run-in period, and the 
treatment period for the diet group, there was the concern of under reporting with the
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converse problem of over reporting a potential issue for the rimonabant group. It has 
been demonstrated that there is a high level of under reporting in studies where 
dietary intake is recorded. Goldberg et al. (1991) have shown that measurements of 
seven day weighed food intake are lower than energy expenditure measured 
simultaneously using doubly labeled water and Prentice et a l (1986) identified a self 
recorded energy intake of only 67% of isotopically measured energy expenditure in 
obese individuals. As the doubly labeled water was too expensive to be used in this 
study, a number of methods were utilised to try and ensure dietary intake was 
accurately provided. Initially Goldberg’s cut off values were utilised to ensure 
dietary information provided by participants was feasible. Dietary intake was then 
recorded daily throughout the run-in period, whilst weight was simultaneously 
monitored to ensure participants were remaining weight stable. Estimated energy 
intake was also compared to energy expenditure and finally reported levels of protein 
excretion were compared to measured urinary nitrogen excretion. The reported 
levels of dietary protein were found to correspond well to the nitrogen excretion 
(data not shown) but it must be acknowledged that the urine samples were only taken 
over two 24 hour periods.
General limitations
In addition to the methodological limitations outlined above, one of the major 
limitations of this study was that it was underpowered due to the suspension of 
rimonabant’s licence and early termination of the trial. Recruitment for the study 
was slow as, although there was much interest regarding the trial, many individuals 
had to be excluded as they did not meet the BMI inclusion criteria or had a previous 
history of depression. Less than 10% of individuals responding to recruitment
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advertisements and letters were actually eligible to participate in the study. 
Additionally during the months of recruiting for the study there was some negative 
publicity in the press surrounding the possible side effects of rimonabant resulting in 
several individuals withdrawing their interest in the trial.
Conclusions and future work
In conclusion this trial did demonstrate, for the first time, that, when energy intake 
was maintained at pre treatment levels, rimonabant still induced weight loss and that 
this reduction in weight could be partly explained by maintenance of REE. Although 
significant increases in oxidation rates and gene expression of key regulators of lipid 
metabolism and decreases in total body fat, IHCL and IMCL were not identified it is 
likely that this is due, in part, to the early termination and subsequent underpowering 
of the trial.
Rimonabant did show good potential as an anti-obesity medication but due to its 
negative side effects is unlikely to be utilised in the future. Further research is 
required to create other medications that antagonise the endocannabinoid system but 
that selectively target the peripheral and not the central receptors.
Due to the limitations discussed above regarding the measurement of activity and 
resting energy expenditure, were a similar trial to be repeated in the future, it would 
be advisable to utilise the doubly labeled water method of measuring TEE in addition 
to the described REE and AEE methodologies. This would provide more 
comprehensive information on the different elements of energy expenditure.
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expression and body fat 
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5.1 Background
Much research has been conducted in an attempt to better understand the 
mechanisms by which obesity is related to chronic diseases. It has been shown that 
gender is an important factor. In the European Union, in 2008, it was estimated that 
a greater number of males than females were overweight (exclusive of obesity), >82 
million versus 61 million respectively, however a greater number of females were 
obese than males, 37 million in comparison to 31 million (International Association 
for the Study of Obesity ( IASO), 2008)
A variety of studies have examined gender differences in REE and body fat 
distribution as described in chapter one. There have also been studies which suggest 
that metabolism in obesity is different between genders. In a study by Nielsen et al. 
(2003) women were reported to release approximately 40% more free fatty acids 
from fat tissue than men relative to REE. However, a major limitation of these 
studies is that the number of participants was small or that the gender groups were 
not matched for the degree of obesity.
Although previous research had investigated gender differences in individual 
elements of energy expenditure and body fat distribution, no one study had 
comprehensively researched resting energy expenditure, activity energy expenditure, 
body fat distribution and gene expression of key regulators of lipid and glucose 
metabolism in the same participants. It was proposed that this approach would 
provide a fuller understanding of the differences in metabolism in obese men and 
women.
This study was a continuation of the work undertaken studying the effect of 
rimonabant in obese postmenopausal woman. At the time that the rimonabant study
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was prematurely terminated, fourteen women had been studied, but only ten had 
completed all of the tests. The aim of this study was to recruit a further six females 
and sixteen BMI and age matched males to participate in a cross sectional study to 
determine gender differences in obesity. Permission was obtained from the ten 
women completing all the baseline tests in the rimonabant study to utilise their data 
in this study. The rationale and hypothesis for the study are described in chapter one, 
section 1.17.
5.2 Overall aim
The overall aim of this study was to determine how gender influences energy 
expenditure, body fat distribution and gene expression in obesity.
This was a collaborative study involving another PhD student (who examined the 
effects of gender on insulin sensitivity, fatty acid and triglyceride metabolism), 
colleagues at the Postgraduate Medical School, the Royal Surrey County Hospital 
and the MRC Clinical Sciences Centre, at Imperial College School of Medicine, 
Hammersmith Hospital.
5.3 Specific aims
To investigate in obese participants the effect of gender on the following:
1. Resting energy expenditure and activity energy expenditure.
2. Fat and carbohydrate oxidation rate.
3. Whole body fat distribution, intrahepatocellular lipid (IHCL) and intramyocellular 
(IMCL) lipid.
4. Adipose tissue and muscle mRNA levels of key regulators of fatty acid 
metabolism.
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5.4 Methodology
5.4.1 Participants
Thirteen males and two postmenopausal females aged 50-70 years were recruited for 
the study from the local Guildford population using the recruitment strategies 
outlined in Chapter 2 and additionally through GP practices with the help of the 
Primary Care Research Network, and through a search of a study volunteer database 
of individuals who had previously participated in research and wished to volunteer 
for future studies at the Clinical Research Centre, University of Surrey. To be 
eligible for the study participants were required to have a BMI of 30-35kg/m and 
must have been weight stable for at least a three month period. Participants were 
excluded from the study if they fulfilled any of the exclusion criteria detailed in 
chapter two (section 2.2.1).
All participants were provided with a participant information sheet and the study 
design was fully explained before written consent was obtained. Ethical approval for 
the study protocol was obtained from the University of Surrey Ethics Committee 
(EC/2009/09/FHMS).
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5.4.2 Study design
The study was of 4 weeks duration and the study schedule is shown in figure 5.1
Screening (Visit 1)
REE and 5 day measurement of AEE by 
Actiheart (Visit 2)
Fat distribution (MRI/MRS) (Visit 4)
Adipose and muscle tissue biopsies taken for 
gene expression. TG/ FFA metabolism* (Visit 5)
Repeated REE, Acetate infusion and Clamp 
(Visit 3)
Figure 5.1 Study schedule (* These procedures were undertaken by another PhD student) 
REE, resting energy expenditure; AEE, activity energy expenditure; MRI, magnetic 
resonance imaging; MRS, magnetic resonance spectroscopy ; TG, triglyceride; FFA, free 
fatty acid.
5.4.3 Protocol 
Screening
Visit 1: Details of the screening visit are described in chapter two. If the participant 
fulfilled all of the inclusion criteria and none of the exclusion criteria they were 
accepted into the study. Following the screening visit, participants were requested to 
complete a four day diet diary.
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Visit 2: The purpose of this visit was to establish the participants’ energy 
expenditure. Participants were weighed. REE was measured as described in chapter 
two (section 2.6). This first REE measurement was undertaken to familiarise 
participants with the equipment.
In order to then estimate the amount of energy expended in everyday activities and 
exercise each participant was fitted with an Actiheart monitor (Chapter two/section 
2 .8).
To establish urinary nitrogen excretion, participants were requested to collect a 24 
hour urine collection throughout the day before the visit. See chapter two/section 
2.7.
Visit 3: This visit was undertaken at least a week after visit 2. As before, REE was 
measured by indirect calorimetry. This REE reading was used in the study analysis.
Visit 4: Measurements of body fat, intrahepatocellular lipid and intramyocellular 
lipid were taken at the MRC Clinical Sciences Centre, Hammersmith Hospital as 
described in chapter two/section 2.9.
Visit 5: This visit was scheduled 5-7 days after visit 3. Participants were weighed and 
a needle biopsy of the vastus lateralis muscle in the thigh and subcutaneous adipose 
tissue was taken under local anaesthesia by a physician trained in this procedure. 
The biopsies were snap frozen in liquid nitrogen and stored at -80 °C in preparation 
for batch analysis. These biopsies were utilised to measure mRNA levels of key 
regulators of fatty acid metabolism (Chapter two/section 2.11).
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5.4.4 Study power
The power calculation was undertaken by a medical statistician. The primary 
outcome measure for the study was triglyceride synthesis rate (examined by Dr 
Sarac). Secondary outcome measures included gene expression of key regulators of 
glucose and fat metabolism, total visceral and peripheral fat content, energy 
expenditure, fatty acid production and oxidation rate.
For the primary outcome measure of the difference in triglyceride secretion rate 
between genders, the SD is 50% according to the published literature. Based on 
previous data a difference in triglyceride secretion rate of 70% was expected between 
genders. From this information is was calculated that 16 participants would be 
required in each gender group to detect this difference with 87% probability at a two- 
sided 1% level of significance.
5.5 Results
5.5.1 Participant characteristics
All participants were screened at Visit 1 and a summary of their characteristics are 
shown in Table 5.1.
Of the 15 participants initially recruited for the study one male did not complete the 
trial, due to a negative reaction during one of the study days, and has been excluded 
from analysis.
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Table 5.1 Participant characteristics at screening. All figures are mean ± SEM
Females
(n=12)
Males
(n=12)
p males 
versus 
females
Age (years) 58.92 ± 1.67 58.08 ± 1.92 NS
Weight (kg) 85.69 ±2.16 104.28 ±3.45 <0.001
Height (cm) 162.58 ±2.01 180.38 ±2.27 <0.001
BMI (kg/m2) 32.39 ±0.53 31.40 ±0.34 NS
Waist circumference (cm) 95.67 ±2.04 110.38 ± 1.54 <0.001
Hip circumference (cm) 114.83 ±2.18 112.29 ± 1.98 NS
Waist hip ratio 0.84 ±0.02 0.98 ±0.01 <0.001
Fat mass (%)* 43.24 ±0.92 30.28 ±0.67 <0.001
Glucose (mmol/1) 5.28 ±0.09 5.69 ±0.12 0.01
Cholesterol (mmol/1) 5.91 ±0.24 5.44 ±0.21 NS
Triglyceride (mmol/1) 1.28 ±0.10 1.76 ±0.24
L— ...................................... J
NS
i ■ . ...........
* Fat mass as measured by impedance.
There was no significant difference in age between the two genders. Body weight 
was 18% greater in males than females primarily due to a greater amount of lean 
body mass. BMI, however, was not significantly different between individuals. 
Both waist circumference and waist hip ratio were significantly greater in males than 
females. Mean hip circumference was larger in females than males but the 
difference was not statistically significant. A significantly higher level of fasting 
glucose in mmol/1 was measured in males than females with no difference in levels 
of cholesterol or triglyceride.
5.5.2 Dietary analysis
Diet diary analysis was undertaken to compare the average intake of the males and 
females (Table 5.2). Dietary data was unavailable for one male participant.
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Table 5.2 Comparison of mean daily macronutrient intake for males and 
females reported in the four day screening diet diary.
Males
(n=12)
Females
(n=12)
p males 
versus 
females
Energy intake 
(kcal/day) 2632± 158 2002 ± 62 p = 0.0006
Fat (g/day) 97 ± 6 84 ±3 NS
SFA (g/day) 35 ± 4 29 ± 2 NS
PUFA (g/day) 15 ± 1 15 ± 1 NS
MUFA (g/day) 31 ±3 26 ± 1 NS
Carbohydrate (g/day) 275 ± 13 235 ± 12 p = 0.03
Protein (g/day) 105 ±5 78 ± 4 p = 0.0004
Alcohol (g/day) 44 ± 15 5 ± 1 TJ II O o
SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated 
fatty acids. Data expressed as mean ± SEM.
In absolute terms, males reported a higher mean daily intake of energy (p = 0.0006), 
carbohydrate (p = 0.03), protein (p=0.0004) and alcohol (p = 0.01) than females over 
a four day period. No significant difference was found in fat intake between the 
genders.
Due to the greater body weight of males versus females, the reported nutrient intake 
was analysed per kg of body weight (Table 5.3). Once expressed in relation to body 
weight, the significant differences in mean energy, carbohydrate and protein intake 
were lost. Alcohol intake still remained significantly higher in males (p = 0.02) and 
PUFA was higher in females (p = 0.05).
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Table 5.3 Comparison of mean daily macronutrient intake per kg body weight 
for males and females reported in the four day screening diet diary.
Males 
(n= 11)
Females
(n=12)
p males versus 
females
Energy intake 
(kcal/day) 26.18 ± 1.72 23.45 ±0.73 NS
Fat (g) 0.96 ±0.06 0.99 ±0.03 NS
SFA (g) 0.34 ±0.03 0.34 ±0.02 NS
PUFA (g) 0.14 ±0.01 0.17 ±0.00 p = 0.05
MUFA (g) 0.31 ±0.03 0.30 ±0.01 NS
Carbohydrate (g) 2.73 ±0.13 2.75 ±0.14 NS
Protein (g) 1.05 ±0.06 0.92 ± 0.04 NS
Alcohol (g) 0.45 ±0.15 0.06 ± 0.02 p = 0.02
SFA, saturated fatty acids; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated 
fatty acids. Data expressed as mean ± SEM.
The mean percentage contribution that each macronutrient provided to total daily 
energy intake in males and females is shown in figures 5.2 and 5.3.
Macronutrient composition of the diet in males
□  Fat ■  Carbohydrate ■  Protein □  Alcohol
11.35%
40.79%
Figure 5.2 Mean percentage contribution of macronutrients to total daily energy 
intake over a four day period in males (n=l 1).
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Macronutrient composition of the diet in females
□ Fat ■ Carbohydrate ■ Protein □ Alcohol
45.60%
Figure 5.3 Mean percentage contribution of macronutrients to total daily energy 
intake over a four day period in females (n=12).
A significantly greater percentage of energy was provided by fat in females than 
males (p = 0.02) and a significantly greater percentage of total energy provided by 
alcohol in males (p = 0.009). No significant differences were found in macronutrient 
composition of the diet in terms of carbohydrate or protein between the two groups.
5.5.3 Resting energy expenditure
In absolute terms, REE was significantly higher in the male group than the female 
group (p <0.01) (Figure 5.4).
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2500
p < 0.01
w 2000
1500
«  1000  -
Males Females
Gender
Figure 5.4 Mean REE in males and females. Data expressed as mean ± SEM 
(males n=12, females n=12).
Once REE measurements were expressed per kg fat free mass, significantly higher 
REE measurements were seen in the female group rather than the male. As shown in 
Figure 5.5 males had a mean REE/kg fat free mass of 26.38 ± 0.66 versus 29.44 ± 
0.91 in the female group (p = 0.01).
p  =0.01
fa 35
Males Females
Gender
Figure 5.5 Mean REE per kg lean body mass in males and females. Data 
expressed as mean ± SEM (males n=12, females n=12).
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5.5.4 Carbohydrate and fa t oxidation
In absolute terms, a significantly higher rate of carbohydrate oxidation was measured 
in males than females (p = 0.003). There was no difference between genders in fat 
oxidation or respiratory quotient (Table 5.4).
Table 5.4 Carbohydrate and fat oxidation rates in g/min for males and females.
Data expressed as mean ± SEM.
------------------------------------------- ----------------------
Males (n=12)
-----------------------
Females (n=12)
--------------------------
p  males vs. 
females
Carbohydrate oxidation (g/min) 0.20 ±0.01 0.12 ±0.01 0.0003
Fat oxidation (g/min) 0.04 ±0.01 0.03 ± 0.00 NS
Respiratory quotient 0.88 ±0.01 0.87 ±0.01 NS
Once oxidation rates were adjusted per kg/fat free mass (FFM) no significant 
differences were found in either carbohydrate or fat oxidation rates (Table 5.5).
Table 5.5 Carbohydrate and fat oxidation rates in kcal/kg/FFM for males and 
females. Data expressed as mean ± SEM.
Males (n=12) Females (n=12) p  males vs. females
Carbohydrate oxidation 
(kcal/kg/FFM) 15.71 ±4.40 14.75 ± 1.05 NS
Fat oxidation (kcal/kg/FFM) 6.99 ± 1.06 8.52 ± 1.17 NS
5.5.5 Activity energy expenditure
AEE was measured in all participants for a five day period. AEE recordings were not 
available for three of the participants due to problems with malfunctioning monitors 
for two individuals and an adverse skin reaction to the ECG pads for the other. In
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the male group absolute mean AEE was significantly higher at 849±103 kcal/day in 
comparison to 448±69 kcal/day (p = 0.005) in the female group (Figure 5.6). If, 
however, the AEE was expressed per kg of body weight, the significant difference 
between the two genders was lost (p = 0.06) as shown in Figure 5.7.
Males Females
Gender
Figure 5.6 Mean activity energy expenditure for males and females over a five 
day period. Data expressed as mean ± SEM (males n=l 1, females n=10).
10 n
Males Females
Gender
Figure 5.7 Mean activity energy expenditure adjusted for body weight for males 
and females over a five day period. Data expressed as mean ± SEM (males n=l 1, 
females n=10).
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Further analysis was undertaken to determine if there was any variation in AEE 
between week days and weekend days for both genders (Figure 5.8). As shown there 
was no significant difference for either gender between week days and weekend days 
and no significant difference in mean AEE during week days and the weekend 
between the two groups (p = 0.11).
■  Weekday ■  Weekend
1200 -j
1000 J
I
« 800 - u
u  600 - u
= 400 -i » ■
0 -
Figure 5.8 C om parison o f m ean activity energy expenditure betw een w eek  days 
and w eekends for m ales and fem ales. Data expressed as mean ± SEM (males 
n=l 1, females n=10).
5.5.6 Total energy expenditure
Total energy expenditure was estimated for participants utilising the measured REE 
and AEE values in conjunction with an estimate of DIT (10% of TEE). The 
estimated DIT and TEE were calculated utilising Actiheart software. The estimated 
mean TEE was then compared to reported mean kcal intake in the four day diet diary 
(Table 5.6).
p =  0.09
p =  0.73
Males Females
Gender
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Table 5.6 Comparison of estimated TEE to mean daily kcal intake in males and
females. Data are mean values.
1
1 Measured 
i REE
i
Measured
AEE
Estimated
DIT
Estimated
TEE
Mean daily 
kcal intake
01M | 1699 497 243 2439 2416
02M ; nil 840 283 2834 1969
04M ; 1942 704 293 2939 2697
05M ! 1753 1204 328 3285 2679
06M ! 1751 995 305 3051 3445
M
al
es 08M i 2082 607 298 2987 2424
09M 1532 647 242 2421 2397
12M ; 1969 564 281 2814 2000
14M | 2184 712 321 3217 3452
15M | 2126 1671 421 4218 2455
Mean 1 1894 883 308 3085 2613
SEM ! 220 359 49 494 537
SD ! 69 114 16 156 170
1
i Measured 
I REE
i
Measured
AEE
Estimated
DIT
Estimated
TEE
Mean daily 
kcal intake
OIF 1730 625 261 2616 2366
03F ! 1340 522 206 2068 2234
04F ! 1267 307 174 1748 2246
05F 1561 670 247 2478 1987
06F 1610 360 218 2188 1759
07F | 1224 222 160 1606 1776
t/3 09F ; 1558 237 199 1994 2211
s 1 IF I 1264 258 169 1691 1825
12F ! 1411 875 253 2539 1973
14F ! 1219 407 180 1806 1952
Mean ' 1418 448 207 2073 2033
SD 184 218 37 371 217
SEM ! 58 69 12 117 69
REE, Resting Energy Expenditure; AEE, Activity Energy Expenditure; DIT, Dietary 
Induced Thermogenesis.
No significant differences were found between the estimated mean TEE and the 
reported mean daily energy intake in kcal for either males or females. There was a 
significant difference in estimated TEE between the two groups (p < 0.001). Due to
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differences in body size between males and females the estimated TEE was 
calculated per kg of FFM (Figure 5.9). This adjustment resulted in the significant 
difference in TEE between the genders being lost (p = 0.93).
■  Males □  Females
P = 0.93
50 n
Males Females
Gender
Figure 5.9 M ean estim ated TEE adjusted for kg o f FFM  for m ales and fem ales.
Data expressed as mean ± SEM (males n = ll, females n=10).
5.5 .7  Body f a t  distribution
Females had a significantly higher level of total body fat (p = 0.002), subcutaneous 
fat (p < 0.001), subcutaneous abdominal fat (p = 0.004) and subcutaneous peripheral 
fat (p = 0.001) than males. Conversely, levels of internal fat (p = 0.001), visceral fat 
(p = 0.003) and non visceral fat (p = 0.002) were significantly higher in males than 
females (Table 5.7).
147
Chapter 5 -  Gender Differences Study
Table 5.7 M RI m easurem ents o f body fat for m ales and fem ales. Data are 
expressed as mean ± SEM.
M ale (n=12) Fem ale (n=12) p  m ales vs. 
fem ales
Total body fat (litres) 38.50 ±2.04 46.16 ± 1.48 0.002
Subcutaneous fat (litres) 26.87 ± 1.88 38.36 ± 1.51 <0.001
Internal fat (litres) 11.64 ±0.59 7.80 ±0.66 0.001
Subcutaneous abdominal fat 
(litres)
Subcutaneous peripheral fat 
(litres)
7.86 ±0.77 11.22 ±0.67 0.004
19.01 ± 1.23 27.14 ±0.97 0.001
Visceral fat (litres) 6.48 ±0.38 4.33 ± 0.42 0.003
Non visceral fat (litres) 5.15 ±0.31 3.48 ±0.30 0.002
Total body fat = total body adipose tissue content; Subcutaneous fat = all subcutaneous 
adipose tissue; Internal fat = all internal adipose tissue compartments i.e. all non- 
subcutaneous adipose tissue; Subcutaneous abdominal fat = subcutaneous adipose tissue in 
the abdominal area, defined as the distance from the slice containing the base of the 
lungs/top of the liver, to the slice containing the femoral heads; Subcutaneous peripheral fat 
= all the other subcutaneous adipose tissue, i.e. subcutaneous fat in peripheral and non­
abdominal parts of the body; Visceral fat = internal adipose tissue in the abdominal area, 
defined as the distance from the slice containing the base of the lungs/top o f the liver, to the 
slice containing the femoral heads; Non visceral fat = all the other internal adipose tissue in 
the body, i.e. internal adipose tissue in peripheral and non-abdominal parts o f the body, (in 
muscle, chest, pelvis, head and neck etc).
As waist circumference is used as a surrogate indicator for subcutaneous abdominal 
fat, a Pearson product-moment correlation coefficient was used to assess the 
relationship between the two measurements in males (Figure 5.10) and females 
(Figure 5.11). In males there was a weak correlation between the two variables, r = 
0.215, n = 12, p = 0.503. In females there was a stronger correlation between the two 
variables, r = 0.638, n = 12, p = 0.026.
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R2 Linear=0.046
85 9080 95 100 105 110
Waist circumference (cm)
Figure 5.10 Correlation between subcutaneous abdominal fat (litres) and waist 
circumference in males (n=12).
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16-
14-
3  12"
'S  1 0 -
R2 Linear = 0.407
100 105 110 115 120 125
Waist circumference (cm)
Figure 5.11 Correlation between subcutaneous abdominal fat (litres) and waist 
circumference in females (n=12).
5.5.8 Intrahepatocellular lipid and intramyocellular lipid measurement
Levels of intrahepatocellular lipid and intramyocellular lipid were not significantly 
different between the genders (Table 5.8 and Figure 5.12).
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Table 5.8 MRS measurements of SIMCL, TIMCL and IHCL in males and 
females.
Male (n=12) Female (n=12) p males vs. females
Median 17.40 12.43 NS
SIMCL Minimum 9.39 7.62
Maximum 25.17 28.63
Median 7.85 6.73 NS
TIMCL Minimum 5.22 2.71
Maximum 16.41 10.73
Median 14.37 2.17 NS
IHCL Minimum 0.95 0.60
Maximum 85.16 65.04
SIMCL, soleus intramyocellular lipid; TIMCL, tibialis intramyocellular lipid; IHCL, 
Intrahepatocellular lipid.
100-
-£
03
S-*
033ao
f j©
a©JS
2
Female Male
Gender
Figure 5.12 Box plots of levels of intrahepatocellular fat for males and females.
Data expressed as median and interquartile range (Males, n=12, Females, n=12).
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As alcohol intake was significantly greater in males than females (P = 0.01), a 
Pearson product-moment correlation coefficient was used to assess the degree of 
association between alcohol intake and IHCL in males (Figure 5.13). An initial 
analysis indicated a very weak correlation between the two variables, r = 0.159, n = 
11, p = 0.641. As shown in Figure 5.13 there are two outliers, participant numbers 
06M and 14M. As the p value obtained indicated a low level of confidence in the 
results, a further analysis was undertaken excluding the two outlying cases (Figure 
5.14). This second analysis indicated a stronger correlation between the two 
variables, r = 0.735, n = 9, p = 0.024.
14M140"
120-
06M
20"
R2 Linear = 0.025
0 20 40 60 80 100
Intrahepatocellular lipid (arbitrary units)
Figure 5.13 Correlation between mean alcohol intake (g/day) and 
intrahepatocellular lipid in males (n=ll).
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60-
40-
R2 Linear = 0.541
20 40 60 1000 80
Intrahepatocellular lipid (arbitrary units)
Figure 5.14 Correlation between mean alcohol intake (g/day) and 
intrahepatocellular lipid in males with outliers excluded (n=9).
5.5.9 Adipose and muscle gene expression
In adipose tissue, a significantly greater expression of LPL was identified in females 
than males (p = 0.01). There were no further significant differences in gene 
expression in adipose tissue found between the genders (Figure 5.15).
No significant differences in gene expression in muscle tissue were found between 
males and females (Figure 5.16).
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□  Females ■  Males
p=0.01
o-o o
Gene
Figure 5.15 Levels of gene expression in adipose tissue normalized to the housekeeping 
gene GAPDH. (Female group, n=l 1. Male group, n=l 1). CD36, Cluster of Differentiation 
36; A, Adiponectin; AR1, adiponectin receptor 1; UCP2, Uncoupling protein 2; LPL, 
lipoprotein lipase; HSL, Hormone sensitive lipase; PG, Peroxisome proliferator-activated 
gamma; PD, Peroxisome proliferator-activated delta.
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Figure 5.16 Levels of gene expression in muscle tissue normalized to the housekeeping 
gene GAPDH. (Female group, n=l 1. Male group, n=l 1). CD36, Cluster of Differentiation 
36; AR1, adiponectin receptor 1; UCP2, Uncoupling protein 2; UCP3, Uncoupling protein 3; 
LPL, lipoprotein lipase; PD, Peroxisome proliferator-activated delta; PA, Peroxisome 
proliferator-activated alpha; AC0X1, acyl CoA oxidase; CPT1, Carnitine 
palmitoyltransferase 1; CPT2, Carnitine palmitoyltransferase 2.
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5.6 Discussion
The overall aim of this study was to comprehensively research how gender 
influences energy expenditure, body fat distribution and gene expression in obesity. 
It was hoped that this novel approach of studying all of these separate elements of 
metabolism in the same participants would provide a greater understanding of some 
of the previously reported differences in metabolism in obese men and women.
Resting energy expenditure
Interestingly, previous research regarding gender differences in REE has been mixed. 
In the hypothesis it was proposed that males would have a higher REE than females. 
In absolute terms males were found to have a higher REE than the females, as would 
be expected, since REE is highly correlated with lean body mass (Ravussin et al., 
1982). This finding is in line with previous studies (Tooze et al., 2007; Carpenter et 
al., 1998). When the REE measurements in this study were adjusted for lean body 
mass, however, the females were found to have a greater REE per kg of lean body 
mass than the males. This is contradictory to findings from previous studies (Morio 
et a l , 1997; Ferraro et a l, 1992) in which, once adjustments had been made for 
differences in fat free mass, women were found to have lower REE than men. There 
are several possible explanations for this. It has been shown that organ masses are 
the body compartments that predominantly contribute to REE and that organs 
including the brain, heart and liver have a higher resting metabolic rate than skeletal 
muscle. The brain, liver, kidneys and heart, account for only approximately 5-6% of 
body weight, but contribute to 80% of REE (Bosy-Westphal et a l,  2009). In 
comparison to males, females have a greater proportion of their FFM as these high 
metabolic rate organs and tissues and this could provide a potential explanation for
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the finding in this study that females had a greater REE per kg of lean body mass 
than the males. Another possible explanation is provided by the work of Hendersen 
et a l (2009) in which they demonstrated that muscle and whole body protein 
synthesis is positively associated with REE, and that women actually have higher 
muscle protein synthesis and higher whole-protein turnover than men.
Fat and carbohydrate oxidation
In this study a significantly higher rate of carbohydrate oxidation was measured in 
males than females in absolute terms but once adjusted per kg/FFM no significant 
differences were found in either carbohydrate or fat oxidation rates. This was 
unexpected as, due to the findings of Nielsen et a l (2003), a greater level of fat 
oxidation was anticipated in women. No significant difference was found in RQ 
between the two groups in this study and this corresponded with the findings in a 
study by Nielsen et a l (2003) which reported no significant difference in respiratory 
quotient measured by indirect calorimetry between obese males and females. It is 
possible that the indirect calorimetry method was too insensitive to detect any 
differences in oxidation rates in this study and, as in the rimonabant study, stable 
isotope investigations may have provided a more accurate view of differences in 
oxidation rates.
Gene expression
It was hypothesised that a greater expression of genes involved in lipolysis would be 
identified in females than males following previous research by Nielsen et a l (2003) 
in which women were reported to release approximately 40% more free fatty acids 
from fat tissue than men relative to REE. No significant differences were found in
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gene expression in this study which could explain this higher fatty acid release. 
Interestingly, in this study, the one significant finding was a greater expression of 
LPL in adipose tissue in females than males. This actually corresponds with the 
findings of Amer et al. (1991) who previously described significantly higher LPL 
mRNA levels in women than men in abdominal and gluteal subcutaneous tissue. As 
LPL will be influencing lipid storage within fat cells, this increased LPL activity may 
contribute to the well documented gender differences in total body fat and body fat 
distribution.
It is possible that few significant differences were found in gene expression between 
genders as the data was variable and the SDs were high for most genes. Large 
differences would need to have been identified in gene expression to detect a 
significant difference between groups. There is little previous research in the 
literature to calculate the exact number of participants that would have been required 
to accurately achieve statistical significance but greater than the 11 participants in 
each group in this study.
Body fat distribution
Previous research by Martin and Jensen (1991) had concluded that upper-body 
subcutaneous fat was more lipolytically active than lower body fat in women and it 
was suggested that this upper body fat was the source of excess FFA release in 
upper-body obese women. As the female participants in this study were 
postmenopausal they had greater levels of upper body subcutaneous fat than the 
males, as reflected in the MRI results, and therefore would possibly have greater 
amounts of more lipolytically active fat tissue than men. It is possible that the
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expected differences in gene expression were not identified due to fairly low 
participant numbers of 11 in each group.
It is well documented that there are gender differences in fat mass and body fat 
distribution. Females are reported to have higher levels of total body fat which was 
reflected in the results from this study. As described in chapter one, body fat 
distribution varies between the genders and changes post menopause in females. In 
this study post menopausal females were compared to males and it is well 
documented that post menopausal females tend to accumulate more abdominal and 
visceral fat due to a reduction in oestrogen levels. Levels of subcutaneous abdominal 
fat were found to be greater in the female group than the male, but as expected males 
were still found to have higher levels of abdominal visceral fat. These increased 
abdominal visceral fat depots put males at higher risk of obesity related chronic 
diseases (Lovejoy and Sainsbury, 2009).
Dietary data
Dietary analysis indicated that, in absolute terms, males reported a higher mean daily 
intake of energy and macronutrients than females over a four day period. This 
finding is consistent with results reported from a study by Paul et al. (2004), in which 
dietary recalls indicated that both energy and macronutrients were greater in men 
than women. Paul et al. found that the differences were no longer significant when 
macronutrient intake was expressed as a percentage of total daily energy intake. In 
this study, once the same analysis was undertaken, a significantly greater percentage 
of energy was provided by fat in females than males and a significantly greater 
percentage of total energy provided by alcohol in males. Although no difference was
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found in IHCL between men and women, there was a moderately strong association 
between alcohol intake and IHCL in males.
Activity energy expenditure
Absolute mean AEE was significantly higher in males than females and this finding 
was unsurprising as males have a greater body weight, and therefore may expend 
more energy in daily activities than females with a lower body weight. Once AEE 
was expressed per kg of body weight, the significant difference between the two 
genders was lost. This finding is consistent with the results of a study by Ferraro et 
al (1992) in which, once adjustments had been made for body composition, no 
significant difference was seen in physical activity levels. A previous study by Paul 
et a l (2004) had also reported no gender difference in physical activity level, 
however physical activity was calculated as TEE-REE and not measured by an 
activity monitor such as the Actiheart. Additionally it should be noted that the study 
participants were of a healthy weight and not obese. One clear limitation of the 
activity measurement in this study is that AEE measured over a five day recording 
period may not reflect habitual levels of physical activity. It has been suggested that 
study participants may knowingly, or otherwise, increase their levels of physical 
activity during times of AEE measurement (Westerterp and Goran, 1997).
Total energy expenditure
Estimated absolute levels of TEE were found to be higher in males than females and 
this was expected, as TEE is known to be highly correlated with FFM (Tooze et a l, 
2007). This finding fits with that of a previous study by Paul et a l (2004) in which 
TEE measured by the doubly labeled water method was found to be higher in healthy
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weight men than women. Once TEE was adjusted per kg of FFM, however, the 
significant finding was lost. Interestingly, this finding contradicts that of Tooze et al. 
(2007) who reported that TEE was actually higher in females than males once 
adjusted per kg of FFM but, contrary to our results, they also reported a higher AEE 
in females which accounted for the greater TEE.
No significant differences were found between the estimated TEE and the reported 
mean daily energy intake in kcal for either males or females, yet if the individual 
participant data in Table 5.5 is examined there are substantial differences in reported 
intake to TEE in some participants. Subject 15M actually has an estimated TEE 
1763 kcal higher than reported energy intake in kcal. There are several possible 
explanations for this. Firstly, the TEE is estimated and, therefore, may not be 
accurate. Secondly, both the AEE measurement and diet diary recordings were taken 
over a 4-5 day period only, which may not have been representative of habitual 
activity or eating patterns. Finally the participant may have under reported his 
dietary intake.
Under reporting
There is much research suggesting that under reporting is an issue when analysing 
dietary information provided by an obese study population. Results of a dietary 
survey by Gregory et al. (1990) indicated that if using a ratio of energy intake to 
BMR the reported energy intakes were unacceptably low in 30% of males and 40% 
of females. In a further study Macdiarmid et al. (1998) found that in obese 
individuals these levels of under reporting were found in 60% of males and 70% of 
females. Previous research has suggested that in obese individuals, fat may be
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selectively under reported (Goris et al., 1999) and obese women have been shown to 
selectively under report sweet, high fat foods (Macdiarmid et al. 1998).
Waist circumference
Mean measurements of waist circumference were in the high risk category for both 
genders. Only one male and one female had a waist circumference that was not in 
the high risk category. Both males and females were also found to have high risk 
waist-hip ratios. Some large epidemiological studies have suggested that a high 
waist hip ratio is a better predictor of cardiovascular disease and all cause mortality 
than a large waist circumference alone (Canoy et a l , 2007). However, as described 
in chapter one, measurements of waist hip ratio may be misleading. Findings from 
further studies have suggested that high levels of abdominal fat and therefore a 
greater abdominal girth are a major risk factor for coronary heart disease and 
therefore waist circumference is actually a better predictor of heart disease (Dagenais 
et al., 2005). For this reason it was interesting to find that there was only a weak 
correlation between waist circumference and subcutaneous abdominal fat in men but 
a stronger correlation in women.
Conclusion
In conclusion, although absolute mean daily REE was higher in males in females as 
predicted in the hypothesis, once expressed as REE/kg lean body mass the findings 
were reversed with significantly higher REE values in the female group. Females 
were found to have greater total body fat and subcutaneous fat and males, higher 
visceral fat as predicted. Although no significant difference was identified in gene 
expression in muscle, a greater expression of LPL in adipose tissue was measured in
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females than males. This increased LPL activity may contribute to the well 
documented gender differences in total body fat and body fat distribution.
A further study involving a greater number of participants may have yielded more 
revealing results with regards to the gene expression data. Further research is still 
required regarding gender differences in obesity in these key genes involved in lipid 
and glucose metabolism. These genes may provide novel targets for future anti­
obesity medications.
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Development o f research skills
This project has provided invaluable experience in the development of independent 
research skills. Training was provided in various scientific techniques including the 
measurement of resting energy expenditure using indirect calorimetry, use of 
Actiheart activity monitors and laboratory techniques for the extraction of mRNA 
and rtPCR for measurement of gene expression. Considerable experience was also 
gained in the practical elements of research management, such as setting up and 
coordinating of a clinical trial and recruitment. Additionally, and most importantly, 
it has also provided a greater understanding of methods of critically analysing data 
and questioning research findings.
Anti-obesity Medications
The recent licence suspensions for rimonabant and sibutramine have resulted in only 
one option of anti-obesity medication, orlistat, being available for prescription. Over 
the past few years, much progress has been made treating high cholesterol and raised 
blood pressure with a selection of medications, but due to negative side effects of the 
weight loss medications and their subsequent withdrawal from the market, treatment 
for obesity still remains a problem. Further research is still required to find a 
pharmacological way to target obesity with its related metabolic complications.
An important consideration is that there are different types of obesity and perhaps 
these different types of obesity need to be treated in alternative ways. Although 
obesity is associated with a number of comorbidities, a sub group of obese 
individuals have been found not to have the associated problems and remain
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metabolically ‘healthy’ (Bliiher, 2010). It is important to identify the ‘unhealthy’ 
obese, who will potentially benefit the most from anti-obesity treatments from the 
‘healthy’ obese. As demonstrated in both the rimonabant and gender differences 
study, fat distribution is not uniform between individuals. Men and post menopausal 
women have greater levels of abdominal obesity which is associated with insulin 
resistance, high triglyceride levels and low HDL cholesterol and thus greater 
cardiovascular risk. An anti-obesity medication which specifically targets high risk 
abdominal obesity is needed. Anti-obesity medications have historically been 
prescribed on the basis of BMI but, if drugs were developed that were more effective 
in a certain sub group of obese individuals than others, then prescription could be on 
the basis of, for example, waist circumference.
Limitations and future studies
It is disappointing that rimonabant was found to have more serious side effects than 
previously thought and that its licence was suspended half way through the trial as 
interesting results were emerging regarding the medications effects on energy 
expenditure. Had the medication not lost its licence it would have been important to 
have undertaken a study similar to the one described in this thesis using doubly 
labeled water which provides a robust measure of TEE over a two week period in a 
free living environment. This approach would compensate for some of the limitations 
of REE and AEE measurements.
Due to the many reasons outlined in this thesis, the endocannabinoid system is still a 
good potential target in the treatment of obesity. Due to the negative side effects of 
anxiety and depression seen with rimonabant, further research is required to find a
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medication that only acts on peripheral and not central receptors. If a drug could be 
developed that could be restricted to the peripheral receptors and could be prevented 
from crossing the blood brain barrier, the mood lowering effects of rimonabant could 
be eliminated (Di Marzo and Szallasi, 2008). However, it must be considered that 
one of the mechanisms of action of rimonabant is through its central effects on 
appetite and reward mechanisms and therefore a peripheral antagonist might be less 
effective as an anti-obesity medication.
Future work also needs to establish the maximum length of time that an individual 
can safely tolerate any newly developed anti-obesity medications. Once patients 
stopped taking rimonabant in the RIO trials they regained their lost weight. It would 
have been interesting to determine how quickly REE returned to baseline levels 
during this period of weight regain.
As all of the weight loss medications developed at this time have only resulted in 
modest weight reductions they should not to be used in isolation but as an adjunctive 
therapy. Rimonabant’s ability to maintain or increase REE made it particularly 
promising as an adjunct to lifestyle modification since, as shown in the diet group of 
the current trial, obese people who lose weight through non pharmacological means 
have metabolic alterations such as a reduced REE. Accompanying this lowered REE 
tend to be feelings of hunger which promote increased food intake and make it 
difficult to maintain a lower body weight. In order to maintain weight loss either 
without, or post treatment with an anti-obesity medication, it is essential to 
encourage obese individuals to maintain lean body mass, and thus increase both 
resting and total energy expenditure, through increasing physical activity.
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At this time the commercial weight loss industry is largely targeted towards women 
and much of the clinical research undertaken has been in females. There are limited 
studies examining gender differences in response to anti-obesity medications. The 
large human clinical trials using rimonabant were undertaken in both genders but 
there was no sub analysis as to the differing effects in males and females. As shown 
in this thesis, there are gender differences in metabolism in obesity, and therefore the 
potential for gender differences in response to anti-obesity medications which need 
to be evaluated. Given that there are also gender differences in response to 
commercial diet plans and physical activity programmes for weight loss, it is likely 
that gender-specific treatment approaches to weight loss would be advantageous.
Conclusion
This project has provided an interesting insight into the metabolic effects of 
endocannabinoid antagonists in humans, and undoubtedly supplies evidence to 
suggest that further research focusing on novel endocannabinoid antagonists is 
warranted. The novel gene expression work has also highlighted the impact that both 
medication and gender may have on genes involved in lipid and glucose metabolism 
and the potential importance of these genes as targets in the development of new 
anti-obesity medications.
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APPENDIX 1
Self-Certificate Medical Questionnaire
Pilot study to establish the feasibility and acceptability of meeting energy 
requirements in target study participants through the use of a commercially 
available modular energy controlled diet (Slim.Fast, Unilever).
Please tick all/any of the following that apply:
□  I have no prior/present history of Coronary Heart Disease, Angina or Stroke
□  I have no prior/present history of Type 1 or Type 2 diabetes
□  I have no prior/present history of liver disease
□  I have no prior/present history of endocrine disorders
□  I have no prior/present history of, nor am I currently being treated for, clinical 
depression and/or other psychological disorders
□  I have no prior/present history of eating disorders, including anorexia or bulimia 
nervosa
□  I have no prior/present history of drug or alcohol abuse within the last 2 years
□  I have not had any surgical procedure to aid weight loss
□  I have no known food allergies or intolerances
□  I am not currently taking or have taken any regular medication prescribed by my
GP in the last 6 months
Signed__________________________________________  Date / /
N am e:...............................................................  DOB:
Address:
Contact Telephone Number:
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GP Name: .. 
GP Address:
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APPENDIX 2
Dutch Eating Behaviour Questionnaire (DEBQ)
Participant code_____________________  Date___/___/_
Please answer the following questions as carefully and honestly as possible. 
Read each question and simply fill in the column which best applies to you.
r* 58 I  S
o  «  c  °  H
> 2  S B  *
<d  O c±r ^  °3Z 00 C/3 O >  Z
1. If you have put on weight, do you eat less than you usually do? *
2. Do you have a desire to eat when you are irritated? *
1
3. If food tastes good to you, do you eat more than you usually do? *
4. Do you try to eat less at meal times than you would like to eat? *
5. Do you have a desire to eat when you have nothing to do? *
6. Do you have a desire to eat when you are depressed or discouraged? *
7. If food smells and looks good, do you eat more than you usually eat? *
8. How often do you refuse food or drink offered because you are concerned about your 
weight? *
9. Do you have a desire to eat when you are feeling lonely? *
10. If you see or smell something delicious, do you have a desire to eat it? *
11. Do you watch exactly what you eat? *
12. Do you have a desire to eat when somebody lets you down? *
13. If you have something delicious to eat, do you eat it straight away? *
14. Do you deliberately eat foods that are slimming? *
15. Do you have a desire to eat when you are cross? *
16. Do you have a desire to eat when you are approaching something unpleasant to happen?
*
17. If you walk past the baker do you have a desire to buy something delicious? *
18. When you have eaten too much, do you eat less than usual the following days? *
19. Do you get a desire to eat when you are anxious, worried or tense? *
20. If you walk past a snack bar or cafe, do you have a desire to buy something delicious? *
21. Do you deliberately eat less in order not to become heavier? *
22. Do you have a desire to eat when things are going against you, or things have gone 
wrong? *
23. If you see others eating, do you have also the desire to eat? *
24. How often do you try not to eat between meals because you are watching your weight? *
25. Do you have a desire to eat when you are frightened? *
26. Can you resist eating delicious food? *
27. How often in the evening do you try not to eat because you are watching your weight? *
28. Do you have a desire to eat when you are disappointed? *
29. Do you eat more than usual when you see other eating? *
30. Do you take your weight into account when you eat? *
31. Do you have a desire to eat when you are emotionally upset? *
32. When preparing a meal are you inclined to eat something? *
33. Do you have a desire to eat when you are bored or restless? *
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DEBQ Categories:
* Emotional eating -  13 items
* External eating -  10 items
* Restrained eating -  10 items
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APPENDIX 3
Name: ___________________________________________  Marital Status: __________  Age:________  Sex: ______
Occupation: _______________________________________ Education:_______________________________________
Instructions; This questionnaire consists of 21 groups of statements. Please read each group of statements carefully, and 
then pick out the one statement in each group that best describes the way you have been feeling during the past two 
weeks, including today. Circle the number beside the statement you have picked. If several statements in the group 
seem to apply equally well, circle the highest number for that group. Be sure that you do not choose more than one 
statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 (Changes in Appetite).
1. S a d n e s s
0 I do not feel sad.
1 I feel sad much of the time.
2 I am sad all the time.
.3 T am so sad or unhappy that 1 can’t stand it.
2. P e s s i m i s m
0 T am not discouraged about my future.
1 T feel more discouraged about my future than I
used to be.
2 I do not expect things to work out for me.
3 I feel my future is hopeless and will only gel
worse.
3. P a s t  Fa i lu re
0 I do not feel like a failure.
1 I have failed more than 1 should have.
2 As I look back, I see a lot of failures.
3 I feel I am a total failure as a person.
4.  Loss  of P l e a s u re
0 I gel as much pleasure as I ever did from the 
things I enjoy.
1 I don’t enjoy things as much as I used to.
2 1 get very little pleasure from the things 1 used
to enjoy.
3 1 can’t get any pleasure from the tilings I used 
to enjoy.
5. Guilty F e e l in g s
0 I don’t feel particularly guilty.
1 I feel guilty over many things I have done or 
should have done.
2 I feel quite guilty most of the time.
3 I feel guilty all of the time.
6. P u n i s h m e n t  F e e l ing s
0 1 don’t feel 1 am being punished.
1 I feel I may be punished.
2 I expect to be punished.
3 I feel I am being punished.
7. Se lf -Dis l ike
0 I feel the same about myself as ever.
1 I have lost confidence in myself.
2 T am disappointed in myself.
3 I dislike myself.
8. S e l f -C r i t i ca ln e ss
0 I don’t criticize or blame myself more than usual.
1 I am more critical of myself than I used to be.
2 I criticize myself for all of my faults.
3 1 blame myself for everything bad that happens.
9. Su ic ida l  T ho ug h ts  or W is h e s
0 I don’t have any thoughts of killing myself.
1 I have thoughts of killing myself, but I would
not carry them out.
2 I would like to kill myself.
3 I would kill myself if I had the chance.
10.  Crying
0 I don’t cry anymore than I used to.
1 I cry more than T used to.
2 I cry over every little thing.
3 1 feel like crying, but I can’t.
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11.  Agi ta t ion
0 I am no more restless or wound up than usual.
1 1 feel more restless or wound up than usual.
2 I am so restless or agitated that it’s hard to stay 
still.
3 I am so restless or agitated that I have to keep 
moving or doing something.
12.  L oss  of In te re s t
0 I have not lost interest in other people or 
activities.
1 I am less interested in other people or things 
than before.
2 1 have lost most of my interest in other people 
or things.
3 It’s hard to get interested in anything.
13.  I n t l e c i s iv c n c s s
0 I make decisions about as well as ever.
1 I find it more difficult to make decisions than
usual.
2 I have much greater difficulty in making 
decisions than I used to.
3 I have trouble making any decisions.
14. W o r t h l e s s n e s s
0 1 do not feel I am worthless,
1 1 don’t consider myself as worthwhile and useful
as 1 used to.
2 I feel more worthless as compared to other 
people.
3 I feel utterly worthless.
15. L os s  of E nergy
0 I have as much energy as ever.
1 I have less energy than I used to have.
2 I don’t have enough energy to do very much.
3 I don’t have enough energy to do anything.
16.  C h a n g e s  in S le e p in g  P a t te rn
0 I have not experienced any change in my 
sleeping pattern.
la 1 sleep somewhat more than usual.
lb 1 sleep somewhat less than usual.
2a I sleep a lot more than usual.
2b I sleep a lot less than usual.
3a I sleep most of the day.
3b I wake up 1-2 hours early and can’t get back
to sleep.
17.  I rr i tabil i ty
0 I am no more irritable than usual.
1 I am more irritable than usual.
2 I am much more irritable than usual.
3 I am irritable ail the time.
18.  C h a n g e s  in A ppe t i te
0 I have not experienced any change in my 
appetite.
la My appetite is somewhat less than usual,
lb My appetite is somewhat greater than usual.
2a My appetite is much less than before.
2b My appetite is much greater than usual.
3a 1 have no appetite at all.
3li 1 crave food all the time.
19.  C o n c e n t ra t io n  ,
0 I can concentrate as well as ever.
1 I can’t concentrate as well as usual.
2 It’s hard to keep my mind on anything for 
very long.
3 1 find I can’t concentrate on anything.
20 .  T i r e d n e s s  or  F a t ig ue
0 1 am no more tired or fatigued than usual.
1 I get more tired or fatigued more easily than
usual,
2 1 am too tired or fatigued to do a lot of the things
I used to do.
3 I am too tired or fatigued to do most of the 
things I used to do,
2 1 .  L oss  of In te re s t  in Sex
0 I have not noticed any recent change in my 
interest in sex.
1 I am less interested in sex than I used to be.
2 1 am much less interested in sex now.
3 I have lost interest in sex completely.
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APPENDIX 5
DIETARY PRESCRIPTION
Participant number:
Week numbers: 1 and 2
Please find your daily dietary prescription below.
Please eat the products listed below on each day and record your dietary intake in the 
diet diary attached.
As you need to fit these foods into your day in a way that works for you, the table 
below has been provided so that you can tick each food product as you eat it and 
easily keep track of what you need to consume over the course of the day.
PRODUCT MON TUE WED THU FRI SAT SUN
1 x Milk Shake
1 x Milk Shake
1 x Milk Shake
1 x Smoothie
1 x Smoothie
1 x Meal Bar
1 x Meal Bar
1 x Soup
1 x Snack Bar
1 x Snack (either Cheddar Bites or Pretzels)
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APPENDIX 6
SLIMFAST PRODUCTS AVAILABLE 
Participant number:
Products marked with an X are unacceptable to the participant.
Banana Milk Shake
Chocolate Milk Shake
Strawberry Milk Shake
Vanilla Milk Shake
Cafe Classic Milk Shake
Banana Milk Shake Powder
Chocolate Milk Shake Powder
Vanilla Milk Shake Powder
Fruits of the Forest Meal Bar
Yoghurt Muesli Meal Bar
Mediterranean Bean and Tomato Soup
Hearty Chicken and Vegetable Pasta Soup
Cream of Chicken and Mushroom Soup
Fruits of the Forest Smoothie
Raspberry Smoothie
Peach and Mango Smoothie
Apricot and Cashew Snack Bar
Cranberry and Almond Snack Bar
Peanut Snack Bar
Caramel Snack Bar
Cheddar Bites
Sour Cream and Chive Pretzels
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APPENDIX 7
END OF PILOT QUESTIONNAIRE
Pilot study to establish the feasibility and acceptability of meeting energy 
requirements in target study participants through the use of a commercially 
available modular energy controlled diet (Slim.Fast, Unilever).
Do you think that you could follow the diet for a seventeen week period? If not, for 
what reasons?
Did you eat any other foods whilst on the diet? If so, what was the reason for that?
Did you experience any changes in your bowel habits whilst following the diet?
Did you experience any other side effects whilst on the diet?
Any other comments?
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